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In 2016, an estimated 246,000 women will be diagnosed with, and 40,000 deaths will be 
attributed to, breast cancer. Polycyclic Aromatic Hydrocarbons (PAHs), a group of over 100 
different chemicals formed during the incomplete combustion of organic substances, may 
influence survival after breast cancer. This dissertation examined whether the primary sources of 
PAH exposure, tobacco smoke and intake of grilled/smoked meat, and changes in exposure after 
diagnosis were associated with mortality after breast cancer. To address the dissertation aims, I 
utilized resources from the Long Island Breast Cancer Study Project (LIBCSP), a population-
based cohort study of 1,508 women who were diagnosed with first primary breast cancer in 
1996/1997. Women were interviewed at baseline, shortly after diagnosis, and again five years 
later and have been followed for 18+ years using the National Death Index. 
Results of Aim 1A showed that smoking in the year before diagnosis was associated with 
a 69% increased risk of long-term all-cause mortality, but not breast cancer-specific mortality. 
Among women who continued smoking after breast cancer, risk of all-cause mortality was 
elevated by 130%, but this was attenuated by approximately 20% among women who quit 
smoking after diagnosis. Results of Aim 1B examining environmental tobacco smoke exposure 
were largely null, a finding that is in agreement with few studies conducted to date examining at-
diagnosis ETS exposure. 
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Results of Aim 2 showed that at-diagnosis high intake of total grilled/barbecued and 
smoked meat was associated with a 23% increased risk of all-cause mortality. At-diagnosis 
intake of smoked beef/lamb/pork was positively associated with all-cause and breast cancer 
mortality, while intake of smoked poultry/fish was inversely associated with mortality. Women 
with continued high post-diagnosis intake of grilled/barbecued and smoked meat had a further 
elevated risk of all-cause mortality; risk increased from 23% to 31%. Consistent with the 
associations observed for at-diagnosis intake, risk of breast cancer-specific mortality was 
inversely associated with high post-diagnosis intake of smoked poultry/fish. 
The results of this dissertation help strengthen smoking cessation efforts and inform the 
limited dietary intake guidelines currently available for the more than 3 million women who are 
survivors of breast cancer. 
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CHAPTER I: BACKGROUND 
This dissertation examined the role polycyclic aromatic hydrocarbon (PAH) sources of 
exposure before and after diagnosis in relation to breast cancer survival. The first aim examined 
the associations between active cigarette smoking and environmental tobacco smoke and 
changes in cigarette smoke exposure and all-cause and breast cancer mortality after diagnosis. 
Similarly, the second aim examined the associations between intake of grilled and smoked meats 
and changes in intake of grilled and smoked meats and all-cause and breast cancer mortality after 
diagnosis. This background section first summarizes the epidemiology of breast cancer 
incidence, which has been extensively studied, along with breast cancer survival, focusing on 
non-PAH factors. I first discuss these established risk and prognostic factors as they provide 
insight into the potential underlying biological mechanisms driving the hypothesized associations 
with PAH exposures. The discussion of risk and prognostic factors is followed by a discussion 
focused on the epidemiology of PAHs in relation to breast cancer incidence and survival, 
summarizes the literature on the studies conducted to date, and highlights the existing gaps in 
research that this dissertation addressed. 
Epidemiology of Breast Cancer 
Breast cancer definitions 
Female breast cancer represents a group of diseases in which malignant tumors arise from 
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the cells of the breast, are able to grow and invade surrounding tissues, and are able to 
metastasize to distant areas of the body (American Cancer Society 2015b). The normal structures 
of the breasts include lobules – the milk-producing glands; ducts – which carry the milk from the 
lobules to the nipples; and stroma – the fatty and connective tissues that surround the lobules, 
ducts, and blood and lymphatic vessels of the breasts (American Cancer Society 2015b). 
Approximately 80% of invasive breast cancers arise from the ductal epithelial cells and are 
referred to as invasive ductal carcinomas (The Johns Hopkins University 2015b). Invasive 
lobular carcinomas arise from the epithelial cells that line the lobules and are the second most 
common invasive breast cancer diagnosed (10%-15%) (The Johns Hopkins University 2015c). A 
small number of breast cancers originate in other tissues of the breast. Ductal and lobular 
carcinomas in situ (DCIS and LCIS, respectively) are considered non-invasive breast tumors 
contained within the duct or lobular basement membranes (Ellis et al. 1992; The Johns Hopkins 
University 2015a). 
Breast cancer prevalence, incidence, and mortality  
Aside from non-melanoma skin cancer, breast cancer is the second most common cancer 
diagnosed in the United States (US) and the most common cancer diagnosed among women 
(National Cancer Institute 2015, 2016; Siegel et al. 2016). It is estimated that more than 246,000 
women will be newly diagnosed in the United States in the year 2016 contributing to the 3.1 
million women who are survivors of breast cancer (American Cancer Society 2015a; National 
Cancer Institute 2016). By the year 2030, the total number of new invasive and in situ tumors 
diagnosed per year is expected to increase to 441,000 (Rosenberg et al. 2015). Using data from 
the Surveillance, Epidemiology, and End Results (SEER) Program, which documents data on 
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cancer statistics across population-based registries since 1973, an increase in the rate of new 
breast cancer cases diagnosed in the 1980’s is evident (Figure I-1) (National Cancer Institute 
2016). This increase is attributed to the adoption and use of mammography screening as 
evidenced by the increase in the number and the proportion of localized and small tumors and in 
situ tumors and the decrease in the incidence of large tumors diagnosed during this time period 
(Chu et al. 1996; White et al. 1990). From 1988 to 2002 the breast cancer incidence rate 
stabilized until it declined in the year 2003. The decline is thought to be temporally related to the 
first report of the Women’s Health Initiative, which confirmed the findings of prior studies 
reporting an increased risk of coronary heart disease and breast cancer associated with the use of 
estrogen-progestin combination therapy (Writing Group for the Women’s Health Initiative 
Investigators 2002) that resulted in a decrease in the use of hormone-replacement therapy among 
postmenopausal women in the United States (Ravdin et al. 2007). Incidence rates have since 
once again stabilized with the most recent data indicating that the age-adjusted incidence rate is 
currently 125.0 per 100,000 women per year across women of all races (National Cancer 
Institute 2016). 
In the US, breast cancer ranks as the second cause of death from cancer among women 
with approximately 40,000 deaths attributed to breast cancer annually (Siegel et al. 2016). 
Mortality rates have steadily declined since the 1990’s (Figure I-1) and today approximately 
90% of women survive at least five years after being diagnosed with breast cancer (National 
Cancer Institute 2016). The age-adjusted mortality rate is 21.5 per 100,000 women per year 
(National Cancer Institute 2016). Regular screening and available treatments contribute to this 
high survival rate (Berry et al. 2005); as discussed in detail in the following section, patient and 
disease characteristics also play a significant role in prognosis (Soerjomataram et al. 2008). 
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Established risk and prognostic factors 
Estrogens are a group of compounds that promote the development and maintenance of 
the female reproductive system. The physiologic functions of estrogens in women include 
development of secondary sexual characteristics, regulation of gonadotropin secretion for 
ovulation, preparation of tissues for progesterone response, maintenance of bone mass, 
regulation of lipoprotein synthesis, and regulation of insulin responsiveness (Nelson and Bulun 
2001). The two  major endogenous estrogens include estrone (E1), estradiol (E2) and are 
synthesized from androgens by the aromatase enzyme primarily in the ovaries and secondarily in 
adipose and skin tissues (Nelson and Bulun 2001). As outlined in a review by Yager and 
Davidson (Yager and Davidson 2006), estrogens are hypothesized to be mammary gland 
carcinogens via nuclear, mitochondrial, and plasma membrane estrogen receptor (ER)-mediated 
pathways. Through these pathways, in estrogen responsive tissues such as the ovaries and the 
mammary gland, the presence of estrogen results in altered gene expression leading to increased 
cell proliferation and decreased cell apoptosis (Katzenellenbogen 1996). By promoting the 
proliferation of cells with existing mutations or by increasing the opportunity for novel 
mutations, estrogens contribute to breast carcinogenesis (Pike et al. 1993). Independent of ER-
mediated pathways, estrogens also undergo extensive metabolism which leads to the production 
of genotoxic, mutagenic, and carcinogenic metabolites (Mueck and Seeger 2007). 
Epidemiologic studies conducted since as early as the 1920’s (Lane-Claypon 1926) have 
implicated reproductive factors in the development of breast cancer. Based on accumulating 
evidence, it was hypothesized that exposure to endogenous hormones influenced breast cancer 
etiology; however, early studies conducted during the 1960’s and 1970’s examining the direct 
role of hormone levels on breast cancer risk yielded mixed results (Cole and MacMahon 1969). 
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This may be due to limitations of early studies that had small sample sizes, utilized timed urine 
samples (rather than 24-hour collection) – a less sensitive method of steroid hormone assessment 
than the use of serum samples (Riad-Fahmy et al. 1982), and employed a case-control study 
design in which samples were collected after the initiation of disease in cases (Toniolo 1997). 
Because disease, treatment, or behavioral changes after diagnosis may influence hormone levels, 
the biomarkers collected after diagnosis may not have been reflective of the etiologically 
relevant time-period, thus leading to mixed results (Toniolo 1997). It was not until the 1990’s 
during which results of several prospective nested case-control studies (Berrino et al. 1996; 
Helzlsouer et al. 1994; Toniolo et al. 1991, 1995) specifically designed to address the role of 
endogenous hormones in breast cancer were published that the hypothesis regained momentum. 
Studies have since continued to further examine both hormones and these and other 
epidemiologic risk factors, and prognostic factors, in relation to breast cancer. These include age 
at menarche, age at menopause, parity, and age at first and multiple pregnancies (Mcpherson et 
al. 2000; The Endogenous Hormones and Breast Cancer Collaborative Group 2002). 
Additionally, exposure to exogenous sources of estrogens through exposure to oral 
contraceptives among premenopausal women (Collaborative Group on Hormonal Factors in 
Breast Cancer 1996) and hormone-replacement therapy among peri-menopausal women 
(Collaborative Group on Hormonal Factors in Breast Cancer 1997) have also been shown to 
contribute to an increased risk of developing breast cancer. These risk factors, in addition to 
genetics (family history and race) and other lifestyle and behavioral factors (alcohol use, non-
steroidal anti-inflammatory use, obesity, and physical activity) are reviewed in the following 




Aging and the molecular, cellular, and physiologic processes that accompany it including 
increased genomic instability, increased oxidative stress, increased DNA damage, and decreased 
DNA repair capacity, are important in the etiology of all cancers, including breast cancers 
(Anisimov 2007). The incidence rate of breast cancer rises rapidly with age, is highest during the 
reproductive years, and increases more slowly until menopause when the rate slows (Clemmesen 
1948; Pike et al. 1983b). In the United States, the median age at diagnosis of breast cancer is 62 
years (National Cancer Institute 2016). 
Particularly poor survival has been observed among women diagnosed at a younger age, 
especially those diagnosed younger than 35 years of age (RR=2.18; 95% CI=1.64-2.89), and 
women diagnosed over the age of 80 (RR=1.80; 95% CI=1.45-2.25) compared to women 
diagnosed between the ages of 40 and 49 (Brandt et al. 2015; Kroman et al. 2000; Reeves et al. 
2000). Although only approximately 2% of all breast cancers are diagnosed in women under the 
age of 35 (National Cancer Institute 2016), it is the most common cancer in women under 35 and 
young women generally present with more advanced and aggressive disease at diagnosis 
including larger tumors, axillary lymph node involvement, high tumor stage and grade, and 
estrogen receptor-negative tumors (Fredholm et al. 2009; Gonzalez-Angulo et al. 2005). On the 
other hand, 20% of all breast cancer patients are diagnosed among women over the age of 75 
years (National Cancer Institute 2016) yet the clinical guidelines for the management and 
treatment of breast cancer in older women, are not well established and so less use of 
mammographic screening, lower diagnostic activity, and lower treatment activity in older 
women lead to a lower relative survival (Eaker et al. 2006). Among older women age-related 
increases in aromatase expression, and thus estrogen synthesis, in peripheral tissues (adipose and 
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skin) may also play an important role in survival, especially among women with hormone-
sensitive tumors (Hemsell et al. 1974). 
Reproductive factors 
Menarche and menopause. Epidemiologic studies show that breast cancer incidence 
increases by 5% for each year younger at menarche and by 3% for each year older at menopause 
(Collaborative Group on Hormonal Factors in Breast Cancer 2012). An earlier initiation of  
menarche results in earlier exposure to hormones and regular menstrual cycles (Kelsey et al. 
1993) and older age at menopause results in continued hormonal exposure. Because most 
(approximately 60-70%) breast cancers are estrogen-sensitive (Dunnwald et al. 2007), increased 
lifetime exposure to these hormones may raise a woman’s risk of developing breast cancer. 
Further evidence is provided by the observation of an inverse association between bilateral 
oophorectomy, or surgical removal of the ovaries, and breast cancer progression, which was 
recognized even before the importance of estrogens was understood (Love and Philips 2002). 
Recent studies show that when performed before the age of 40, bilateral oophorectomy reduces 
the risk of breast cancer by 20% to 50% (Nichols et al. 2011). 
Age at menarche and menopausal status at diagnosis, however, do not appear to be 
independently associated with breast cancer mortality (Barnett et al. 2008; Giordano et al. 2004). 
Because chemotherapy can often lead to amenorrhea, an abnormal absence of menstruation, and 
premature initiation of menopause in pre- and peri-menopausal women (Ganz 2005; Goodwin et 
al. 1999; Morgan et al. 2012) post-treatment menopausal status may be more relevant. 
Nonetheless, the impact of chemotherapy-induced amenorrhea on breast cancer survival remains 
controversial (Berliere, F.P. Duhoux, Ch. Galant, F. Dalenc, J.F. Baurain, I. Leconte, L. Fellah, 
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L. Dellvigne 2011). Several studies report longer disease free survival for patients who 
developed drug-induced amenorrhea as compared with non-amenorrheic women (Aebi et al. 
2000; Bianco et al. 1991; Del Mastro et al. 1997; Pagani et al. 1998), though not all studies are in 
agreement (Collichio and Pandya 1994; Del Mastro et al. 1997; Vanhuyse et al. 2005). 
Parity and age at first and multiple pregnancies. Numerous epidemiologic studies have 
reported an increased risk of developing breast cancer among nulliparous women and a long-
term reduced risk of breast cancer for increasing number of full-term births and early age at first 
birth (Kelsey et al. 1993). In a meta-analysis (Ma et al. 2006) of ten case-control and cohort 
studies, each additional birth was associated with a reduced the risk of developing ER+/PR+ 
breast cancer by 11% (RR=0.89, 95% CI=0.84-0.94) and women in the oldest age group at first 
birth had a 27%  increased (RR=1.27, 95% CI=1.07-1.50) risk of ER+/PR+ breast cancer than 
women in the youngest age group. Each pregnancy; however, is also associated with a transient 
increased risk of developing breast cancer for 5, but up to 15, years after childbirth (Lambe et al. 
1994; Liu et al. 2002). Subsequently, women who are diagnosed with breast cancer at or shortly 
after a pregnancy experience particularly poor survival. These tumors are more likely to be 
hormone receptor-negative, high histologic grade, node positive, and have higher mitotic count, 
and higher stage compared to tumors of nulliparous women (Alsaker et al. 2011; Daling et al. 
2002). Few studies have examined whether parity is associated with survival after breast cancer, 
but recent studies indicate that higher parity is associated with worse survival (Butt et al. 2009; 
Trivers et al. 2007a), which may be due to enhanced initiation or progression of malignant cells 
or delayed diagnosis and thus worse prognosis, among women with high parity (Butt et al. 2009). 
Breastfeeding. Breastfeeding is hypothesized to reduce the risk of breast cancer incidence 
by reducing a woman’s lifetime number of menstrual cycles, thereby reducing a woman’s 
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exposure to endogenous hormones, and by increasing the differentiation of ductal cells, making 
them less susceptible to carcinogenic insult (Lipworth et al. 2000; Russo et al. 2001; Visvader 
and Stingl 2014). Breastfeeding also provides a route of excretion of many lipophilic and 
potentially carcinogenic chemicals as there is rapid assimilation of lipid-soluble chemicals 
during milk production (Sim and McNeil 1992). Before these underlying mechanisms were fully 
understood, animal studies, followed by epidemiologic studies, generated these hypotheses 
documenting an inverse association between breastfeeding and risk of breast cancer. The results 
of epidemiology studies show that for every 12 months of breastfeeding the risk of developing 
breast cancer decreases by 4%-5%, compared to no breastfeeding (Collaborative Group on 
Hormonal Factors in Breast Cancer 2002; Ma et al. 2006). 
Studies examining whether breastfeeding influences prognosis after a breast cancer 
diagnosis have been limited and results have been mixed. One study (Phillips et al. 2009) 
reported no association between breastfeeding and mortality and two studies (Alsaker et al. 2011; 
Trivers et al. 2007a) reported an inverse association between a short, but not long, duration of 
breast feeding and mortality. In the Long Island Breast Cancer Study (LIBCSP) on which this 
dissertation was based, the hazard ratio of breast cancer-specific mortality was 0.76 (95% 
CI=0.57-1.01) among women who breastfed for ≤6 months compared to women who never 
breast fed (Trivers et al. 2007a). A recent study that examined the association between history of 
breast feeding (ever/never) and lifetime duration of breast feeding (never, <6 months, ≥6months) 
and mortality after breast cancer stratified by breast cancer intrinsic subtype found that women 
with basal-like tumors, which often lack ER, PR, or HER2 expression (Badve et al. 2011), were 
less likely to have breastfed before diagnosis and that any prior breastfeeding and long-term 
duration of breastfeeding were associated with decreased risk of breast cancer-specific mortality 
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(Kwan et al. 2015). The inverse associations between a history of breast feeding and breast 
cancer mortality were more pronounced among hormonally-sensitive (ER+ or PR+) Luminal A 
and Luminal B tumors (HR=0.52, 95% CI=0.31-0.89 and HR=0.60, 95% CI=0.26-1.41), but also 
among non-hormonally sensitive (ER- and PR-) basal-like tumors (HR=0.64, 95% CI=0.24-1.72). 
The authors hypothesized that the transformation of breast cells during pregnancy could lead to 
the development of more differentiated (ER+ and PR+) breast cancers which are better prognostic 
tumor subtypes. 
Exogenous hormone use 
Oral contraceptive (OC) use. Use of oral contraceptives (OCs) is highly prevalent in the 
US with approximately 10.7 million women reporting current use (Mosher 2010). OC pills were 
first introduced in the US in 1960 and since the early 1970’s there has been an interest in 
understanding the impact of OC use on breast cancer incidence. Results of very early studies 
reported no increased risk of breast cancer (Arthes et al. 1971; Fasal and Paffenbarger, Ralph S. 
1975; Henderson et al. 1974; Ory et al. 1976), likely due to an insufficient amount of time 
between the introduction of oral contraceptives and development of breast cancer and the relative 
rarity of breast cancer among young women, which were underpowered to detect an association. 
Subsequent studies reported an increased risk of breast cancer particularly among very young 
women associated with oral contraceptive use before first full-term pregnancy or before age 25 
(Chilvers and Deacon 1990; Paffenbarger et al. 1977; Pike et al. 1981, 1983a). While changes in 
oral contraceptive formulations, hormonal constituents, dosages, and schedules of administration 
and changes in patterns and of usage have led conflicting epidemiologic results (Marchbanks et 
al. 2012), since the 1980’s studies have reported an elevated risk of premenopausal breast cancer 
in both parous (OR=1.29, 95% CI=1.20-1.40) and nulliparous (OR=1.24, 95% CI=0.92-1.67) 
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women who ever used oral contraceptives (Hunter et al. 2010; Kahlenborn et al. 2006). This risk 
is further elevated among women who use OCs before their first full-term pregnancy (OR=1.44, 
95% CI=1.28-1.62) compared to women who use OCs after their first full-term pregnancy 
(OR=1.15, 95% CI=1.06-1.26), which is consistent with observations of inverse associations 
between pregnancy and breast cancer incidence (Kahlenborn et al. 2006). 
 The use of oral contraceptives after a diagnosis of breast cancer in considered 
contraindicated (World Health Organization. 4th ed. 2001) due to the proliferative effects of 
estrogens on cancerous breast cells. Although most studies have failed to find an association 
between OC use and mortality (Ewertz et al. 1991; Greenberg et al. 1985; Holmberg et al. 1994; 
Lees et al. 1989; Millard et al. 1987; Mohle-Boetani et al. 1988; Rosner and Lane 1986; 
Sauerbrei et al. 1998), these studies focused on ever/never use of oral contraceptives and all-
cause mortality. In contrast to these studies, three studies have examined current OC use at breast 
cancer diagnosis (Lu et al. 2011; Trivers et al. 2007b; Wingo et al. 2007). In the first study, 
among women in the LIBCSP, Trivers and colleagues reported an increased HR of all cause-
mortality (HR=1.97, 95% CI=1.15-3.38) among women who currently used OCs or who used 
OCs within 1 year of breast cancer diagnosis (Trivers et al. 2007b). Additionally, risk of breast 
cancer mortality was further elevated (HR=3.03, 95% CI=1.61-5.69) among women who used 
high-dose estrogen formulations (Trivers et al. 2007b). In the second study published in 2007 
and in the third study published in 2011, both failed to reach the same conclusions finding no 
association between current OC use or recent high-dose estrogen OC use and breast cancer-
specific mortality (Lu et al. 2011; Wingo et al. 2007). Additional studies examining recent and 
post-diagnosis use of oral contraceptives are needed to help clarify these associations. 
Hormone replacement therapy (HRT) use. Hormone replacement therapy (HRT) is 
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effective for the treatment of menopausal symptoms. Therapies include estrogen alone (“estrogen 
therapy”) or estrogen plus progestin (“combined hormone therapy”) and are administered as 
pills, and more recently as skin patches, gels and sprays that are applied to the skin. These 
hormones can act systemically or locally. While effective in managing menopausal symptoms, 
HRT use also has health risks. In 2002, after a follow-up of 5 years, the Women’s Health 
Initiative (WHI) trial of estrogen plus progestin (1 daily tablet containing 0.625 mg of 
conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate) versus placebo was 
terminated early due to an observed increased risk of developing breast cancer (HR=1.26, 95% 
CI=1.00-1.59), heart disease (HR=1.29, 95% CI=1.02-1.63), and stroke (HR=1.41, 95% 
CI=1.07-1.85) among women assigned to the intervention (Writing Group for the Women’s 
Health Initiative Investigators 2002). Similar effect estimates had been previously reported in a 
meta-analysis of 51 case-control studies that included 52,705 women with invasive breast cancer 
and 108,411 women without breast cancer; a 35% increased risk of breast cancer incidence 
(RR=1.35, 95% CI=1.21-1.49) among women who had used HRT for 5 years or longer 
(Collaborative Group on Hormonal Factors in Breast Cancer 1997). The meta-analysis also 
showed that the risk of developing breast cancer increased with increasing duration of use (≥15 
years of use versus never-use, RR=1.58, SE=0.121) with an apparent attenuation in risk after 
cessation of use of HRT, which largely disappeared after 5 years of cessation (current use versus 
never use, RR=1.21, SE=0.04; last use 1-4 years versus never use, RR=1.10, SE=0.06; last use 5-
9 years versus never use, RR=1.01, SE=0.07) (Collaborative Group on Hormonal Factors in 
Breast Cancer 1997). 
 The use of hormone replacement therapy after a diagnosis of breast cancer, which could 
result in an increased risk of recurrence (Pritchard 2001), is also contraindicated. Epidemiologic 
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evidence supporting this hypothesis, however, has been mixed. In a meta-analysis (Col et al. 
2001) of 11 studies published through May 1999 of post-diagnosis HRT use and breast cancer 
recurrence, a statistically non-significant inverse association (RR=0.82, 95% CI=0.58-1.15) was 
found between HRT use and breast cancer recurrence. In one study published shortly after the 
meta-analysis, the rate of recurrence was significantly lower (RR=0.50, 95% CI=0.30-0.85) 
among women who used HRT after diagnosis compared to nonusers (O’Meara et al. 2001). 
Similarly, reduced rates were also observed for breast cancer mortality (RR=0.34, 95% CI=0.13-
0.91) and all-cause mortality (RR=0.48, 95% CI=0.29-0.78) (O’Meara et al. 2001) among 
women who used HRT after diagnosis. In the Stockholm trial of HRT use (n=188 women 
randomized HRT and n=190 randomized to no HRT) and breast cancer recurrence, after 10.8 
years of follow-up a 30% increased (HR=1.3, 95% CI=0.9-1.9) risk was observed among HRT-
users compared to non-users (Fahlén et al. 2013). Several possible explanations for these 
contradictory findings include unmeasured confounding, including confounding by indication, 
and more aggressive screening among breast cancer survivors who use HRT. In contrast to these 
findings, a randomized clinical trial (Holmberg and Anderson 2004) that investigated the safety 
of a 2-year HRT treatment in women who were previously treated for breast cancer was 
terminated early because women with a history of breast cancer allocated to receive HRT for 
menopausal symptoms experienced an unacceptably high rate of breast cancer compared with 
breast-cancer survivors allocated to best symptomatic treatment without hormones (HR=3.5, 
95% CI=1.5-8.1). These conflicting results may require additional studies to help elucidate the 
true association between HRT use and breast cancer recurrence and mortality, though another 
clinical trial may not be feasible since it is unethical to prescribe HRT to breast cancer patients 
given the known proliferative effects of estrogens. 
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Genetics 
Race. From 2009-2013, the age-adjusted incidence rate of breast cancer was 125.0 per 
100,000 women across all races (National Cancer Institute 2016). White women and Black 
women experience the highest, but similar incidence rates of breast cancer (128.0 per 100,000 
women and 125.2 per 100,000 women, respectively). In contrast, Asian/Pacific Islander and 
Hispanic women have lower incidence rates of breast cancer (97.3 per 100,000 women and 92.4 
per 100,000 women, respectively) and American Indian/Alaska Native women have the lowest 
incidence rate of breast cancer (81.2 per 100,000 women). Mortality rates, however, are highest 
among Black women (29.6 per 100,000 women) followed by White women (21.0 per 100,000), 
American Indian/Alaska Native (14.7 per 100,000), Hispanic (14.5 per 100,000), and Asian 
American/Pacific Islander women (11.2 per 100,000) (National Cancer Institute 2016; Siegel et 
al. 2016). Biological variability, such as differences in tumor subtype, response to therapy, and 
comorbidities are often cited as contributors to the disparities in survival between white and 
black women (Roseland et al. 2015). For example, Black women, are more likely to be 
diagnosed with more aggressive disease including ER-/PR- (Roseland et al. 2015) and higher 
stage and histologic grade tumors (Cunningham and Butler 2004; Henson et al. 2003), which 
contribute to poor prognosis. Premenopausal Black women are also more likely to be diagnosed 
with basal-like breast cancers, which are negative for ER, PR, and HER-2, and overexpress 
cytokeratins 5/6 and HER-1/epidermal growth factor receptor (EGFR), have high proliferation 
rates (Bauer et al. 2007), and have lymph node and distant metastases (Iqbal et al. 2015; 
Satariano et al. 1986). However, recent studies suggest that socioeconomic status leading to 
differences in access to care, treatment, and presentation characteristics (Li et al. 2003; Silber et 
al. 2013) could account for most, but not all, racial differences in breast cancer mortality 
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(O’Brien et al. 2010). 
Family history. A positive family history of breast cancer is well recognized to increase 
the risk of developing breast cancer with risk varying according to the type of relative affected, 
the age at which the relative developed breast cancer, and the number of relatives affected. While 
the total number of breast cancer genes is unknown, at least two tumor suppressor genes BRCA1 
and BRCA2, which are located on the long arms of chromosomes 17 and 13, respectively, are 
believed to account for a substantial proportion of high risk families (Mcpherson et al. 2000), 
though, only about 5~10% of breast cancer cases can be attributed to the presence of an inherited 
deleterious mutation in a gene that predisposes to the development of breast cancer (Ganz 2005). 
A systematic review and meta-analysis (Pharoah et al. 1997) of 52 case-control studies and 22 
cohort studies published through 1995 examined various family history patterns and showed that 
the risk of breast cancer incidence was elevated among women with a history of breast cancer 
diagnosis in any relative (RR=1.9, 95% CI=1.7-2.0),  a first-degree relative (RR=2.1, 95% 
CI=2.0-2.2), a mother (RR=2.0, 95% CI=1.8-2.1), a sister (RR=2.3, 95% CI=2.1-2.4), a daughter 
(RR=1.8, 95% CI=1.6-2.0), a mother and a sister (RR=3.6, 95% CI=2.5-5.0), and a second-
degree relative (RR=1.5, 95% CI=1.4-1.6). These risks are further elevated when the family 
member develops breast cancer at an earlier age. BRCA1-mutation associated breast cancers are 
more likely to be ER-/PR- and HER-2- (Lakhani 2002) and high grade (Eccles et al. 2015), 
therefore it is hypothesized that women with BRCA1 and BRCA2 mutations might have a worse 
prognosis. However, despite the numerous published studies, the association between BRCA1 or 
BRCA2 mutation carriership and breast cancer prognosis is inconclusive and current evidence 




Although the relationship between diet and breast cancer incidence has received 
considerable scientific attention, few consistent associations are observed (Vera-Ramirez et al. 
2013). This is possibly due to methodological issues including differences in measurement of 
dietary intake, potential misclassification of exposures, high correlations among nutrients, and 
insufficient time for follow-up (Moorman and Terry 2004; Vera-Ramirez et al. 2013). As 
reviewed below, of the dietary exposures that have been examined, only alcohol intake is 
consistently associated with increased risk of breast cancer incidence and inconsistently with 
mortality (Rock 2002; Vera-Ramirez et al. 2013). Several studies, including randomized trials, 
report an inverse association between fruit and vegetable intake and breast cancer incidence or 
mortality and a positive association between fat intake and breast cancer incidence and mortality, 
but results are inconsistent. 
Alcohol intake. Alcohol use is a well-established risk factor for breast cancer incidence 
(Bagnardi et al. 2001; Corrao et al. 2004; Key et al. 2006; Longnecker 1994; Smith-Warner et al. 
1998). A daily intake of 100g of alcohol is associated with a relative risk of breast cancer of 2.71 
(95% CI=2.33-3.08) compared to no intake (Bagnardi et al. 2001). The mechanisms of ethanol-
induced carcinogenesis are closely related to the metabolism of ethanol. As Seitz and Stickel 
review, acetaldehyde, the first metabolite produced during alcohol degradation, interferes with 
DNA synthesis and repair, causes point mutations, induces sister chromatid exchanges and 
chromosomal aberrations, and binds to proteins resulting in structural and functional alterations, 
which can lead to cancer (Seitz and Stickel 2007). In addition to being carcinogenic, increased 
alcohol intake (>20g/d alcohol) is also associated with increased levels of endogenous sex 
hormones and decreased levels of sex hormone-binding globulin (SHBG), which bind and 
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transport estrogens as biologically inactive forms, in premenopausal and postmenopausal women 
(Key et al. 2011; Rinaldi et al. 2006). Through these mechanisms, it is hypothesized that alcohol 
intake may also affect survival after breast cancer diagnosis. While several studies have found a 
positive association between the highest levels of intake of alcohol and breast cancer-specific 
mortality (HRs ranging from 1.51 to 4.32) when exposed before, at, and after diagnosis 
(Allemani et al. 2011; Fuchs et al. 1995; Hebert et al. 1998; Kwan et al. 2010; McDonald et al. 
2002; Vrieling et al. 2012) and an inverse association between moderate intake of alcohol and 
all-cause mortality (Barnett et al. 2008; Flatt et al. 2010; Reding et al. 2008; Saxe et al. 1999), 
results of most studies have been null as summarized in a meta-analysis of 25 follow-up studies 
of alcohol use (14 studies of pre-diagnosis drinking, 10 studies of post-diagnosis drinking, and 1 
study of both pre- and post-diagnosis drinking) and breast cancer mortality published in 2013 
(Gou et al. 2013). In the meta-analysis (Gou et al. 2013), neither pre- nor post-diagnosis alcohol 
consumption were associated with breast cancer mortality (HR=1.05, 95% CI=0.93-1.19 and 
HR=1.08, 95% CI=0.94-1.25); however drinking >20g/d of alcohol was associated a 14% (95% 
CI=2%-27%) increased hazard of breast cancer-specific mortality. 
Fruit and vegetable intake. Intake of fruits and vegetables – sources of vitamins, anti-
oxidants, and fiber which can mitigate the damaging effects of oxidative stress and free radical 
damage (Block et al. 1992) – has been studied in relation to breast cancer incidence in more than 
25 case-control studies. The case-control studies report a 25% reduced (RR=0.75, 95% CI=0.66-
0.85) risk of breast cancer incidence among women with high intake of fruits and vegetables 
compared to women with low intake (Block et al. 1992; Gandini et al. 2000; Howe et al. 1990). 
On the other hand, prospective studies report a much smaller magnitude of association; in a 
meta-analysis (Smith-Warner et al. 2001) of eight cohort studies including the Nurse’s Health 
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Study, the New York State Cohort, and the Netherlands Cohort Study, the highest quartile of 
total intake of fruits and vegetables was associated with only a 7% reduction (RR=0.93, 95% 
CI=0.86-1.00, PTrend = 0.12) in breast cancer risk. 
In the few observational studies that have examined fruit and vegetable intake and breast 
cancer-specific mortality, higher intake of fruits and vegetables and intake of micronutrients such 
as beta carotene, calcium, vitamin A, vitamin C, vitamin E have been shown to be inversely 
associated with breast cancer mortality (Fink et al. 2006; Jain et al. 1994; Patterson et al. 2010). 
In the Long Island Breast Cancer Study Project, among post-menopausal women, intake of any 
fruits and vegetables at diagnosis was associated with a reduced (HR=0.68, 95% CI=0.42-1.09) 
risk of all-cause mortality; the association was reported to be similar for breast cancer-specific 
mortality although the estimates were not provided (Fink et al. 2006). In the survival cohort 
study within National Breast Screening Study in Canada, the HR of breast cancer mortality 
among women with the highest quartiles of intake of beta carotene was 0.48 (95% CI=0.23-0.99) 
and vitamin C was 0.43, (95% CI=0.21-0.86) relative to women with intake in the lowest 
quartiles (Jain et al. 1994). Higher intake of fruits and vegetables is also inversely associated 
with all-cause mortality (Dal Maso et al. 2008; McEligot et al. 2006). In randomized clinical 
trials, fruit and vegetable intake has also been shown to be inversely associated with breast 
cancer mortality when combined with high physical activity (Pierce et al. 2007b), although 
modification of fruits and vegetable intake alone does not appear to reduced mortality from 
breast cancer (Pierce et al. 2007a, 2013). Given these suggestive findings, current guidelines 
recommend that women be encouraged to adopt a diet high in fruits and vegetables after breast 
cancer diagnosis (Runowicz et al. 2016). 
Fat intake. Intake of dietary fat from meat and dairy products – which are high in 
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saturated fat, can concentrate lipophilic carcinogenic chemicals including pesticides, and may 
contain growth factors such as insulin-like growth factor I – has also been extensively studied in 
relation to breast cancer incidence. Results, however, are inconclusive and the data available do 
not support they hypothesis that dietary fat increases the risk of breast cancer incidence 
(Moorman and Terry 2004). 
Studies have examined dietary fat intake in relation to breast cancer survival since the 
1980’s. A recently published review by Makarem and colleagues summarized 18 studies that 
were published since 1986 (Makarem et al. 2013). Of the 18 studies reported in the review, 5 
examined the association between pre-diagnosis total dietary fat and breast cancer-specific 
survival. Among the 5 studies, the Iowa Women’s Health Study reported a more than 2-fold 
increased hazard of breast cancer specific mortality among women with the highest tertiles of 
intake of total fat (HR=2.5, 95% CI=1.2-5.3), saturated fat (HR=2.4, 95% CI=1.1-4.9), and 
monounsaturated fat (HR=2.3, 95% CI=1.1-4.7) relative to women with intake in the lowest 
tertiles (Zhang et al. 1995). Of the 18 studies, 9 examined post-diagnosis total fat intake and 
breast cancer mortality, two of which reported an increased risk of breast cancer mortality. The 
first, a study of Japanese and Caucasian women living on the Hawaiian island of Oahu who were 
diagnosed with breast cancer between 1975 and 1980, reported a more than three-fold increased 
(HR=3.2, 95% CI=1.2-8.6) risk of breast cancer mortality (Nomura et al. 1991). The second 
study, the Nurse’s Health Study, reported a 44% increased (HR=1.44, 95% CI=1.01-2.04) risk of 
breast cancer mortality for the highest versus lowest quintile of total fat intake (Holmes et al. 
1999). Lastly, as summarized in the review (Makarem et al. 2013), two randomized clinical trials 
that have been conducted examining post-diagnosis fat intake and breast cancer recurrence; the 
Women’s Intervention Nutrition Study, observed a 24% reduced risk of recurrence among 
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women assigned to a low-fat diet intervention compared to controls (Chlebowski et al. 2006), 
while the Women’s Healthy Eating and Living Trial found no association between the 
intervention designed to reduce fat intake and the control groups and recurrence (Pierce et al. 
2007a). Despite these mixed findings, current guidelines for breast cancer survivors recommend 
that women limit intake of saturated fats (Runowicz et al. 2016). 
Other lifestyle factors 
NSAID use. Non-steroidal anti-inflammatory drugs (NSAIDs) such as Aspirin, 
Acetaminophen, and Ibuprofen are chemically distinct compounds that share a common 
therapeutic action; they inhibit the cyclooxygenase-2 (COX-2) enzyme, which catalyzes the 
synthesis of prostaglandins from dietary arachidonic acid (Vane 1971). Prostaglandins increase 
aromatase gene expression in breast cells and in surrounding tissue resulting in estrogen 
biosynthesis (Brueggemeier and Díaz-Cruz 2006). Prostaglandins also stimulate the EP receptor 
resulting in enhancement of cellular proliferation, promotion of angiogenesis, inhibition of 
apoptosis, and suppression of immune responses (Wang and Dubois 2006). Given the role of 
prostaglandins in carcinogenesis and the observations that COX enzymes and prostaglandins are 
abnormally upregulated in breast cancer (Bennett et al. 1977; Parrett et al. 1997), NSAIDS have 
the potential to lower risk of breast and other cancers via COX-2 inhibition. While epidemiologic 
studies examining the association between NSAID use and breast cancer risk have provided 
conflicting results (Kirsh et al. 2007; Marshall et al. 2005), a meta-analysis (Khuder and Mutgi 
2001) that included 16 prospective studies of NSAID use and breast cancer incidence yielded a 
relative risk of 0.82 (95% CI=0.75-0.89). A more recent meta-analysis (Luo et al. 2012) found a 
similar reduced risk of breast cancer (OR=0.86; 95% CI=0.81-0.92). The potential benefits of 
NSAIDs as chemopreventive agents, however, must be examined in light of the potential side 
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effects from treatment with NSAIDs, such as gastrointestinal bleeding and perforation (Agrawal 
and Fentiman 2008). 
After breast cancer initiation, the primary prostaglandin produced by COX-2, PGE2, can 
transactivate EGFR leading to stimulation of migration of tumor cells (Wang and Dubois 2006). 
Intratumoral aromatase may also be an important source of estrogens available for tumor growth 
(Esteban et al. 1992). Therefore, inhibiting COX-2 and EGFR tyrosine kinase could block the 
spread of metastatic disease. Several observational studies have explored whether aspirin use is 
associated with survival after breast cancer. At least three have reported a reduced risk of breast 
cancer mortality among women who used aspirin at- (Holmes et al. 2010) and post- (Blair et al. 
2007; Fraser et al. 2014) diagnosis with hazard ratios ranging from 0.53 to 0.57 for all cause-
mortality and from 0.36 to 0.53 for breast cancer mortality; however, not all have results have 
been in agreement (Holmes et al. 2014; Kwan et al. 2007; Li et al. 2012; Wernli et al. 2011). 
Additionally, three studies examining de novo post-diagnosis use of aspirin found no association 
with breast cancer mortality suggesting that the benefits of aspirin use may be attributable to pre-
diagnosis use (Zhang et al. 2012). 
Obesity. In postmenopausal women, with cessation of estrogen synthesis in the ovaries, 
the major pathway of estrogen production becomes the conversion of androstenedione into 
estrone in adipose tissue and skin (Grodin et al. 1973; Lønning et al. 1990). Additionally, 
postmenopausal obese women may have a higher proportion of bioavailable estrogen due to 
lower levels of SHBG (Key et al. 2011; Zhang et al. 1984). Adipose tissues also secrete 
inflammatory factors and are associated with hyperinsulinemia and insulin resistance, which are 
also hypothesized to increase breast cancer risk (Goodwin and Stambolic 2011; Morris et al. 
2011). Long before these mechanisms were understood, observational studies reported an 
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increased risk of breast cancer incidence among postmenopausal women with increased height 
and weight (de Waard and Baanders-Van Halewijn 1974; Valaoras et al. 1969). More recently, 
body mass index (BMI) – a surrogate for adiposity that incorporates both height and weight – 
and waist-to-hip ratio (WHR) are more consistently used measures of obesity. A recently 
published secondary analysis of the Women’s Health Initiative (WHI) randomized clinical trial 
reported that women in the highest categories of obesity (BMI ≥35 kg/m2) had a 58% increased 
(HR=1.58, 95% CI=1.40-1.79) risk of breast cancer incidence compared to normal weight 
women and obesity was associated with more advanced disease, including larger tumors, lymph 
node involvement, and regional or distant stage at diagnosis (Neuhouser et al. 2015). These 
observations were consistent with most previous studies and meta-analyses of breast cancer 
incidence (Cheraghi et al. 2012; Endogenous Hormones Breast Cancer Collaborative Group 
2003; Munsell et al. 2014), but not all (Cecchini et al. 2012). In contrast, among premenopausal 
women increased obesity is associated with a small reduced risk of developing breast cancer 
(Amadou et al. 2013; Munsell et al. 2014; Renehan et al. 2008; Ursin et al. 1995) possibly due to 
anovulation and lower levels of circulating estrogen levels (Potischman et al. 1996). 
The association between obesity at diagnosis and survival has been extensively studied; a 
meta-analysis by Protani and colleagues identified 45 studies published from 1963-2005 and 
reported an increased risk of all-cause (HR=1.33, 95% CI=1.21-1.47) and breast cancer-specific 
(HR=1.33, 95% CI=1.19-1.50) mortality among women who were obese compared to women 
who were not obese at diagnosis (Protani et al. 2010). When stratified by menopausal status the 
magnitude of the association was larger among premenopausal (HR=1.47, 95% CI=1.19-1.83) 
than among postmenopausal (HR=1.22, 95% CI=0.95-1.57) women, but the interaction was not 
statistically significant (P=0.25) possibly due to insufficient power (Protani et al. 2010). In 
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addition to the studies examining pre- and at-diagnosis weight and breast cancer survival, several 
studies have also shown that post-diagnosis weight gain after breast cancer, a common 
occurrence after chemotherapy treatment (Demark-Wahnefried et al. 1997), negatively impacts 
survival. In the LIBCSP, Bradshaw and colleagues reported an increased (HR=2.84, 95% 
CI=1.15-6.65) hazard of breast cancer-specific mortality among women who had more than 10% 
weight gain after diagnosis compared to women who maintained their weight within 5% 
(Bradshaw et al. 2012), consistent with findings of several prior studies (Kroenke et al. 2005; 
Nichols et al. 2009), but not all (Caan et al. 2008, 2012; Chen et al. 2010). While the causal 
mechanism remains unresolved, the authors posit two hypotheses that could explain the poorer 
survival observed among obese women. The first is that obese patients may have more 
biologically aggressive tumors thought to be a result of increased leptin production in adipose 
tissue which, among many functions, stimulates tumor cell mitogenesis, tumor cell migration and 
invasion, induces angiogenesis, and induces aromatase activity (Rose et al. 2002). The second is 
that obese women may be undertreated with regards to chemotherapy since doses of most 
chemotherapy drugs are based on body surface area and physicians may have concerns that 
obese women will experience toxic effects at high doses, thus, reducing doses (Griggs et al. 
2005). 
Physical activity (PA). Physical activity (PA) is hypothesized to lower the risk of breast 
cancer through several mechanisms including altered menstrual characteristics (Malina et al. 
1978; Moisan et al. 1991), reduced lifetime exposure to sex steroid hormones (Bertone-Johnson 
et al. 2009; Rinaldi et al. 2014; van Gils et al. 2009), reduced exposure to insulin and insulin-like 
growth factors (Schmitz et al. 2002; Wieczorek-Baranowska et al. 2011), prevention of obesity 
or induction of weight loss (Haskell et al. 2007), and improved immune function and reduced 
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levels of inflammation (Gleeson 2007). 
Epidemiologic studies examining the associations between physical activity and breast 
cancer incidence have been complicated by methodological issues in assessing PA including the 
potential for misclassification of exercise due to variation in sources of physical activity (e.g. 
recreational PA, occupational PA, and activities of daily living), use of varying definitions of 
physical activity (e.g. frequency, duration, and intensity), and inaccurate assessment of physical 
activity during etiologically relevant time period(s), which are unknown (Gammon et al. 1998), 
but studies have consistently observed an inverse association between increased levels of 
physical activity and breast cancer incidence. A systematic review (Monninkhof et al. 2007) of 
19 cohort studies and 29 case-control studies published through February 2006 provides strong 
evidence for an inverse association between physical activity and incidence of breast cancer 
(15%-20% reduced risk) though the evidence was stronger for postmenopausal breast cancer 
(20%-80% reduced risk) than premenopausal breast cancer. 
Physical activity is thought to influence the progression of breast cancer through the same 
mechanisms by which it is believed to influence incidence. Indeed, observational studies report 
an inverse association between PA and breast cancer survival. In a meta-analysis (Lahart et al. 
2015) of 22 prospective cohort studies, inverse associations were observed between breast 
cancer-specific mortality and lifetime pre-diagnosis (HR=0.73, 95% CI=0.54-0.98), recent pre-
diagnosis (HR=0.84, 95% CI=0.73-0.97), and post-diagnosis recreational PA (HR=0.59, 95% 
CI=0.45-0.78). In addition, meeting recommended PA guidelines post-diagnosis was associated 
with a HR of breast cancer mortality of 0.67 (95% CI=0.50-0.90) (Lahart et al. 2015). Substantial 
heterogeneity was found in several of the comparisons, but results were in agreement with 
previous reviews and meta-analyses (Ellsworth et al. 2012; Ibrahim and Al-Homaidh 2011). 
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Several issues regarding the benefits of physical activity in relation to breast cancer prognosis 
remain unresolved including understanding the optimal frequency and duration of physical 
activity. 
Disease characteristics and treatment 
Disease characteristics at the time of breast cancer diagnosis including higher stage 
(Reeves et al. 2000), larger tumor size (Anderson et al. 2001; Narod 2012), lymph node 
involvement (Carter et al. 1989; Lethaby et al. 1996; Reeves et al. 2000), negative hormone 
receptor status (Aaltomaa et al. 1991; Crowe et al. 1991; Dunnwald et al. 2007; Fisher et al. 
1988; Parl et al. 1984), high histological grade (Elston and Ellis 1991), and histological type 
(Ellis et al. 1992) are known to impact treatment and, thus, survival. For example, chemotherapy 
may be given to patients with high grade larger tumors before surgery (neoadjuvant treatment) to 
reduce the size of the tumor (National Cancer Institute 2009) whereas it is not recommended for 
the treatment of in situ cancers (Breastcancer.org 2015). Chemotherapy can also be given after 
surgery (adjuvant treatment) to women who have no measurable metastases, but who are at risk 
of recurrence (National Cancer Institute 2009). Women diagnosed with hormone receptor-
positive tumors can be treated with hormone therapies such as tamoxifen – a selective estrogen-
receptor modulator that is an antagonist of the estrogen receptor in the breast – and letrozole – an 
aromatase inhibitor that blocks aromatase activity – which have high efficacy for the treatment of 
breast cancer (Robert 1997).  
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Epidemiology of Polycyclic Aromatic Hydrocarbons (PAHs) and Breast Cancer 
PAH Definition 
Polycyclic Aromatic Hydrocarbons (PAHs) include over 100 different chemicals that are 
formed during the incomplete combustion of coal, oil and gas, and other organic substances like 
tobacco and charbroiled/smoked meats (Agency for Toxic Substances and Disease Registry 
(ATSDR) 1995a). These molecules consist of two or more fused aromatic rings and are, by 
definition, composed of hydrogen and carbon (see Figure I-2 for the structures and 
nomenclatures of the 16 PAHs on the US Environmental Protection Agency (EPA) priority 
pollutant list (Yan et al. 2004)). PAHs are generally lipophilic and this property increases with 
increasing complexity of the compounds (Boström et al. 2002). As pure chemicals PAHs are 
solid and range in appearance from colorless to white or pale yellow-green (US Environmental 
Protection Agency, 2008). The sources of exposure and metabolism, measurement of PAH 
exposure, PAH exposure prevalence and how PAH and PAH sources of exposure relate to breast 
cancer incidence and survival as reviewed in the following sections. 
Sources of Exposure and Metabolism 
Non-occupational PAH sources of exposure in the US include, primarily, cigarette 
smoking and, among non-smokers, diet; and, secondarily, outdoor and indoor air pollution 
(Skupińska et al. 2004). Among non-smokers, dietary sources account for up to 70% of 
exposure, but in urban areas with high air pollution, air can be a significant contributor to PAH 
exposure (Hemminki et al. 1990; Menzie et al. 1992; Phillips 1999; Skupińska et al. 2004). 
Given the varied and complex sources of PAH exposure, PAHs occur as complex mixtures 
(Agency for Toxic Substances and Disease Registry (ATSDR) 1995a). In addition to the more 
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than 100 possible different PAHs that can be originate within a single source, PAHs can also co-
occur with other chemicals some of which are known carcinogens. For example, in vehicular 
traffic air pollution, PAHs, including the estrogenic PAH fluoranthene (see Table I-2 adapted 
from White, 2015), are found as a mixture with ozone, carbon monoxide, nitrogen oxides, heavy 
metals, and other particulate matter (Wu et al. 2012). Synthetic logs can contain PAHs such as 
chrysene/triphenylene as well as polychlorinated biphenyls which show estrogenic and anti-
estrogenic effects in vitro (Gullett et al. 2003; Wolff et al. 1997) (Table I-2). In cigarette smoke, 
PAHs, including benzo[a]pyrene which has been documented to exert both estrogenic and anti-
estrogenic effects in vitro and naphthalene (Table I-2), are found with the carcinogens benzene, 
arsenic, heavy metals, formaldehyde, vinyl chloride, and N-Nitrosamines (IARC 2004). In meats 
and high-fat foods, PAHs can bioaccumulate along with dioxins and other persistent lipophilic 
pollutants such as organochlorine pesticides and polychlorinated biphenyls (Loomis et al. 2015). 
In high temperature-cooked foods, PAHs including benzo[a]pyrene, fluoranthene, pyrene, and 
phenanthrene (Table I-2), are formed along with heterocyclic amines (HCAs) depending on the 
method of food preparation – HCAs are formed when amino acids pyrolyze in meat juice, though 
pan-frying foods produces more HCAs than grilling and smoking foods (Knize et al. 1999). 
Although PAHs co-occur with many chemicals, PAHs are common across all sources and only 
PAHs and PAH sources of exposure have been consistently associated with breast cancer 
incidence. Although dioxin has been found to be associated with breast cancer incidence, results 
have been mixed; in a study of the 1976 Seveso, Italy industrial disaster, dioxin exposure 
measured in serum was associated with a RR of breast cancer incidence of 2.1 (95% CI=1.0-4.6) 
(Warner et al. 2002), but in a French study examining dioxin exposure from diet sources, no 
increased (0.4 pg/kg BW/d RR=1.00, 95% CI=0.96-1.05) risk of breast cancer was observed and 
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a decreased (quartile 4 versus quartile 1 RR=0.65, 95% CI=0.45-0.96) risk of ER-/PR- breast 
cancer was found (Danjou et al. 2015). In addition to PAHs being the most common contaminant 
across these sources of exposure, there is a plausible biologically mechanism linking PAHs and 
breast cancer (Gammon and Santella 2008). 
Inhalation, ingestion, and dermal contact are the possible routes by which PAHs can enter 
the body. Once in the body, PAHs induce expression of Phase I and Phase II metabolizing 
enzymes; the most important being CYPs 1A1, 1A2, 1B1, and 3A4 – the cytochrome P450 
(CYP) superfamily of enzymes – and epoxide hydrolase (Luckert et al. 2013). During Phase I 
metabolism, PAH parent compounds are activated to potentially estrogenic reactive dihydrodiol 
intermediates by cytochrome p540 enzymes (Kummer et al. 2008; Luckert et al. 2013; Menzie et 
al. 1992). The dihydrodiols are further oxidized into diol epoxides, which are able to covalently 
bond to exocyclic amino groups of guanine and adenine, forming stable adducts on DNA (Lin et 
al. 2001). The metabolites of the PAHs benzo[j]fluoranthene, benzo[b]fluoranthene, 
benzo[k]fluoranthene, benzo[a]pyrene and dibenzo[a,h]anthracene are known carcinogens able 
to form adducts in laboratory studies (Cavalieri et al. 1991; IARC 2010). The DNA adducts can 
cause mismatch in DNA replication and may alter promoter methylation or promoter binding, 
leading to inheritable DNA mutations or abnormal gene expression (Moorthy et al. 2015). Phase 
II metabolism includes conjugation of metabolites from Phase I – the hydroxyl-PAH metabolites 
– with small molecules catalyzed by specific enzymes such as sulfotransferases, UDP-glucoronyl 
transferases, and glutathione S-transferases. Sulfation and glucoronidation produces polar 
conjugates that are readily eliminated from the body through urine or feces. 
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Measurement of PAH exposure 
Measures of exposure 
Exposure to PAHs can be measured indirectly by questionnaire by querying study 
participants about exposures to the primary sources of PAH exposure. Questionnaires have the 
advantage of being able to elicit information about the lifetime while being relatively 
inexpensive. 
• Self-reported active smoking, including history, duration, and intensity of smoking, and 
exposure to environmental tobacco smoke are widely accepted and reliable measures of 
exposure (Krall et al. 1989). Smoking and ETS exposure can further be confirmed by 
measuring serum, hair, salivary, or urinary cotinine – the predominant metabolite of 
nicotine (Binnie et al. 2004). 
• Intake of grilled and smoked foods and methods of food preparation via questionnaire 
can be used to estimate the dietary contribution of PAHs (Gammon et al. 2002b; Steck et 
al. 2007). 
• Indoor air pollution can also be measured by questionnaire as a proxy for PAH exposure. 
In the LIBCSP, White and colleagues estimated exposure to PAHs by asking participants 
about their use of indoor stoves and fireplaces, which included the frequency of use, the 
type of material burned and the ages of participants during the time they lived in 
residences (White et al. 2014). 
Because PAHs are also found in ambient air, predominantly in particulate form, measures 
of exposure of PAHs also include those related to the measurement of air pollution (Agency for 
Toxic Substances and Disease Registry (ATSDR) 1995b). In particular, ambient air monitors 
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specifically designed to measure particulate matter combined with meteorological data and 
participant residential information can be useful for predicting a person’s exposure to particulate 
matter, and thus PAHs (Hu et al. 2013). Personal air monitors can also provide information about 
personal exposure to particulate matter/PAHs (Binková et al. 1995). 
Measures of internal dose 
PAHs can be measured in body tissues and blood, but the high cost of measuring PAH 
parent compounds in these media makes their use in epidemiologic studies challenging (Agency 
for Toxic Substances and Disease Registry (ATSDR) 1995a). Instead, urinary monohydroxy 
PAHs (OH-PAHs) are a less expensive biomarker alternative for assessing exposure to PAHs 
which show high correlations with PAH exposures. For example, feeding studies report 
significantly increased concentrations of urinary 1-hydroxypyrene levels after consumption of 
charbroiled meat (Kang et al. 1995; van Maanen et al. 1994). Urinary metabolites have the 
advantage of being able to account for PAH exposures from all sources and all routes of 
exposure, but concentrations will be reflective of recent exposures unless there is chronic 
exposure with little variation (Agency for Toxic Substances and Disease Registry (ATSDR) 
1995b). In the feeding studies, urinary metabolite concentrations returned to baseline within 24-
72 hours of cessation of exposure (Kang et al. 1995). Often, one or several PAH metabolites can 
be used as a surrogate for assessing exposure to several PAHs. For example, 1-hydroxypyrene, 
the urinary metabolite of pyrene, is often measured since levels show strong positive correlations 
with several environmental PAHs (Binnie et al. 2004; Ciarrocca et al. 2014). 
Measures of biologically effective dose 
The adducts formed between PAHs and deoxyribonucleic acid (DNA) and proteins 
(hemoglobin and albumin) can also be measured in various tissues to assess exposure to PAHs 
 31
(Agency for Toxic Substances and Disease Registry (ATSDR) 1995b); however, in population 
studies it is often too invasive or infeasible to sample specific tissues, for example breast tissue. 
Therefore, adducts measured in blood are often used as a surrogate for tissue adduct levels 
(Santella 1999). These measures have the disadvantage that adduct levels measured in blood may 
not accurately reflect those of the tissue of interest, but studies show strong correlations between 
formation of PAH-DNA adducts in peripheral white blood cells and exposures such as charcoal-
broiled beef consumption (Rothman et al. 1990; van Maanen et al. 1994) and ambient air 
pollution in occupational settings (Santella et al. 1993). Also, like the urinary metabolites, DNA-
adducts and protein-adducts reflect of short term exposures (Binková et al. 1995). These 
biomarkers of biologically effective dose, however, are objective measures not subject to 
participant recall of past exposures, unlike self-reported questionnaire data, and they represent a 
biologically relevant end-point associated with carcinogenesis. 
PAH Exposure Prevalence 
PAHs are highly ubiquitous exposures that occur in mixtures; human exposure to PAHs 
occurs on a daily basis (Agency for Toxic Substances and Disease Registry (ATSDR) 1995a). 
The National Health and Nutrition Examination Survey (NHANES) conducted by the Centers for 
Disease Control and Prevention (CDC) conducts biomonitoring of several urinary PAH 
metabolites. These measurements provide estimates of PAH exposure prevalence in a population 
based sample of the US. In one study (Xu et al. 2010) examining the associations between eight 
OH-PAHs (urinary metabolites of naphthalene, fluorene, phenanthrene, and pyrene) and 
prevalent cardiovascular disease among US adults (age ≥20 years) and utilizing two waves of 
NHANES data (2001-2002 and 2003-2004 data cycles) all eight OH-PAHs were above the limits 
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of detection (LOD) for >95% of participants. Median levels were lowest for the phenanthrene 
metabolite 2-hydroxyphenanthrene (61 ng/L in 2001-2002, 63.6 ng/L in 2003-2004) and highest 
for the naphthalene metabolite 2-hydroxynaphthalene (2,646 ng/L in 2001-2001 and 3,118.5 
ng/L in 2003-2004) (Xu et al. 2010). Median concentrations of 1-hydroxypyrene measured 46 
ng/L in 2001-2002 and 80.8 ng/L in 2003-2004 (Xu et al. 2010). For comparison, in (Table I-3), 
I provide the concentrations for adults (age ≥20 years) of the 10 measured OH-PAHs in National 
Health and Nutrition Examination Survey (NHANES) 2011-2012 (Centers for Disease Control 
and Prevention 2014a), the most recently available NHANES data, by smoking status. From 
these data, it is evident that all OH-PAH concentrations are elevated for smokers and those 
exposed to ETS compared to non-smokers/never-smokers. For 10 measured OH-PAHs, 
proportions above the LOD were at least 98% for all participants. Patterns of exposure are 
similar in 2011-2012 as compared to those reported by Xu and colleagues (Xu et al. 2010). 
PAH adducts and breast cancer 
Epidemiologic studies evaluating the association between DNA damage (adducts) and 
breast cancer incidence have been limited, but modest associations are observed. In the LIBCSP, 
the first large-scale case-control study designed to examine these associations among a large 
number of participants (n cases = 576 and n controls = 427), women with the highest levels of 
PAH-DNA adducts measured in peripheral blood samples collected shortly after breast cancer 
diagnosis were observed to have a 50% increased (>21.9357 adducts per 108 nucleotides versus 
non-detects OR=1.49, 95% CI=1.00-2.21) risk of breast cancer incidence (Gammon et al. 
2002b). These results were consistent with several previously reported, but much smaller, 
hospital-based studies. In the smaller studies, DNA adduct levels in the normal adjacent breast 
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tissue of breast cancer patients were higher than in the samples of the reduction mammoplasty 
controls (Li et al. 1996; Perera et al. 1995; Rundle et al. 2000). In the LIBCSP, after a second 
round of assays, the pooled (n cases = 873 and n controls = 941) OR for the association between 
detectable PAH-DNA adduct levels and breast cancer incidence was 1.29 (95% CI=1.05-1.58); 
the association was more pronounced among premenopausal (OR=1.56, 95% CI=1.09-2.23) than 
among postmenopausal (OR=1.14, 95% CI=0.88-1.47) women (Gammon et al. 2010). 
The LIBSCP has also been the first (and only) study to examine the associations between 
PAH-DNA adducts measured in peripheral blood and survival after breast cancer (Sagiv et al. 
2009) (see Table I-4). The hazard ratio for breast cancer specific mortality was elevated 
(HR=1.26, 95% CI=0.56-2.86) in relation to the highest quintile of PAH-DNA adduct levels, but 
estimates were imprecise and included the null (Sagiv et al. 2009). The magnitude of the 
association between PAH-DNA adducts and survival is suggestive of an association. As it is 
possible that the LIBCSP was underpowered to adequately address this issue, additional studies 
with a larger sample sizes or longer follow-up are needed to help clarify this association. 
Outdoor/Indoor Air pollution and breast cancer 
Several studies have suggested an association between outdoor, as well as indoor, air 
pollution and risk of breast cancer incidence. In an ecological study utilizing SEER data for 
estimates of breast cancer incidence and emission data from the US EPA for estimates of air 
pollution at the US national level from 1973-2007, similar trends were observed for breast cancer 
incidence and for nitrogen dioxides with an offset of 20 years (Chen and Bina 2012). In a second 
US ecological study published in the same year, emissions of nitrogen oxides, carbon monoxide, 
sulfur dioxide, and volatile organic compounds – PAH correlates (Tham et al. 2008) – were 
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found to be positively associated with breast cancer incidence (r=0.89, 0.82, 0.71, and 0.68, 
respectively) (Wei et al. 2012). In the LIBCSP, using a historical geographic exposure model, 
Mordukhovich and colleagues estimated the association between long-term, individualized 
residential traffic benzo[a]pyrene exposure estimates, as a proxy for exposure to particulate 
traffic PAHs, and breast cancer incidence. Consistent with prior studies of traffic-related air 
pollution (Crouse et al. 2010) including a study conducted on Long Island, NY (Lewis-Michl et 
al. 1996) and a study using similar methodology (Nie et al. 2007), in the LIBCSP women with 
vehicular traffic estimates in the top 5% had a 44% increased (OR=1.44, 95% CI=0.78-2.68) 
odds of breast cancer incidence and the magnitude of the association was more pronounced 
(OR=1.67, 95% CI=0.91-3.05) among women with ER-/PR- tumors (Mordukhovich et al. 2016). 
The LIBCSP has been the first study to examine the association between use of indoor 
stoves/fireplaces, an indicator of indoor air pollution and breast cancer incidence (White et al. 
2014). In their study, White and colleagues reported a 42% increased (OR=1.42, 95% CI=1.11-
1.84) risk of breast cancer incidence among women who reported ever burning synthetic logs, 
but not among women who reported ever burning wood alone (White et al. 2014). 
Only one study has examined the associations between outdoor air pollution and breast 
cancer survival (Hu et al. 2013) and no studies have examined the association between indoor air 
pollution in relation to survival (see Table I-4). In their study, using SEER and US EPA data 
from 1999-2009, Hu and colleagues observed an increased risk of breast cancer-specific 
mortality among women exposed to high levels of particulate matter less than 10 μm in diameter 
(PM10) (PM10 ≥28.82 μg/m3 versus <23.09 μg/m3 HR=1.44, 95% CI=1.18-1.76) and high levels 
of PM2.5 (PM2.5 ≥15.04 μg/m3 versus <11.64 μg/m3 HR=1.76, 95% CI=1.24-2.49) (Hu et al. 
2013). Additional studies are needed examining outdoor or indoor air pollution in relation to 
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both breast cancer incidence and survival. 
Post-diagnosis changes in outdoor/indoor air pollution and breast cancer 
No studies have examined whether post-diagnosis changes in exposure to outdoor or 
indoor air pollution are associated with survival after breast cancer diagnosis. However, outdoor 
and indoor air pollution exposures, which account for a relatively smaller proportion of PAH 
exposure (Skupińska et al. 2004), are unlikely to change drastically after diagnosis. Additionally, 
in the LIBCSP, on which this dissertation is based, the prevalence of the outdoor measures that 
were most strongly associated with breast cancer incidence were comparatively low (<5% for 
outdoor air pollution) (White, 2015). 
Smoking-related PAH exposures and breast cancer 
Active smoking 
Tobacco smoke is known to contain over 7,000 chemicals including 69 known 
carcinogens such as benzene, arsenic and heavy metals, formaldehyde, vinyl chloride, N-
Nitrosamines, and PAHs (IARC 2004); at least 539 PAHs and PAH-derivatives have been 
identified in tobacco smoke including the highly carcinogenic PAHs benzo[a]pyrene and 
dibenzo[a,l]pyrene (Rodgman et al. 2000). Therefore, it is not surprising that the association 
between active cigarette smoking and breast cancer incidence has been extensively studied; at 
least 130 epidemiologic studies have examined smoking in relation to breast cancer incidence, 
yet there is no scientific consensus (Gaudet et al. 2013). In addition to differences in study design 
and differences in measurement assessment of smoking throughout the lifetime, the conflicting 
results of active smoking may in part be explained both the carcinogenic and estrogenic effects 
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of cigarette smoke constituents on breast epithelial cells (Meek and Finch 1999; Rodgman et al. 
2000) and the anti-estrogenic effects of smoking on menstrual function which can result in an 
earlier initiation of menopause (Baron et al. 1990; Windham et al. 1999). In their meta-analysis 
(Gaudet et al. 2013) of 15 cohort studies totaling 991,100 women of which 31,198 developed 
breast cancer, however, Gaudet and colleagues showed that active cigarette smoking was 
associated with a 1.12 (95% CI=1.08, 1.16) increase in breast cancer incidence. Additionally, the 
association was stronger among women who initiated smoking before a first birth (HR=1.21, 
95% CI=1.14-1.28) and among women who developed ER+ tumors (HR=1.20, 95%: 1.00-1.45 
(Gaudet et al. 2013). 
Examining active cigarette smoking in relation to survival after breast cancer has 
received much less scientific attention (Table I-4), despite the potential of smoking to adversely 
affect health outcomes by increasing the risk of treatment complications (Zhan et al. 2007), 
recurrence (Bishop et al. 2014), and second primary cancers (Neugut et al. 1994) via suppression 
of the immune system (Sopori 2002), increasing oxidative stress (Danielsen et al. 2011), and 
disrupting the endocrine system (Bekki et al. 2013; Fertuck et al. 2001; Sievers et al. 2013). Most 
studies of survival after breast cancer conducted to date show that active smoking at diagnosis is 
associated with an increased risk of all-cause and breast cancer-specific mortality; hazard ratios 
range from 1.16 to 2.63 and from 1.73 to 2.08, for all-cause and breast cancer-specific mortality, 
respectively (Bérubé et al. 2014; Braithwaite et al. 2012; Calle et al. 1994; Dal Maso et al. 2008; 
Hellmann et al. 2010; Holmes et al. 1999, 2007; Manjer 2000; Passarelli et al. 2016; Pierce et al. 
2014; Tominaga et al. 1998; Warren et al. 2012; Yu et al. 1997). 
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Environmental Tobacco Smoke (ETS) 
Exposure to environmental tobacco smoke (ETS) (U.S. Department of Health and Human 
Services 2006)– which has a nearly identical qualitative composition, but a total PAH content 
lower than sidestream (released by the cigarette) smoke (Lodovici et al. 2004; U.S. Department 
of Health and Human Services 2006). – has also been extensively examined in relation to breast 
cancer (Rodgman et al. 2000). In a meta-analysis (Khuder and Simon 2000) of three cohort 
studies and eight case-control studies published from 1984-2000, a relative risk of breast cancer 
incidence of 1.41 (95% CI=1.14-1.75) was observed among women who reported ever exposure 
to environmental tobacco smoke, although there was significant heterogeneity between studies. 
In the LIBCSP, an increased OR (OR=2.10, 95% CI=1.47-3.02) of developing breast cancer was 
found among nonsmokers who lived with a smoking spouse for more than 27 years (Gammon et 
al. 2004). Additionally, among women who developed ER+/PR+ tumors, the OR of breast cancer 
incidence was 1.42 (95% CI=1.00-2.00) for women who reported ever exposure to both active 
and passive smoke compared to those who were never exposed. Bing ever exposed to passive 
smoke only was slightly, but not significantly associated with ER+/PR+ breast cancer incidence 
(OR=1.15, 95% CI=0.80-1.65) (Gammon et al. 2004). In a more recently published meta-
analysis of 24 studies published through January 2008 and the Million Women Study, in the 
eight prospective studies, the relative risk of breast cancer incidence was not elevated (RR=0.99, 
95% CI=0.93-1.05) in relation to ever exposure to passive smoke, but the 17 case-control studies 
showed a 21% (RR=1.21, 95% CI=1.11-1.32) elevated risk in breast cancer incidence suggesting 
that there could be systematic differences in the reporting of past exposures between cases and 
controls (Pirie et al. 2008). 
To date, few studies (Boone et al. 2015; Kakugawa et al. 2015; Sagiv et al. 2007; 
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Wartenberg et al. 2000) have examined whether exposure to ETS is associated with survival 
after breast cancer (Table I-4) and most (Kakugawa et al. 2015; Sagiv et al. 2007; Wartenberg et 
al. 2000) have found no increased risk of mortality. One group of collaborators (Boone et al. 
2015) reported a two-fold (HR=2.12, 95% CI=1.24-3.63) increased risk of breast cancer-specific 
mortality among women with at-diagnosis moderate and/or high (>10 hours per week) recent 
ETS exposure among never smokers. 
The paradoxical results of a no-to-weak association between active smoking and the 
stronger association between passive smoking and breast cancer incidence may be explained by 
the differences in routes of exposure. It is hypothesized that most of the breast carcinogenic 
damage of cigarettes may be coming from vapor phase constituents in cigarette smoke (Wells 
1991). Because up to 70% of tar, a source of PAHs, in ETS is in the vapor phase, whereas all of 
the tar in direct smoking is in the particulate phase, ETS may be a more important source of 
exposure to carcinogens since particulate smoke is cleared into the mouth and swallowed, but 
vapor phase constituents are inhaled and absorbed into the bloodstream and into the lymph 
system (Wells 1991). 
Post-diagnosis changes in smoking and breast cancer survival 
To date, only one recently published study (Passarelli et al. 2016) has examined whether 
changes in active smoking after breast cancer are associated with survival. This is of particular 
importance since it is estimated that approximately 70% of smokers diagnosed with breast cancer 
continue smoking after diagnosis (Westmaas et al. 2015), and hormone withdrawal can rapidly 
influence the growth of hormone-sensitive tumors (Powles and Hickish 1995; Prasad et al. 
2003). In their study, Passarelli and colleagues report elevated hazard ratios for women who 
continued smoking after breast cancer for all-cause (HR=2.57, 95% CI=2.06-3.21, versus 2.30, 
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95% CI=1.56-3.39, respectively) and breast cancer (HR=1.73, 95% CI=1.13-2.60, versus 
HR=1.60, 95% CI=0.79-3.23, respectively) mortality. No studies have examined whether ETS 
and changes in ETS are associated with survival following breast cancer. 
Diet-related PAH exposures and breast cancer 
Up to 70% of PAH exposure for a non-smoking person can be attributed to diet (Phillips 
1999; Skupińska et al. 2004). PAH-containing foods include barbecued, grilled, broiled, and 
smoked meats; roasted, baked, or fried foods; and breads, cereals, and grains, and vegetables 
(IARC 2010). Thus, PAHs in food arise from two sources, food-preparation and environmental 
contamination – although food preparation methods such as charring or barbecuing meat over 
charcoal, wood, or an open flame introduces far more PAHs than contamination (Larsson et al. 
1983). During grilling and barbecuing, PAHs are generated through pyrolysis of meat products 
when fat drips from the meat onto a heated surface and produces smoke that coats the food with 
the compounds (Larsson 1986). The type of cooking, cooking temperature, time, amounts of fat, 
and oil, and proximity to the flame influence the formation of PAHs (Larsson et al. 1983; Perez 
2002). Drying techniques used for cereal preservation such as combustion gas heating and 
smoking leads to an increase in the concentration of PAHs (Ramesh et al. 2004). Environmental 
contamination of plant foods occurs through deposition on leafy plants with high surface area; 
contamination of livestock occurs through the consumption of contaminated pastures and 
vegetation; contamination of fish and shellfish occurs through contamination of fresh and coastal 
waters. 
Because of the importance of diet as a primary source of exposure to PAHs, several 
epidemiologic studies have investigated the association between intake of high-temperature 
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cooked meat and cancer incidence, including breast cancer. Studies have consistently shown an 
increased risk of breast cancer incidence among women who consume the largest quantities of 
well-done meat (Dai et al. 2002; De Stefani et al. 1997; Iscovich et al. 1989; Knekt et al. 1994; 
Sinha et al. 2000; Steck et al. 2007; Zheng et al. 1998). For example, in the Iowa Women’s 
Health Study of more than 40,000 women aged 55-69 who completed a mailed questionnaire in 
1986, women who consumed well-done hamburger, beef steak and bacon had a 4.62 increased 
risk of breast cancer incidence compared to women who consumed the meat rare or medium 
done (Zheng et al. 1998). In a study conducted in China, a 92% increased (OR=1.92, 95% 
CI=1.30-2.83) risk of breast cancer was observed among women with high intake of well-done 
red meat and a 52% increased (OR=1.52, 95% CI=1.05-2.22) risk for high intake of well-done 
freshwater fish (Dai et al. 2002). In hospital-based case-control study of Uruguayan women – a 
population exposed to a diet with large amounts of red beef – the OR of breast cancer incidence 
was 2.26 (95% CI=1.24-4.12) among women with meat intake in the highest quartile relative to 
women with meat intake in the lowest quartile (De Stefani et al. 1997). 
Several studies have specifically examined whether the intake of grilled and smoked meat 
is associated with increased risk of breast cancer incidence (Han et al. 2004; Lee et al. 2012; 
Mourouti et al. 2015; Steck et al. 2007). Most studies report an elevated odds of breast cancer 
(ORs ranging from 1.47-2.58) among women who consume the highest levels of grilled and 
smoked meats compared to women who consume the lowest levels (Han et al. 2004; Lee et al. 
2012; Steck et al. 2007). In the LIBCSP a modest increased risk of breast cancer was observed 
among postmenopausal, but not premenopausal, women consuming the most grilled or 
barbecued and smoked meats over the life course (OR=1.47; 95CI: 1.12-1.92), which was similar 
for ER+/PR+ and ER-/PR- tumors (Steck et al. 2007). Although no significant association was 
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observed in the study by Mourouti and colleagues and the ORs for the association between 
intake of grilled and smoked meats and breast cancer incidence were not reported, cases were 
more likely to consume grilled meat at least once per week (26% versus 21%). In their study, 
adjustment for BMI may have resulted in over-adjustment since BMI could be a potential 
mediator: grilling and smoking meats results in lower fat intake compared to other cooking 
methods such as pan-frying and deep-frying which often use hydrogenated cooking oils – one of 
the major sources of trans-fatty acids (WC et al. 1993). Additionally, intake of grilled and 
smoked meats could also result in increased fat intake depending on the fat content of the meat 
(Rock et al. 2012). 
To date, no studies have examined whether food sources of PAH-containing foods, 
particularly those that have been grilled or smoked, influence survival after breast cancer. 
Post-diagnosis changes in dietary intake of PAH-containing foods 
Observational studies suggest that women with a prior diagnosis of breast cancer report 
more healthful diets including diets high in fruits and vegetables and fiber and low in high-fat 
foods after diagnosis (Salminen et al. 2000; Thomson et al. 2002). In the Women’s Healthy 
Eating and Living Study of 3,084 breast cancer survivors (women diagnosed, on average, in the 
past 24 months before study enrollment), 91% of women reported consuming grilled foods in the 
12 months before diagnosis. Approximately 23% reported decreasing and 11% reported 
increasing their intake of grilled foods since diagnosis (Thomson et al. 2002). How dietary 
changes related to grilled and smoked foods after breast cancer diagnosis influence survival, 
however, has not been examined in any epidemiologic study. 
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Summary 
Many of the established epidemiologic risk factors for breast cancer incidence are closely 
related to lifetime hormone exposures and in particular, estrogen exposure. These risk factors 
include, primarily, endogenous (reproductive factors such as parity, breastfeeding, menarche and 
menopause and obesity) as well as exogenous (oral contraceptive and hormone therapy use) 
sources of hormone exposure, which highlight the central role of estrogens and other hormones 
in directly and indirectly influencing the development of breast cancer. Other established factors 
such as age, family history, and genetics highlight the molecular, cellular, and biological 
processes that lead to the development of cancer. Other factors such as obesity, physical activity, 
alcohol use and NSAID use underscore the importance of endogenous estrogen exposure, but 
also highlight other hypothesized mechanisms of carcinogenesis, including insulin resistance, 
oxidative stress and inflammation. 
Several of these risk factors have also received considerable scientific attention in 
relation to survival after breast cancer diagnosis, though most have only received limited 
attention. Existing survival studies, however, provide support that exposure to estrogens and 
estrogen-like compounds shortly before diagnosis and after diagnosis also have the ability to 
influence prognosis since they have the potential to induce cell proliferation in hormone-
sensitive tissues. For example, ever using oral contraceptives is not associated with breast cancer 
mortality, but current or recent use of OCs is associated with an increased risk of breast cancer 
mortality; obesity, which leads to increased levels of circulating estrogens in postmenopausal 
women, at diagnosis and post-diagnosis are also associated with an increased risk of breast 
cancer mortality. Physical activity, which contributes to a reduced lifetime exposure to sex 
steroid hormones, is inversely associated with breast cancer mortality with increasing magnitude 
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of association with recreational PA closer to diagnosis and the highest benefit among women 
who meet PA guidelines post-diagnosis. Therefore, it is plausible that environmental chemicals, 
particularly those with the ability to mimic estrogens and thus promote tumor growth and 
metastases, such as polycyclic aromatic hydrocarbons, may also influence prognosis. By 
examining the two primary non-occupational sources of exposure to PAHs, active smoking and 
diet, results of these studies of this dissertation we can better understand whether these and other 
similar chemicals influence survival. Additionally, documenting the relationships between 
changes in these smoking and diet-related behaviors and survival would strengthen smoking 
cessation efforts and help inform dietary intake guidelines among breast cancer patients. Given 
the high burden of breast cancer in the United States, this study has the potential to affect more 
than 3.1 million women living with breast cancer (American Cancer Society 2015a; National 
Cancer Institute 2016).  
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Table I-1. Summary of breast cancer risk and prognostic factors. 
Risk/Prognostic Factor Breast Cancer Incidence Breast Cancer Survival 
Age Incidence rate is highest during the 
reproductive years until menopause 
when the rate slows, but continues to 
increase.  
There is poor survival among women 
with diagnosis at a younger age (<35 
years) and older age (>80 years) 
compared to women aged 40-49 years 
at diagnosis. 
Reproductive factors   
Menarche and Menopause 
 
Incidence increased by 5% for each 
year younger at menarche and the risk 
increases by 3% for each year older at 
menopause. 
Menopausal status at diagnosis does 
not appear to be associated with 
mortality; however, studies report 
survival benefits among women who 
develop drug-induced amenorrhea. 
Parity, age at first and 
multiple pregnancies 
There is an increased risk among 
nulliparous women and a long-term 
reduced risk among parous women, 
which decreases with increasing 
number of full-term births.  
Higher parity has been associated with 
worse survival, but few studies have 
examined this association. 
Breastfeeding The risk of breast cancer decreases by 
4%-5% for every 12 month of 
breastfeeding compared to no 
breastfeeding. 
Results of studies examining 
breastfeeding and breast cancer 
mortality have been mixed, but few 
have examined this association. 
Exogenous hormone use   
Oral contraceptive (OC) 
use 
The risk of premenopausal breast 
cancer is increased by 29% among 
parous and by 24% among nulliparous 
women who ever used OCs. Risk is 
further increased (44%) among women 
who used OCs before their first full-
term pregnancy compared to women 
who use OCs after their first full-term 
pregnancy. 
OC use is contraindicated in women 
with a history of breast cancer, but 
epidemiologic evidence supporting this 
is lacking. Ever using OCs is not 
associated with an increased risk of 
breast cancer mortality. However, 
current or recent use of OCs appears to 
increase the risk of breast cancer 
mortality.  
Hormone replacement 
therapy  (HRT) use 
HRT use is associated with a 35% 
increased risk of breast cancer 
incidence for up to 5 years after 
cessation of use. Longer duration (≥15 
years) is associated with a 58% 
increased risk in breast cancer 
incidence. 
HRT use is contraindicated in women 
with a history of breast cancer, but 
epidemiologic evidence supporting this 
is lacking; studies report an inverse 
association between HRT use at 
diagnosis and breast cancer mortality.  
Genetics   
Race  White women experience the highest, 
but similar rates of breast cancer 
incidence. 
Mortality rates are highest among 
Black women. 
Family history Women with a family history of breast 
cancer diagnosed in any relative have a 
90% increased risk of developing 
breast cancer.  
Inconclusive and current evidence does 
not support worse breast cancer 
survival of BRCA1/2 mutation carriers   
Diet A daily intake of 100g of alcohol is 
associated with a RR of 2.71 (95% 
CI=2.33-3.08). 
No consistent associations between 
fruit and vegetable intake or fat intake 
and risk of breast cancer. 
More than 20g/d of alcohol is 
associated with a 14% increased risk of 
breast cancer mortality. 
There is accumulating evidence of an 
association between pre-, at-, and post-
diagnosis dietary fat intake and breast 
cancer survival. 
Other lifestyle factors   
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Risk/Prognostic Factor Breast Cancer Incidence Breast Cancer Survival 
NSAID use NSAID use is inversely associated 
(OR=0.85, 95% CI=0.75-0.89) with 
breast cancer incidence. 
At- and post-diagnosis NSAID use is 
associated with a reduced risk (HRs 
range: 0.36-0.53) of breast cancer 
mortality. De novo post-diagnosis use 
of aspirin does not appear to be 
associated with breast cancer mortality. 
Obesity Postmenopausal women have a 58% 
increased risk while premenopausal 
women have a slight reduced risk of 
breast cancer incidence. 
Women who are obese at diagnosis 
have a 33% increased risk of breast 
cancer mortality as compared to non-
obese women. 
Physical activity (PA) PA is associated with a 15%-20% 
reduced risk of breast cancer incidence. 
Evidence is strong for postmenopausal 
breast cancer. 
Lifetime and recent pre-diagnosis and 
post-diagnosis recreational PA are 





Table I-2. Evidence of estrogenic and anti-estrogenic activity of selected PAH compounds 
by PAH exposure source. 
  
PAH Exposure Source Relevant PAH Compounds Estrogenica Anti-estrogenica 
Synthetic Log Burning Chrysene/triphenylene + + 
 Benzo[e]pyrene - + 
 Retene no evidence no evidence 
Vehicular traffic Benzo[g,h,i]perylene - - 
 Pyrene - - 
 Fluoranthene + - 
 Phenanthrene - - 
Tobacco smoke Benzo[a]pyrene + + 
 Naphthalene  no evidence no evidence 
 Pyrene - - 
 Fluoranthene + - 
Grilled/smoked meat Benzo[a]pyrene + + 
 Phenanthrene - - 
 Pyrene - - 
  Fluoranthene + - 
Note: Table is adapted from White 2016. 
aEvidence from Arcaro 1999; Chaloupka 1992;  Fertuck 2001; Gozgit 2004; Kummer 2008; van Lipzig 2004;  
Vondracek 2002. 
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Table I-3. Median Percentiles of OH-PAHs in NHANES 2011-2012 among participants 









ng/L LOD n P50  n P50  n P50 
Naphthalene metabolites          
1-hydroxynaphthalene (ng/L) 42 1310 1186.00  61 1588.00  332 9879.00 
2-hydroxynaphthalene (ng/L) 44 1310 3750.50  61 4495.00  332 13478.00 
Fluorene metabolites          
2-hydroxyfluorene (ng/L) 10 1310 177.00  61 310.00  332 1249.00 
3-hydroxyfluorene (ng/L) 10 1306 61.00  61 117.00  332 665.50 
9-hydroxyfluorene (ng/L) 10 1310 208.50  61 409.00  332 666.50 
Phenanthrene metabolites          
1-hydroxyphenanthrene (ng/L) 10 1310 113.00  61 127.00  332 200.50 
2-hydroxyphenanthrene (ng/L) 10 1307 56.00  61 75.00  332 128.50 
3-hydroxyphenanthrene (ng/L) 10 1309 54.00  61 81.00  332 159.50 
4-phenanthrene (ng/L) 10 1307 18.00  60 21.00  331 42.00 
Pyrene metabolite          
1-hydroxypyrene (ng/L) 10 1307 87.00  61 108.00  332 242.50 









ng/g creatinine LOD n P50  n P50  n P50 
Naphthalene metabolites          
1-hydroxynaphthalene (ng/L) 42 1309 1160.98  61 1600.00  332 10015.21 
2-hydroxynaphthalene (ng/L) 44 1309 3788.71  61 4408.68  332 13060.87 
Fluorene metabolites          
2-hydroxyfluorene (ng/L) 10 1309 183.33  61 243.37  332 1257.26 
3-hydroxyfluorene (ng/L) 10 1305 62.50  61 101.56  332 657.50 
9-hydroxyfluorene (ng/L) 10 1309 222.69  61 369.32  332 671.20 
Phenanthrene metabolites          
1-hydroxyphenanthrene (ng/L) 10 1309 119.21  61 117.31  332 197.81 
2-hydroxyphenanthrene (ng/L) 10 1306 59.00  61 69.34  332 121.68 
3-hydroxyphenanthrene (ng/L) 10 1308 54.55  61 88.15  332 156.63 
4-phenanthrene (ng/L) 10 1306 20.22  60 20.36  331 38.64 
Pyrene metabolite          
1-hydroxypyrene (ng/L) 10 1306 94.12  61 111.43  332 247.36 
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Table I-4. Studies examining the associations between PAH sources of exposure and 
survival after breast cancer. 
Citation 
Year N Population Exposure Assessment/Follow-up Covariate-Adjusted Results 
PAH-DNA Adducts 
Sagiv SK, Gaudet MM, Eng SM, et al. Polycyclic aromatic hydrocarbon-DNA adducts and survival among women with breast cancer. Environ 
Res. 2009;109:287–91. 
2009 722 
Population-based study of 
women residing in Long Island, 
NY diagnosed with invasive 
disease in 1996-1997  
PAH-DNA adducts assayed from non-
fasting blood samples using competitive 
ELISA 
All-cause mortality 
Quintile 1: Ref 
Quintile 5: HR=0.82 (95% CI=0.44-1.52) 
 
Breast cancer-specific mortality 
Quintile 1: Ref 
Quintile 5: HR=1.26 (95% CI=0.56-2.86) 
97 deaths (54 brca) determined from the 
NDI. Median follow-up of 5.8 yrs. 
(range: 0.4-7.4 yrs.) 
Outdoor/Indoor air pollution 
Hu H, Dailey AB, Kan H, Xu X. The effect of atmospheric particulate matter on survival of breast cancer among US females. Breast Cancer Res 
Treat. 2013;139(1):217–26. 
2013 255,128 
Female breast cancer cases from 
1999-2009 SEER 
EPA-linked county estimates of PM10 
and PM2.5 
Breast cancer-specific mortality  
PM10 
Tertile 1: Ref 
Tertile 2: HR=0.96 (95% CI=0.64-1.44) 
Tertile 3: HR=1.44 (95% CI=1.18-1.76) 
 
PM2.5 
Tertile 1: Ref 
Tertile 2: HR=1.24 (95% CI=0.79-1.94) 
Tertile 3: HR=1.76 (95% CI=1.24-2.49) 
Number of deaths not reported. From the 
KM survival curves ~10% of cases died. 
Median follow-up time not reported 
(range: 0-10+ yrs.) 
Grilled and smoked foods 
[No studies] 
Active smoking and environmental tobacco smoke exposure 
Passarelli MN, Newcomb PA, Hampton JM, et al. Cigarette smoking before and after breast cancer diagnosis: mortality from breast cancer and 
smoking-related diseases. J Clin Oncol. 2016;34:1-8. 
2016 4,562 
Participants of the Collaborative 
Breast Cancer and Women’s 
Longevity Study, a population-
based prospective observational 
study conducted in Wisconsin, 
New Hampshire, and 
Massachusetts 
Smoking assessed by self-report by 
mailed questionnaire 
All-cause mortality 
Never smoker: Ref. 
Former smoker: HR=1.11 (95% CI=1.05-1.17) 
Current smoker: HR=1.67 (95% CI=1.57-1.79) 
 
Never/Never smoker: Ref. 
Former/Former smoker: HR=1.45  
(95% CI=1.24-1.69) 
Current/Former smoker: HR=2.34  
(95% CI=1.85-2.96) 
Current/Current smoker: HR=2.57  
(95% CI=2.06-3.21) 
 
Breast cancer-specific mortality 
Never smoker: Ref. 
Former smoker: HR=0.93 (95% CI=0.85-1.02) 
Current smoker: HR=1.25 (95% CI=1.13-1.37) 
 
Never/Never smoker: Ref. 
Former/Former smoker: HR=0.98  
(95% CI=0.72-1.34) 
Current/Former smoker: HR=1.15  
(95% CI=0.70-1.90) 
Current/Current smoker: HR=1.72  
(95% CI=1.13-2.60) 
6,778 deaths (2,894 brca) determined by 
linkage to the NDI. Median follow-up of 
12 years. 
Boone SD, Baumgartner KB, Baumgartner RN, et al. Active and passive cigarette smoking and mortality among Hispanic and non-Hispanic 
white women diagnosed with invasive breast cancer. Ann Epidemiol. 2015;25(11):824-831. 
2015 2,218 
Participants of the Breast 
Cancer Health Disparities 
Study (BCHDS) 
Smoking assessed by self-report by 
interviewer-administered questionnaire 
All-cause mortality 
Never smoker: Ref. 
Ever smoker: HR=1.21 (95% CI=0.99-1.47)  
Former smoker: HR=1.00 (95% CI=0.79-1.26) 
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Citation 
Year N Population Exposure Assessment/Follow-up Covariate-Adjusted Results 
445 deaths (243 brca) determined by 
linkage to statewide cancer registries. 
Median follow-up of 10.6 years. 
Current smoker: HR=1.68 (95% CI=1.30-2.17) 
 
Among recent passive smoke exposed non-
smokers 
No ETS: Ref. 
Low: HR=1.29 (95% CI=0.86-1.93) 
Moderate/High: HR=1.83 (95% CI=1.17-2.88)  
 
Breast cancer-specific mortality 
Never smoker: Ref. 
Current smoker: HR=1.55 (95% CI=1.11-2.16) 
 
Among recent passive smoke exposed non-
smokers 
No ETS: Ref. 
Low: HR=1.43 (95% CI=0.89-2.31) 
Moderate/High: HR=2.12 (95% CI=1.24-3.63)  
 
Izano M, Satariano WA, Hiatt RA, Braithwaite D. Smoking and mortality after breast cancer diagnosis: the health and functioning in women 
study. Cancer Med. 2015;4(2):315–24. 
2015 975 
Participants of the US Health 
and Functioning in Women 
(HFW) Study 
Smoking assessed by self-report by 
questionnaire once 2-4 months after breast 
cancer diagnosis 
All-cause mortality 
Never smoker: Ref. 
Current smoker: HR=2.45 (95% CI=1.81-3.32) 
Former smoker: HR=1.47 (95% CI=1.13-1.90) 
 
Breast cancer-specific mortality 
Never smoker: Ref. 
Current smoker: HR=1.38 (95% CI=0.99-1.91) 
Former smoker: HR=0.94 (95% CI=0.70-1.26) 
 
436 deaths (317 brca) determined by vital 
status follow-up from the Metropolitan 
Detroit Cancer Surveillance System at the 
Michigan Cancer Foundation. Median 
follow-up of 11.0 yrs. (IQ range: 4.5-22.4 
yrs.) 
Kakugawa Y, Kawai M, Nishino Y, et al. Smoking and survival after breast cancer diagnosis in Japanese women: A prospective cohort study. 
Cancer Sci. 2015. 
2015 871 
Female patients aged 21 years 
or over at the Miyagi Cancer 
Center Hospital (MCCH) 
Smoking assessed by self-administered 
questionnaire completed at admission 
All-cause mortality 
 
 Premenopausal women 
Never smoker: Ref. 
≤21.5 years duration: HR=0.95 (95% CI=0.35-
2.63) 
>21.5 years duration: HR=3.09 (95% CI=1.17-
8.20) 
Postmenopausal women 
Never smoker: Ref. 
≤21.5 years duration: HR=0.72 (95% CI=0.22-
2.35) 
>21.5 years duration: HR=0.53 (95% CI=0.20-
1.36) 
 
Breast cancer-specific mortality 
 
Premenopausal women 
Never smoker: Ref. 
≤21.5 years duration: HR=1.10 (95% CI=0.39-
3.15) 
>21.5 years duration: HR=3.35 (95% CI=1.22-
9.23) 
Postmenopausal women 
Never smoker: Ref. 
≤21.5 years duration: HR=0.72 (95% CI=0.22-
2.35) 
>21.5 years duration: HR=0.53 (95% CI=0.20-
1.36) 
 
170 deaths (132 brca) determined by 
reference to the MCCH Cancer Registry 
and active follow up. 
Median follow-up of 6.7 yrs. (range: 0-13 
yrs.) 




Year N Population Exposure Assessment/Follow-up Covariate-Adjusted Results 
2015 127,754 
Data were obtained from the 
linkage of two population- 
based databases, the Florida 
cancer data system (FCDS) and 
the Agency for Health Care 
Administration (AHCA) with 
the U.S. census to form a 
dataset of Floridian women 
diagnosed and treated for breast 
cancer from 1996–2007 
Smoking assessed by self-report 
All-cause mortality 
Never smoker: Ref. 
Current smoker: HR=1.33 (95% CI=1.28-1.38) 
Former smoker: HR=1.09 (95% CI=1.06-1.13) 
 
38,054 deaths defined as the time from 
diagnosis to death or last treatment 
encounter. 
Mean follow-up 4.9 yrs. (range: 0-15.0 
yrs.) 
Bérubé S, Lemieux J, Moore L, Maunsell E, Brisson J. Smoking at time of diagnosis and breast cancer-specific survival: new findings and 
systematic review with meta-analysis. Breast cancer Res. 2014;16(2):R42. 
2014 5,892 
Women with invasive breast 
cancer treated in one Canadian 
center (1987 to 2008).  
Smoking assessed by review of hospital 
records 
All-cause mortality 
Never smoker: Ref. 
Current smoker: HR=1.38 (95% CI=1.20-1.60) 
Former smoker: HR=1.17 (95% CI=1.01-1.34) 
 
Breast cancer-specific mortality 
Never smoker: Ref. 
Current smoker: HR=1.15 (95% CI=0.97-1.37) 
Former smoker: HR=1.04 (95% CI=0.88-1.24) 
 
Breast cancer-specific mortality (meta-analysis) 
Never smoker: Ref. 
Current smoker: HR=1.33 (95% CI=1.12-1.58) 
1,408 deaths were documented, of which 
953 (67.7%) were from breast cancer, 441 
(31.3%) from other causes and 14 (1.0%) 
from unknown causes. 41,255 person-years 
of follow-up (maximum: 22 years) 
Pierce JP, Patterson RE, Senger CM, et al. Lifetime cigarette smoking and breast cancer prognosis in the After Breast Cancer Pooling Project. J 
Natl Cancer Inst. 2014;106(1):1–8. 
2014 9,975 
three US cohorts included in 
the ABCPP were the Women’s 
Healthy Eating and Living 
(WHEL) Study, the Life After 
Cancer Epidemiology (LACE) 
Study, and the Nurses’ Health 
Study (NHS) 
Smoking assessed by self-report on 
average 2 years after breast cancer 
diagnosis. 
All-cause mortality 
Never smoker: Ref. 
Current smoker: HR=2.17 (95% CI=1.85-2.54) 
Former smoker ≥35pack-yrs: HR=1.68 (95% 
CI=1.44-1.96) 
 
Breast cancer-specific mortality 
Never smoker: Ref. 
Current smoker: HR=1.61 (95% CI=1.28-2.03) 
Former smoker ≥35pack-yrs: HR=1.54 (95% 
CI=1.24-1.91) 
1,803 deaths (1,059 brca) assessed by 
periodic reviews of the Social Security 
Death Index and the National Death Index 
for NHS and WHEL and by Kaiser 
Permanente North California electronic 
data sources for LACE. 
Median follow-up of 11.1 yrs. 
Braithwaite D, Izano M, Moore DH, et al. Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic 
review. Breast Cancer Res Treat. 2012;136(2):521–533. 
2012 2,258 
LACE Cohort of women 
diagnosed with stage I, II, IIIa, 
breast cancer from 1997-2000 
in the Kaiser and Utah Cancer 
registries or in the WHEL 
Study  
Smoking assessed by self-report on 
average 23 (range: 11-39) mos. after breast 
cancer diagnosis.  
All-cause mortality 
Never smoker: Ref 
Current smoker: HR=2.63 (95% CI=1.93-3.58) 
Former smoker: HR=1.28 (95% CI=1.05-1.56) 
 
Breast cancer-specific mortality 
Never smoker: Ref 
Current smoker: HR=2.01 (95% CI=1.27-3.18) 
Former smoker: HR=1.24 (95% CI=0.94-1.64) 
485 deaths (244 brca) determined by 
Kaiser HER, mailed questionnaires, or by 
telephone. 
Median follow-up of 12.3 yrs. (range: 1.5-
15.5 yrs.). 
Warren GW, Kasza KA, Reid ME, Cummings KM, Marshall JR. Smoking at diagnosis and survival in cancer patients. Int J cancer. 
2012;132(2):401–10. 
2012 882 
Patients who received 
diagnosis, consultation or 
treatment at Roswell Park 
Cancer Institute (RPCI) 
between 1982 and 1998 
Smoking assessed by self-report within 1 
month of diagnosis 
Breast cancer-specific mortality 
Never smoker: Ref 
Current smoker: HR=1.73 (95% CI=1.28-2.33) 
 
 Premenopausal women 
Never smoker: Ref 
Current smoker: HR=2.10 (95% CI=1.36-2.99) 
 Postmenopausal women 
Never smoker: Ref 
Current smoker: HR=1.40 (95% CI=0.88-2.25) 
Number of deaths not reported.  
Median follow-up not reported (range: 0-
27.7 yrs.). 
Hellmann SS, Thygesen LC, Tolstrup JS, Grønbæk M. Modifiable risk factors and survival in women diagnosed with primary breast cancer: 
results from a prospective cohort study. Eur J Cancer Prev. 2010;19(5):366–373. 
2010 528 
Women participating in the 
Copenhagen City Heart Study 
Smoking assessed by self-administered 
questionnaire  
All-cause mortality 
Never smoker: Ref 
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Citation 
Year N Population Exposure Assessment/Follow-up Covariate-Adjusted Results 
(CCHS)  
323 deaths (174 of 300 brca) determined 
by linkage to the National Danish Central 
Personal Registry and the Danish Causes 
of Death Registry. 
Median follow-up of 7.8 yrs. (range: 0.04-
29.2 yrs.) 
Current smoker: HR=1.16 (95% CI=1.05-1.29) 
Former smoker: HR=1.04 (95% CI=0.88-1.23) 
 
Breast cancer-specific mortality 
Never smoker: Ref 
Current smoker: HR=1.07 (95% CI=0.94-1.23) 
Former smoker: HR=0.98 (95% CI=0.77-1.24) 
Dal Maso L, Zucchetto A, Talamini R, et al. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer. 
2008;123(9):2188–94. 
2008 1,453 
Women with incident invasive 
breast cancer, diagnosed 
between 1991 and 1994 and 
interviewed within the 
framework of an Italian 
multicenter case-control study 
Smoking assessed by questionnaire 
All-cause mortality 
Never smoker: Ref 
Current smoker: HR=1.42 (95% CI=1.17-1.71) 
 
Breast cancer-specific mortality 
Never smoker: Ref 
Current smoker: HR=1.30 (95% CI=1.05-1.61) 
503 deaths (398 brca) determined by 
linkage to regional health system databases 
Barnett GC, Shah M, Redman K, Easton DF, Ponder BAJ, Pharoah PDP. Risk factors for the incidence of breast cancer: do they affect survival 
from the disease? J Clin Oncol. 2008;26(20):3310–6. 
2008 4,560 
3,312 incident and 1,248 
prevalent breast cancer cases of 
the Studies of Epidemiology 
and Risk Factors in Cancer 
Heredity breast cancer study. 
Smoking assessed by self-administered 
questionnaire All-cause mortality 
Never smoker: Ref 
Current smoker: HR=1.11 (95% CI=0.89-1.41) 
Former smoker: HR=1.01 (95% CI=0.83-1.23) 
620 deaths identified from the East 
Anglian Cancer Registry. 
Median follow-up of: 5.05 yrs. (range: 
0.03-8.92 yrs.) 
Sagiv SK, Gaudet MM, Eng SM, et al. Active and passive cigarette smoke and breast cancer survival. Ann Epidemiol. 2007;17(5):385–93. 
2007 1,273 
Population-based study of 
women residing in Long Island, 
NY diagnosed with invasive 
disease in 1996-1997  
Smoking assessed by interviewer-
administered questionnaire at diagnosis. 
All-cause mortality 
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Figure I-1. Breast Cancer Incidence and Mortality Rates among Women of 
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Figure I-2. Structures and nomenclatures of the 16 PAHs on the EPA priority pollutant list. 
Adapted from Yan J, Wang L, Fu PP, Yu H. Photomutagenicity of 16 polycyclic aromatic 
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CHAPTER II: RESEARCH METHODS 
This dissertation examined whether PAH exposure from tobacco smoke and food 
sources, before and after diagnosis, was associated with an increase in mortality after breast 
cancer. This dissertation utilized resources from the Long Island Breast Cancer Study Project 
(LIBCSP), a population-based study of adult female residents of Nassau and Suffolk counties of 
New York (Gammon et al. 2002a). Specifically, I drew upon the follow-up component of the 
LIBCSP that included a second post-diagnosis interview that occurred about five years after 
diagnosis, along with subsequent determination of vital status, of the women diagnosed with 
breast cancer (n=1,508) in 1996 and 1997. In the LIBCSP, PAH exposure from tobacco smoke 
and grilled/smoked meat was assessed before and up to five years after diagnosis, and women 
have been followed for vital status for 18+ years using the National Death Index, which provides 
high quality ascertainment of vital status (Cowper et al. 2002).  
This dissertation addressed the following Specific Aims (Figure II-1). 
Aim 1. Determine whether active cigarette smoking and ETS exposure among a 
population-based sample of women diagnosed with first primary breast cancer is associated with 
all-cause and breast cancer-specific mortality. 
Aim 1A:  
• Determine whether at-diagnosis active smoking among women with breast cancer 
is associated with all-cause and breast cancer-specific mortality.  
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• Among women with breast cancer, determine whether changes in active smoking 
within five years after breast cancer (i.e., cessation of active smoking after 
diagnosis, time since smoking cessation after diagnosis, and cumulative pack-
years (calculated as pre-diagnosis + post-diagnosis pack-years)) are associated 
with subsequent all-cause and breast cancer-specific mortality. 
Aim 1B:  
• Determine whether pre-diagnosis ETS exposure among women with breast cancer 
is associated with all-cause and breast cancer-specific mortality. 
• Among women with breast cancer, determine whether changes in ETS exposure 
within five years after breast cancer diagnosis (i.e., cessation of ETS exposure) 
are associated with subsequent all-cause and breast cancer-specific mortality. 
Aim 2. Determine whether intake of grilled, barbecued, and smoked meat among a 
population-based sample of women diagnosed with first primary breast cancer is associated with 
all-cause and breast cancer-specific mortality after breast cancer diagnosis. 
• Determine whether at-diagnosis intake of grilled, barbecued, and smoked meat 
among women with breast cancer is associated with all-cause and breast cancer-
specific mortality. 
• Among women with breast cancer, determine whether changes intake of grilled 
and smoked meats within 5 years after breast cancer diagnosis (i.e., change in 





Breast cancer is the most common cancer and the second leading cause of death 
from cancer among women in the United States (US) (Siegel et al. 2016). In 2016, it is 
estimated that more than 246,000 US women will be diagnosed with breast cancer, contributing 
to the 3.1 million breast cancer survivors (National Cancer Institute 2016). By 2030, it is 
projected that the number of breast cancer survivors will increase by as much as 50%, driven 
predominantly by hormonally sensitive (estrogen receptor (ER)- or progesterone receptor (PR)-
positive) tumors (AACR 2015). Survival following a diagnosis of breast cancer is high with 
nearly 90% of women surviving at least five years (National Cancer Institute 2016), yet 
approximately 40,000 deaths continue to be attributed to breast cancer annually (Siegel et al. 
2016). Early breast cancer detection through routine gynecological and general physical 
examination and the use of mammography and access to high quality surgery and adjuvant and 
anti-estrogen therapies contribute to this high survival rate (Shulman et al. 2010). As reviewed in 
CHAPTER I: BACKGROUND of this dissertation, survival is adversely impacted by tumor 
characteristics (including larger tumor size, higher grade, lymph node involvement, and ER and 
PR-negative status), as well as patient characteristics (such as younger (<35 years) and older age 
(>80 years), lower socio-economic status, a recent pregnancy, recent oral contraceptive use, and 
comorbidities present at diagnosis (including obesity and diabetes) (Brandt et al. 2015; 
Cleveland et al. 2012; Fredholm et al. 2009; Kroman et al. 2000; Soerjomataram et al. 2008; 
Trivers et al. 2007b). A better understanding of the contribution of environmental exposures, 
especially exogenous compounds with the potential to influence estrogen, estrogen receptors, or 
biologically relevant pathways involved in breast cancer progression, on survival – among the 
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largest group of cancer survivors in the US – can help us to substantially reduce the burden of 
breast cancer. 
Polycyclic Aromatic Hydrocarbons (PAHs) are ubiquitous environmental 
contaminants to which most people are exposed on a regular basis (Agency for Toxic 
Substances and Disease Registry (ATSDR) 1995b; IARC 2010). PAHs include over 100 
different chemicals, including benzo[a]pyrene, and are common byproducts formed during the 
incomplete combustion of coal, oil and gas, and other organic substances like tobacco and 
charbroiled/smoked meats (Agency for Toxic Substances and Disease Registry (ATSDR) 
1995b). The term PAH generally refers to a large class of compounds that contain only carbon 
and hydrogen and are comprised of two or more fused aromatic rings. Sources of non-
occupational PAH exposure in the US include, primarily, cigarette smoking and, among non-
smokers, diet; and, secondarily, outdoor and indoor air pollution (Skupińska et al. 2004). 
Smoking increases personal daily PAH exposure by 30-fold on average (Woodard and Snedeker 
2001); one cigarette yields an intake of B[a]P of 20-40 ng (Phillips 1996). PAH levels from 
charring meat can be as high as 10-20 µg/kg (Skupińska et al. 2004). This gradient of exposure 
due to differences in behavioral practices can help to guide the development of an optimal 
research strategy to clarify the association between PAH exposures and breast cancer survival. 
In laboratory studies, PAHs have been shown to induce tumors through mechanisms 
involving PAH-DNA adducts (Baird et al. 2005) and oxidative stress and inflammation 
(Danielsen et al. 2011). Given this evidence, IARC recognizes benzo[a]pyrene and 
benz[a]anthracene as a probable and benzo[b]fluoranthene, benzo[j]fluoranthene, 
benzo[k]fluoranthene, and indeno[1,2,3-c,d]pyrene as possible carcinogens to humans, 
particularly to the lung (Agency for Toxic Substances and Disease Registry (ATSDR) 1995b). 
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PAHs are demonstrated mammary carcinogens (Cavalieri et al. 1991), but their role in breast 
carcinogenesis, particularly progression after diagnosis in humans, is less well understood. PAHs 
and PAH metabolites, including hydroxylated PAHs and PAH quinones, may influence breast 
carcinogenesis and progression by acting as endocrine disruptors by directly binding to estrogen 
receptors (Bekki et al. 2013; Fertuck et al. 2001; Sievers et al. 2013). Of importance is that PAHs 
and metabolites are lipophilic (Ferreira 2001) and known to be stored in adipose tissues, 
including the breast (Li et al. 1999; Perera et al. 1995). These characteristics of PAHs highlight 
the need to better understand how these exposures influence survival after breast cancer, an 
understudied area of research. 
A diagnosis of breast cancer is a “teachable moment” during which patients may be 
especially motivated to make changes and direct their priorities to restoration and 
maintenance of good health (McBride and Ostroff 2003). A healthful lifestyle including 
nutritional care and exercise may help mitigate the effects of treatment, prevent new diseases, 
and reduce the impact of existing conditions (Rock et al. 2012). Therefore women, particularly 
those with newly diagnosed breast cancer, may seek out information on lifestyle modifications 
(Galloway et al. 1997). Post-diagnosis changes in two possible modifiable behaviors and the 
predominant sources of exposure to PAHs, smoking and diet, may have the maximal impact on 
survival among breast cancer patients because changes are likely to be sustained (Demark-
Wahnefried et al. 2005). This teachable moment may also extend to family members of breast 
cancer patients who may also adopt more healthful behaviors such as smoking cessation 
(Mazanec et al. 2015). Documenting the relationships between changes in these behaviors and 




This dissertation examined the associations between changes in cigarette smoking 
and environmental tobacco smoke (ETS) and survival following breast cancer diagnosis. 
Tobacco smoke contains more than 4,000 chemicals, at least 20 of which are known mammary 
carcinogens in rodents (IARC 2004; Johnson et al. 2011) including polycyclic aromatic 
hydrocarbons (PAHs) (Rodgman et al. 2000). Cigarette smoking may be weakly associated with 
breast cancer incidence; a recent meta-analysis of 15 cohort studies showed that active cigarette 
smoking was associated with a 1.12-fold (95% CI=1.08-1.16) increase (Gaudet et al. 2013). ETS 
and breast cancer incidence associations are consistent with a modest magnitude of 1.20 (95% 
CI=1.08-1.35) (Johnson et al. 2011; U.S. Department of Health and Human Services 2006). 
Examining cigarette smoking in relation to survival after breast cancer has received much less 
scientific attention, despite the potential of smoking to adversely affect health outcomes by 
increasing the risk of treatment complications (Zhan et al. 2007), recurrence (Bishop et al. 2014), 
and second primary cancers (Neugut et al. 1994) via suppression of the immune system (Sopori 
2002), increasing oxidative stress (Danielsen et al. 2011), and disrupting the endocrine system 
(Bekki et al. 2013; Fertuck et al. 2001; Sievers et al. 2013). Most studies of survival conducted to 
date show that active smoking at the time of diagnosis is associated with an increased risk of all-
cause and breast cancer-specific mortality; hazard ratios range from 1.16 to 2.63 and from 1.73 
to 2.08, for all-cause and breast cancer-specific mortality, respectively (Braithwaite et al. 2012; 
Calle et al. 1994; Hellmann et al. 2010; Holmes et al. 1999, 2007; Manjer 2000; Tominaga et al. 
1998; Warren et al. 2012; Yu et al. 1997). However, only one prior study has examined whether 
changes in smoking after breast cancer are associated with survival. This is of particular 
importance since it is estimated that ~30% of women quit smoking after being diagnosed with 
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breast cancer (Westmaas et al. 2015) and hormone withdrawal can rapidly influence the growth 
of hormone-sensitive tumors (Powles and Hickish 1995; Prasad et al. 2003). Additionally, no 
studies have examined whether post-diagnosis changes in ETS exposure are associated with 
survival following breast cancer. 
This dissertation is the first to examine the association between dietary sources of 
exposure to PAHs and survival following breast cancer diagnosis. Up to 70% of PAH 
exposure for a non-smoking person can be attributed to diet (Phillips 1999; Skupińska et al. 
2004). PAH-containing foods include barbecued, grilled, broiled, and smoked meats; roasted, 
baked, or fried foods; and breads, cereals, and grains, and vegetables (IARC 2010). PAHs in 
food arise from two sources, food-preparation and environmental contamination. For example, 
during grilling and barbecuing, PAHs are generated through pyrolysis of meat products when fat 
drips from the meat onto a heated surface and produces smoke that coats the food with the 
compounds (Larsson 1986). Environmental contamination of plant foods occurs through 
deposition on leafy plants with high surface area; contamination of livestock occurs through the 
consumption of contaminated pastures and vegetation; contamination of fish and shellfish occurs 
through contamination of fresh and coastal waters. Because of the importance of diet as a 
principal source of exposure to PAHs, epidemiologic studies have investigated the association 
between dietary PAH sources and cancer incidence, including breast cancer. One study 
conducted in China, showed a 92% (OR=1.92, 95% CI=1.30-2.83) increased breast cancer 
incidence for high intake of well-done red meat and a 52% (OR=1.52, 95% CI=1.05-2.22) 
increased risk for high intake of well-done freshwater fish (Dai et al. 2002). In a previous study 
with this sample a modest elevation in breast cancer incidence was observed among 
postmenopausal, but not premenopausal, women consuming the most grilled or barbecued and 
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smoked meats over the life course (OR=1.47; 95% CI=1.12-1.92 for the highest tertile vs. the 
lowest) (Steck et al. 2007). However, no studies have examined whether food sources of PAH-
containing foods influence survival after breast cancer and whether dietary changes related to 
grilled and smoked foods after diagnosis influence survival. 
Approach 
Research Strategy 
To address my study aims, I utilized resources from the Long Island Breast Cancer Study 
Project (LIBCSP), a population-based study of women diagnosed with first primary breast 
cancer, who were interviewed shortly after diagnosis and again about five years later and who 
have been followed for vital status for 18+ years (Bradshaw et al. 2012; Gammon et al. 2002a). 
This prospective study represented an optimal approach in which to examine my hypotheses – 
that post-diagnosis changes in the primary sources of PAH-exposure, tobacco smoke and diet, 
are associated with all-cause and breast cancer-specific mortality – because these exposures ex 
estimated for before and at diagnosis (i.e., at-diagnosis exposure) and approximately 5 years after 
diagnosis (i.e., post-diagnosis exposure) (Figure II-1). Additionally, I applied the use of 
methods to address missing data, which is important to consider since a complete-case analysis, 
in addition to being inefficient, may also lead to biased estimates (Ibrahim et al. 2012). The 
proposed study is much more time efficient and cost-effective than a de novo study; and another 
study design such as a clinical trial could never be conducted on whether changes in smoking 
after diagnosis is associated with mortality following breast cancer, because it would be 
considered unethical to withhold smoking cessation programs to anyone, including breast cancer 
survivors. Similarly, it is next to impossible to blind participants in a dietary intervention trial. 
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Thus, an existing observational study focused on a cohort of incident breast cancer patients with 
long-term follow-up, as conducted in this dissertation, was the best alternative. 
Study Population 
LIBCSP identification and recruitment of women with a newly diagnosed first primary 
breast cancer was conducted in 1996-1997 in the counties of Nassau and Suffolk on Long Island, 
New York. Details of the study and participants have been previously published (Bradshaw et al. 
2012; Gammon et al. 2002a; Sagiv et al. 2009; Steck et al. 2007). Women with a first diagnosis 
of in situ or invasive breast cancer were identified for inclusion using rapid-case ascertainment 
via active daily or weekly contact with local hospitals confirmed by a physician and medical 
records. Additional eligibility criteria included being over the age of 20, residing in Nassau or 
Suffolk counties of New York, and being diagnosed during August 1, 1996, through July 31, 
1997. This dissertation used data from the 1,508 women who were interviewed at baseline, on 
average within three months of diagnosis (mean=3.19 months) and who provided signed 
informed consent. These women were primarily white (94%) and black (5%), with a mean age of 
59 years (range: 25-98 years), and postmenopausal (59%) at baseline. The demographic 
characteristics of the women in the LIBCSP reflect those of the underlying geographic area, and 
include those at highest risk of breast cancer (American Cancer Society 2012). Many established 
risk factors for breast cancer, including parity, late age at first birth and a family history of breast 
cancer were confirmed among the LIBCSP participants (Gammon et al. 2002a). 
Of the 1,508 women with breast cancer who completed the 100-minute, in-home, 
interviewer-administered, structured baseline questionnaire and a self-administered Food 
Frequency Questionnaire (Block FFQ; (Block et al. 1986)) that assessed diet in the year previous 
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to diagnosis, 1,414 initially agreed to participate in the follow-up component of the study. 
Approximately five years after the initial diagnosis of breast cancer, the 1,414 women, or a proxy 
identified at the time of diagnosis (usually a mother or sister), who expressed interest in 
participating in the follow-up study were contacted to obtain informed consent for participation. 
Proxy interviews comprised <8% of all follow-up interviews. Informed consent was obtained by 
telephone from 1,120 of the 1,414 women (i.e., 60 refused by mail, 83 refused by telephone, no 
proxy was identified for 96 women who were not alive at follow-up, and 55 could not be 
located). A 45-minute interviewer-administered, structured questionnaire that assessed 
information similar to that obtained at the time of diagnosis, but regarding the time period since 
the initial diagnosis of breast cancer (i.e., post-diagnosis exposures), was completed by telephone 
with the consenting 1,033 (68.5%) of the 1,508 women with breast cancer completed the follow-
up questionnaire (Bradshaw et al. 2012).  
Exposure Assessment 
Tobacco Smoke Exposure. At baseline, approximately on average within 3 months of 
breast cancer diagnosis, participants were asked about their active smoking and exposure to 
environmental tobacco smoke (ETS) prior to baseline interview via interviewer-administered 
questionnaire (Gammon et al. 2004) (APPENDIX: EXCERPTS FROM THE LIBSCP 
BASELINE QUESTIONNAIRE). The variables from the smoking section of the baseline 
questionnaire were used to define the following at-diagnosis exposures: 
• Smoking status. Never, former, and current smoker. 
• Intensity of smoking. Number of cigarettes smoked per day, which was categorized as 
<20 cigarettes per day versus ≥20 cigarettes per day. 
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• Duration of smoking. Number of years of smoking, which was categorized as <15 years, 
≥15 years to <30 years, and ≥30 years. 
• Pack-years of smoking. Calculated as intensity times duration and categorized as <15 
pack-years, ≥15 pack-years to <30 pack-years, and ≥30 pack-years. 
• Smoking cessation recency. Number of years since smoking cessation, which was 
categorized as <5 years, ≥5 years to <10 years, and ≥10 years. 
At the 5-year follow-up assessment participants were asked the same questions, but 
regarding the time-period since the baseline questionnaire. At both time-points, current active 
cigarette smokers were defined as women who smoked within the past 12 months prior to the 
questionnaires and former smokers were defined as women who reported quitting more than 12 
months prior to the questionnaires. In Aim 1A, which examined post-diagnosis tobacco smoke 
exposure, changes in exposures included:  
• Change in smoking status. At-diagnosis never smoker and post-diagnosis never smoker 
(i.e., never/never smoker); at-diagnosis former smoker and post-diagnosis former smoker 
(i.e., former/former smoker); at-diagnosis current smokers and post-diagnosis former 
smoker (i.e., current/former smoker); and at-diagnosis current smoker and post-diagnosis 
current smoker (i.e., current/current smoker). 
• Cumulative duration of smoking. Former/former smokers <30 years versus ≥30 years, 
current/former smokers <30 years versus ≥30 years; and current/current smokers <30 
years versus ≥30 years. 
• Cumulative pack-years of smoking. Former/former smokers <30 pack-years versus ≥30 
pack-years, current/former smokers <30 pack-years versus ≥30 pack-years; and 
current/current smokers <30 pack-years versus ≥30 pack-years. 
90 
Similarly, in Aim 1B, at-diagnosis ETS exposures and post-diagnosis changes in 
exposures included:  
• ETS exposure status. Never, former, and current ETS exposure. 
• Change in ETS exposure status. At-diagnosis never ETS exposed and post-diagnosis 
never ETS exposed (i.e., never/never ETS exposed); at-diagnosis former ETS exposed 
and post-diagnosis never ETS exposed (i.e., former/never ETS exposed); at-diagnosis 
former ETS exposed and post-diagnosis former ETS exposed (i.e., former/former ETS 
exposed); at-diagnosis former ETS exposed and post-diagnosis current ETS exposed (i.e., 
former/current ETS exposed); at-diagnosis current ETS exposed and post-diagnosis never 
ETS exposed (i.e., current/never ETS exposed); at-diagnosis current ETS exposed and 
post-diagnosis former ETS exposed (i.e., current/former ETS exposed); and at-diagnosis 
current ETS exposed and post-diagnosis current ETS exposed (i.e., current/current ETS 
exposed). 
Intake of grilled, barbecued, and smoked meat. At baseline, approximately on average 
within 3 months of breast cancer diagnosis, participants were asked about their intake (number of 
times per week, month, or year) of four categories of grilled, barbecued, and smoked meat 
(smoked beef, lamb, and pork; grilled/barbecued beef, lamb, and pork; smoked poultry or fish; 
and grilled/barbecued poultry or fish) to estimate consumption of grilled, barbecued, and smoked 
foods during the decade before their diagnosis of breast cancer (Gammon et al. 2002b; Steck et 
al. 2007) (APPENDIX: EXCERPTS FROM THE LIBSCP BASELINE 
QUESTIONNAIRE). At the 5-year follow-up participants who completed the questionnaire 
responded to the same questions, but regarding the time-period since baseline to determine 
whether any changes in intake of grilled, barbecued, and smoked meat had occurred. In the 
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analysis of pre-diagnosis intake of grilled, barbecued, and smoked meat in the decade prior to 
diagnosis exposure variables included: 
• Lifetime intake of grilled, barbecued, and smoked meat. The sum of all intake of grilled 
and smoked meat. 
• Total annual intake of grilled, barbecued, and smoked meat. The sum of annual intake of 
the four types of meat, categorized at the median. 
• Annual intake of grilled/barbecued beef, lamb, and pork. Annual intake of 
grilled/barbecued beef, lamb, and pork was categorized at the median. 
• Annual intake of smoked beef, lamb, and pork. Annual intake of smoked beef, lamb, and 
pork was categorized at the median. 
• Annual intake of grilled/barbecued poultry and fish. Annual intake of grilled poultry and 
fish was categorized at the median. 
• Annual intake of smoked poultry and fish. Annual intake of smoked poultry and fish was 
categorized at the median. 
In the analysis of post-diagnosis intake of grilled and smoked meat, changes in intake 
included:  
• Change in annual intake of grilled, barbecued, and smoked meat. Pre-diagnosis low 
intake and post-diagnosis low intake of grilled, barbecued, and smoked meat (i.e., 
low/low intake), pre-diagnosis low intake and post-diagnosis high intake of grilled, 
barbecued, and smoked meat (i.e., low/high intake), pre-diagnosis high intake and post-
diagnosis low intake of grilled, barbecued, and smoked meat (i.e., high/low intake), and 
pre-diagnosis high intake and post-diagnosis high intake of grilled, barbecued, and 
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smoked meat (i.e., high/high intake). 
• Change in annual intake of grilled/barbecued beef, lamb, and pork. Pre-diagnosis low 
intake and post-diagnosis low intake of grilled/barbecued beef, lamb, and pork (i.e., 
low/low intake), pre-diagnosis low intake and post-diagnosis high intake of 
grilled/barbecued beef, lamb, and pork (i.e., low/high intake), pre-diagnosis high intake 
and post-diagnosis low intake of grilled/barbecued beef, lamb, and pork (i.e., high/low 
intake), and pre-diagnosis high intake and post-diagnosis high intake of grilled/barbecued 
beef, lamb, and pork (i.e., high/high intake). 
• Change in annual intake of smoked beef, lamb, and pork. Pre-diagnosis low intake and 
post-diagnosis low intake of smoked beef, lamb, and pork (i.e., low/low intake), pre-
diagnosis low intake and post-diagnosis high intake of smoked beef, lamb, and pork (i.e., 
low/high intake), pre-diagnosis high intake and post-diagnosis low intake of smoked 
beef, lamb, and pork (i.e., high/low intake), and pre-diagnosis high intake and post-
diagnosis high intake of smoked beef, lamb, and pork (i.e., high/high intake). 
• Change in annual intake of grilled/barbecued poultry and fish. Pre-diagnosis low intake 
and post-diagnosis low intake of grilled/barbecued poultry and fish (i.e., low/low intake), 
pre-diagnosis low intake and post-diagnosis high intake of grilled/barbecued poultry and 
fish (i.e., low/high intake), pre-diagnosis high intake and post-diagnosis low intake of 
grilled/barbecued poultry and fish (i.e., high/low intake), and pre-diagnosis high intake 
and post-diagnosis high intake of grilled/barbecued poultry and fish (i.e., high/high 
intake). 
• Change in annual intake of smoked poultry and fish. Pre-diagnosis low intake and post-
diagnosis low intake of smoked poultry and fish (i.e., low/low intake), pre-diagnosis low 
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intake and post-diagnosis high intake of smoked poultry and fish (i.e., low/high intake), 
pre-diagnosis high intake and post-diagnosis low intake of smoked poultry and fish (i.e., 
high/low intake), and pre-diagnosis high intake and post-diagnosis high intake of smoked 
poultry and fish (i.e., high/high intake). 
Covariate Assessment 
Fixed and time-varying covariates for consideration as potential moderators and 
confounders were collected at baseline by interviewer-administered questionnaire and by 
medical record review and at follow-up by interview. Possible moderators include, from the 
baseline questionnaire: 
• Pre-diagnosis BMI (kg/m2) – calculated as self-reported weight in kilograms (“One year 
prior to (REFERENCE DATE), how much did you weigh?”) divided by the square of 
self-reported height in meters (“One year prior to (REFERENCE DATE), how tall were 
you?”) (Centers for Disease Control and Prevention 2015). 
• ER/PR status (ER+ versus ER-) 
Possible confounders were selected based on prior research of breast cancer incidence 
and survival and using directed acyclic graphs (Figure II-2, Figure II-3, and Figure II-4) 
(Greenland et al. 1999). Given the dearth of literature examining factors associated with changes 
in active smoking, exposure to ETS, and grilled and smoked meat intake, I empirically examined 
whether each covariate confounded the associations with all-cause and breast cancer-specific 
mortality. From the baseline questionnaire, potential confounders included: 
• Age (years) – Age at reference date (date of diagnosis). 
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• Education (<high school – high school graduate, some college – college graduate, post-
college) – “What was the highest grade or year of school that you completed before 
(REFERENCE DATE)?” with response options: “none or kindergarten, first grade, 
second grade, third grade, fourth grade, fifth grade, sixth grade, seventh grade, eighth 
grade, ninth grade, tenth grade, eleventh grade, high school graduate or GED, post high 
school training or other than college, some college, associate degree, graduated from 
college, post graduate”. 
• Annual income (categorical). 
• Physical activity (recreational physical activity in which participants engaged for at least 
1 hour per week for 3 months or more in the year before diagnosis and in the year before 
the follow-up assessment (Bernstein et al. 1994; McCullough et al. 2012)) –  
o At baseline: “In what activity did you participate on a regular basis? Looking at 
the calendar, at what age did you start (ACTIVITY) regularly? At what age did 
you stop (ACTIVITY)? For how many years did you (ACTIVITY) regularly? For 
how many months each year did you do this? On average, about how many hours 
per week did you actually (ACTIVITY)?” 
• Energy intake – estimated from the baseline frequency questionnaires (Block FFQ; 
(Block et al. 1986)). 
For women who provided signed medical record release at baseline (97.7%), tumor stage, 
and ER/PR status were abstracted from the medical records. At the follow-up, the medical 
records were again abstracted for 598 women who again provided signed medical record release 
to obtain information on tumor size, nodal status, and complete course treatment for the primary 
breast cancer diagnosis. These data were also assessed by interview which showed high 
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agreement (radiation therapy κ = 0.97; chemotherapy κ = 0.96; hormone therapy κ = 0.92 
(Cleveland et al. 2007)) with the medical record data. Therefore, the following disease and 
treatment characteristics were examined as potential confounders. 
• From the baseline medical records abstraction: 
o Stage (in situ versus invasive) 
o Tumor size (≥2cm versus <2cm) 
o Lymph node involvement (yes/no) 
• Self-reported at the follow-up interview: 
o Chemotherapy (yes/no) - “Did you have…Chemotherapy…to treat your breast cancer 
diagnosed in REFERNCE DATE?” 
o Radiation therapy (yes/no) – “Did you have…Radiation therapy… to treat your breast 
cancer diagnosed in REFERENCE DATE?” 
o Hormone therapy (yes/no) – “Since (REFERENCE DATE) were you prescribed any 
hormones, such as Tamoxifen (also called Nolvadex), for treatment of the breast 
cancer or the prevention of cancer recurrence?” 
Missing Data 
As indicated above, 1,033 (68.5%) of the 1,508 women with breast cancer completed the 
follow-up questionnaire. The high proportion of missing data could potentially influence the 
validity of these results since valid statistical inference in the presence of missing data requires 
assumptions about the missing data mechanism the generated the missing data. As stated by 
Ibrahim (2012), data are said to be: 
• “Missing completely at random (MCAR) if the failure to observe a value does not 
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depend on any observed or unobserved data,  
• Missing at random (MAR), if, give then observed data, the failure to observe a value 
does not depend on the data that are unobserved, and  
• Missing not at random (MNAR) if the failure to observe a value depends on the value 
that would have been observed or other missing values in the dataset.” 
When data are MCAR, a complete-case (CC) analysis in which data from participants 
with any missing data are omitted while resulting in larger standard errors in the model 
parameter estimates does not result in biased parameter estimates (Ibrahim et al. 2012). In the 
case of data that are MAR, if missingness depends only on the fully observed covariates and not 
on the response, then a CC analysis will lead to unbiased estimates. However, if the missingness 
depends on the response variable, then a CC analysis when data are MAR will result in biased 
parameter estimates (Ibrahim et al. 2012). Lastly, when data are MNAR, a CC analysis leads to 
biased and inefficient parameter estimates and will require specifying the correct model for the 
missing data mechanism, distributional assumptions for the response, or both (Ibrahim et al. 
2012). In the LIBCSP, prior analyses have not indicated that data are MNAR. Therefore, to 
account for the large proportion of data at the 5-year follow-up assessment, the analyses of post-
diagnosis changes in exposure were first imputed using multiple followed as described below.  
Outcome Assessment 
All-cause and breast cancer-specific mortality. The National Death Index (NDI), a 
centralized database of death record information maintained by the National Center for Health 
Statistics (Centers for Disease Control and Prevention 2014c), has been used to ascertain date 
and cause of death from diagnosis in 1996-1997 until December 31, 2014. International 
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Statistical Classification of Diseases (ICD) codes 174.9 and C-50.9 listed anywhere on the death 
certificate were used to identify breast cancer-related deaths. The median duration of follow-up 
was 17.61 years (range: 0.23-18.41). Among the 1,508 women, 597 deaths occurred by the end 
of follow-up at 18 years. Of the deaths that occurred within 18 years of diagnosis, 237 were due 
to breast cancer. For the analyses, outcomes included time to death, or censoring if alive through 
December 21, 2014 (years), an indicator of all-cause mortality, and an indicator of breast cancer-
specific mortality (Table II-1).  
Data Analysis 
To address my dissertation aims, I used multivariable Cox proportional hazards models 
(Collett 2003) to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the 
associations between at-diagnosis as well as at-/post-diagnosis cigarette smoking, environmental 
tobacco smoke exposure, and grilled/barbecued, and smoked meat intake and all-cause and 
breast cancer mortality. The outcome and exposure variables used in all analyses are described in 
Table II-1. All analyses were done using the Cox Regression function in IBM SPSS Statistics 
Version 22.0 (IBM Corp., Armonk, NY). In the analyses of at-diagnosis exposures, survival time 
began at the date of breast cancer diagnosis to the date of death or December 31, 2014, if alive. 
Age-adjusted and multivariable-adjusted models were fit for each of the exposures and for all-
cause and breast cancer-specific mortality. 
The analyses examining post-diagnosis changes were restricted to women who survived 
at least 5 years after diagnosis (n=1,339). Accordingly, survival time began at the date of 
completion of the follow-up questionnaire to the date of death or December 31, 2014, if alive. 
Because a complete-case analysis when data are not missing completely at random is inefficient 
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and can potentially lead to biased results (Ibrahim et al. 2012), I first used multiple imputation to 
account for the missing data. Missing values were imputed using SPSS, which employs a fully 
conditional specification (FCS) algorithm (van Buuren 2007). The FCS method is an iterative 
Markov Chain Monte Carlo procedure that sequentially imputes missing values starting from the 
first variable with missing values by specifying a linear regression or logistic regression model 
for each continuous or categorical variable, respectively. I used 25 imputations with 1,000 
iterations and included demographics (age at diagnosis, menopausal status, income, education, 
marital status, BMI, physical activity, and alcohol intake), post-diagnosis exposures, disease 
characteristics (stage, tumor size, nodal status, estrogen receptor status), treatment (radiation 
therapy, chemotherapy, and hormone therapy), and the outcome (the event indicator and the 
Nelson-Aalen estimator of the cumulative hazard (White and Royston 2009)). 
Study Statistical Power 
Analyses for aims 1 and 2 of this dissertation consisted of Cox proportional hazards 
regression. Power calculations were conducted for the analyses that examined post-diagnosis 
changes in exposures as those are the primary analyses of interest. Given the categorization of 
several of the change variables (e.g., changes in smoking status are categorized as never/never, 
former/former, current/former, and current/current smokers), power analyses were conducted for 
specific comparisons (e.g., never/never versus current/former smokers) using PROC POWER 
with the TWOSAMPLESURVIVAL statement on SAS version 9.4 (SAS Institute, Cary, NC). 
Specific details of the power analyses and results for each aim are detailed below. 
Aim 1 power calculations were based on a comparison of survival rates between women 
who were never smokers and those who quit after diagnosis. Using 80% as the observed 
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proportion of women who were never smokers and 20% as the proportion of women who quit 
smoking after diagnosis, under a full-case analysis, 601 are never/never smokers and 153 are 
current/former smokers and under a complete-case analysis, 601 women are never/never smokers 
and 73 women are current/former smokers, at follow-up. Using the 2014 all-cause mortality rate 
of 27.69 deaths per 1,000 person-years (i.e., 597 death from any cause per 21,561.00 person-
years), a survival probability of 0.61 [i.e., S(18 years)=EXP(-18 x 27.69 deaths per 1,000 person-
years], and a significance level of 5% based on the two-sided log-rank test yields 80% power to 
detect a HR of all cause-mortality between 1.4 and 1.6 (Figure II-5, Panel A). Using the 
observed breast cancer-specific mortality rate of 10.99 deaths per 1,000 person-years (i.e., 237 
breast cancer deaths per 21,561.00 person-years), a survival probability of 0.82 [i.e., S(18 
years)=EXP(-18 x 10.99 deaths per 1,000 person-years], and a significance level of 5% based on 
the two- sided log-rank test yields 80% power to detect a HR of breast cancer-specific mortality 
between 1.7 and 1.9 (Figure II-5, Panel A).  
 Aim 2 power calculations were based on a comparison of survival rates between women 
who had low pre-diagnosis and post-diagnosis intake of grilled, barbecued, and smoked meat and 
women who had high at-diagnosis intake and high post-diagnosis intake of grilled, barbecued, 
and smoked meat. Using 50% as the observed proportion of women who were had low/low 
intake and 50% as the proportion of women who had high/high intake, under a full-case analysis, 
455 had low/low intake and 409 had high/high intake and under a complete-case analysis, 281 
had low/low intake and 297 had high/high intake, at follow-up. Using the mortality rate of 27.69 
deaths per 1,000 person-years, survival probability of 0.61, and a significance level of 5% based 
on the two-sided log-rank test yields 80% power to detect a HR of all cause-mortality between 
1.3 and 1.4 (Figure II-5, Panel B) and 80% power to detect a HR of breast cancer-specific 
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mortality between 1.5 and 1.6 (Figure II-5, Panel B). 
Summary 
The burden of breast cancer in United States is high and breast cancer survivors account 
for the majority of survivors (Siegel et al. 2016) yet breast cancer survivorship is an understudied 
area of research as compared to breast cancer incidence. In addition, how epidemiologic factors 
impact survival after breast cancer has received little scientific attention. While at least 10 
studies s have examined active smoking in relation to survival after breast cancer (Bérubé et al. 
2014), this number is small compared to the more than 100 studies of smoking and breast cancer 
incidence (Gaudet et al. 2013). Few (less than 5) studies have examined environmental tobacco 
smoke exposure in relation to survival and no studies have examined intake of grilled, 
barbecued, and smoked meat in relation to survival.  
This chapter outlined the research methods used to address the dissertation aims 
including: the study population – a population-based cohort of women diagnosed with first 
primary invasive or in situ breast cancer; assessment of outcomes – date of death and cause of 
death including death from any cause and from breast cancer as identified using data from the 
National Death Index; assessment of exposures – smoking status, intensity of smoking, years of 
smoking, pack-years of smoking, post-diagnosis changes in smoking, ETS exposure status, post-
diagnosis changes in ETS exposure status; and assessment of covariates – potential confounders 
of the associations between PAH sources of exposure and survival; and the analytic approach – 
multiple imputation followed by Cox proportional hazards regression to estimate hazard ratios 
and 95% confidence intervals of the associations between the exposures of interest and survival. 
A special emphasis was made in describing epidemiologic issues related to missing data, which 
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are common in longitudinal studies and the potential biases that may arise from a complete-case 
analysis when there is high missingness. 
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Table II-1. Coding of outcome and exposure variables for Aims 1 and 2. 
Variable Variable label Value Value label 
    
OUTCOME VARIABLES 
TIME 
Time-to-event variable (continuous) defined as time to death 
(all cause) if NDI_2014=1 (or deceased) based on NDI records 
updated through 2014 or time to censor December 31, 2014 if 
NDI_2011=0 (or alive) 
[0-18] [none] 
    
NDIACM 
Vital status (based on all-cause mortality) for all 1508 LIBCSP 
cases. Vital status determined from National Death Index (NDI) 
records updated through December 31, 2014 
0 Alive 
  1 Death from any cause 
NDIBCM 
Indicator variable for breast cancer-related death (any mention 
of breast cancer on death certificate) based on NDI records 
updated through December 31, 2014 
0 Alive/Censored 
  1 Death from breast cancer 
AIM 1  
EXPOSURE VARIABLES 
SMOKSTAT_T1 At-diagnosis smoking status: Never, Former >12 months, and 
Current ≤12 months 
0 Never smoker 
 1 Former smoker 
 2 Current smoker 
    
INTENSITY_T1 At-diagnosis smoking intensity (cigs per day) 0 Never smoker 
  1 Former smoker, <20 cigs per day 
  2 Former smoker, ≥20 cigs per day 
  3 Current smoker, <20 cigs per day 
  4 Current smoker, ≥20 cigs per day 
    
DURATION_T1 At-diagnosis smoking duration (years) 0 Never smoker 
  1 Former smoker, <15 yrs 
  2 Former smoker, ≥15-<30 yrs 
  3 Former smoker, ≥30 yrs 
  4 Current smoker, <15 yrs 
  5 Current smoker, ≥15-<30 yrs 
  6 Current smoker, ≥30 yrs 
    
PACKYEARS_T1 At-diagnosis smoking intensity and duration (pack-years) 0 Never smoker 
  1 Former smoker, <15 pack-yrs 
  2 Former smoker, ≥15-<30 pack-yrs 
  3 Former smoker, ≥30 pack-yrs 
  4 Current smoker, <15 pack-yrs 
  5 Current smoker, ≥15-<30 pack-yrs 
  6 Current smoker, ≥30 pack-yrs 
    
RECENCY_T1 At-diagnosis recency (years) of smoking cessation 0 Never smoker 
  1 Former smoker, <5 yrs 
  2 Former smoker, ≥5–<10 yrs 
  3 Former smoker, ≥10 yrs 
  4 Current smoker 
    
ippSMOKSTAT At-/Post-diagnosis smoking status, missing values imputed 0 Never/Never smoker 
  1 Former/Former smoker 
  2 Current/Former smoker 
  3 Current/Current smoker 
    
ippINTENSITY_ 
At-/Post-diagnosis smoking intensity (cigs per day), missing 
values imputed 
0 Never/Never smoker 
  1 Former/Former smoker, <20 cigs per day 
  2 Former/Former smoker, ≥20 cigs per day 
  3 Current/Former smoker, <20 cigs per day 
  4 Current/Former smoker, ≥20 cigs per day 
  5 Current/Current smoker, <20 cigs per day 
  6 Current/Current smoker, ≥20 cigs per day 
    
ippDURATION 
At-/Post-diagnosis smoking duration (years), missing values 
imputed 
0 Never/Never smoker 
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Variable Variable label Value Value label 
    
  1 Former/Former smoker, <30 yrs 
  2 Former/Former smoker, ≥30 yrs 
  3 Current/Former smoker, <30 yrs 
  4 Current/Former smoker, ≥30 yrs 
  5 Current/Current smoker, <30 yrs 
  6 Current/Current smoker, ≥30 yrs 
    
ippPACKYEARS At-/Post-diagnosis smoking intensity and duration (pack-years), 
missing values imputed 
0 Never/Never smoker 
 1 Former/Former smoker, <30 pack-yrs 
 2 Former/Former smoker, ≥30 pack-yrs 
 3 Current/Former smoker, <30 pack-yrs 
 4 Current/Former smoker, ≥30 pack-yrs 
 5 Current/Current smoker, <30 pack-yrs 
 6 Current/Current smoker, ≥30 pack-yrs 
    
ETSSTAT_T1 At-diagnosis ETS exposure status 0 Never ETS exposure 
  1 Former ETS exposure 
  2 Current ETS exposure 
    
ETSDURATION_T1 At-diagnosis ETS exposure duration (years) 0 Never ETS exposure 
  1 Former ETS exposure, <15 yrs 
  2 Former ETS exposure, ≥15-<30 yrs 
  3 Former ETS exposure, ≥30 yrs 
  4 Current ETS exposure, <15 yrs 
  5 Current ETS exposure, ≥15-<30 yrs 
  6 Current ETS exposure, ≥30 yrs 
    
ETSRECENCY_T1 At-diagnosis recency (years) of ETS exposure cessation 0 Never ETS exposure 
  1 Former ETS exposure, <5 yrs 
  2 Former ETS exposure, ≥5–<10 yrs 
  3 Former ETS exposure, ≥10 yrs 
  4 Current ETS exposure 
    
ippETSSTAT At-/Post-diagnosis ETS exposure status 0 Never/Never ETS exposure 
  1 Former/Never ETS exposure 
  2 Former/Former ETS exposure 
  3 Former/Current ETS exposure 
  4 Current/Never ETS exposure 
  5 Current/Former ETS exposure 
  6 Current/Current ETS exposure 
    
    
    
AIM 2  
EXPOSURE VARIABLES 
LIFEGSM_MED_T1 Lifetime intake of grilled, barbecued, and smoked meat intake 0 Low 
  1 High 
    
GSM_MED_T1 
Pre-diagnosis annual grilled, barbecued, and smoked meat 
intake 
0 Low 
  1 High 
    
GBBLP_MED_T1 Pre-diagnosis annual grilled/barbecued beef/lamb/pork intake 0 Low 
  1 High 
    
GBPOF_MED_T1 Pre-diagnosis annual grilled/barbecued poultry/fish intake 0 Low 
  1 High 
    
SMBLP_MED_T1 Pre-diagnosis annual smoked beef/lamb/pork intake 0 Low 
  1 High 
    
SMPOF_MED_T1 Pre-diagnosis annual smoked poultry/fish intake 0 None 
  1 Low-High 
    
ippGSM_MED_T1 Pre-/Post-diagnosis annual grilled, barbecued, and smoked meat 
intake, missing values imputed 
0 Low/Low 
 1 Low/High 
 2 High/Low 
 3 High/High 
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Variable Variable label Value Value label 
    
    
ippGBBLP_MED_T1 Pre-/Post-diagnosis annual grilled/barbecued beef/lamb/pork 
intake, missing values imputed 
0 Low/Low 
 1 Low/High 
 2 High/Low 
 3 High/High 
    
ippGBPOF_MED_T1 Pre-/Post-diagnosis annual grilled/barbecued poultry/fish intake, 
missing values imputed 
0 Low/Low 
 1 Low/High 
 2 High/Low 
 3 High/High 
    
ippSMBLP_MED_T1 Pre-/Post-diagnosis annual smoked beef/lamb/pork intake, 
missing values imputed 
0 Low/Low 
 1 Low/High 
 2 High/Low 
 3 High/High 
    
ippSMPOF_MED_T1 Pre-/Post-diagnosis annual smoked poultry/fish intake, missing 
values imputed 
0 None/None 
 1 None/Low-High 
 2 Low-High/None 




Figure II-1. Pre/At-diagnosis and Post-diagnosis PAH Exposures and 








Figure II-2. Directed Acyclic Graphs of the association between 
breast cancer survival and at-diagnosis active smoking (A) and 











Figure II-3. Directed Acyclic Graphs of the association between 
breast cancer survival and at-diagnosis ETS exposure (A) and post-










Figure II-4. Directed Acyclic Graphs of the association between 
breast cancer survival and at-diagnosis grilled/barbecued and 




Figure II-5. Study Statistical Power for Aims 1 (Panel A) and 2 (Panel B). 
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CHAPTER III: POST-DIAGNOSIS CHANGES IN SMOKING AND SURVIVAL 
FOLLOWING BREAST CANCER 
Overview 
Cigarette smoking at the time of breast cancer diagnosis is associated with increased 
mortality, but whether changes in smoking behavior after diagnosis impact mortality is 
understudied. We examined whether at-diagnosis smoking and post-diagnosis changes in 
smoking within 5 years after breast cancer were associated with long-term all-cause and breast 
cancer mortality. The population-based cohort study was conducted in Nassau and Suffolk 
Counties on Long Island, NY beginning in 1996. Participants were 1,508 English-speaking 
women over the age of 20 who were residents of Long Island, NY and who were diagnosed with 
first primary invasive or in situ breast cancer during August 1, 1996 through July 31, 1997. 
History of smoking status, intensity, and duration was assessed by self-report using interviewer-
administered questionnaires at baseline shortly after diagnosis and again approximately 5 years 
post-diagnosis. Participants were followed for vital status through December 31, 2014 using the 
National Death Index. After 18+ years of follow-up, 597 deaths were identified, of which 237 
were breast cancer-related. Multivariable Cox regression was used to estimate adjusted hazard 
ratios (HRs) and 95% confidence intervals (CIs) for mortality as related to at-diagnosis and at-
/post-diagnosis changes in smoking. Compared to never smokers, risk of all-cause mortality 
among women with breast cancer was elevated among the 19% of women who were smokers at-
diagnosis (HR=1.69, 95% CI=1.36-2.11), those who smoked ≥20 cigarettes/day (HR=1.85, 95% 
CI=1.42-2.40), women who had smoked for ≥30 years (HR=1.62, 95% CI=1.28-2.05), and 
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women who had smoked ≥30 pack-years (HR=1.82, 95% CI=1.39-2.37). At-diagnosis smoking 
was not associated with breast cancer-specific mortality. Risk of all-cause mortality was further 
increased among the 8% of women who were at- and post-diagnosis smokers (HR=2.30, 95% 
CI=1.56-3.39), but was attenuated among the 11% of women who quit smoking after diagnosis 
(HR=1.83, 95% CI=1.32-2.52). Risk of breast cancer-specific mortality was elevated in 
association with post-diagnosis pack-years (HR=2.75, 95% CI=1.26-5.99). Smoking negatively 
impacts long-term survival after breast cancer. Smokers who quit smoking after breast cancer 
diagnosis may have an attenuated, but still elevated risk of all-cause mortality. 
Introduction  
Breast cancer is a significant public health problem in the United States with more than 
246,000 new breast cancer cases expected in 2016 (Siegel et al. 2016). Although there have been 
vast improvements in breast cancer treatment over the last few decades (Sledge et al. 2014) and 
breast cancer survival rates are high, estimated at 90% at 5-years after diagnosis, approximately 
40,000 women will die from breast cancer in 2016.(Siegel et al. 2016) This makes breast cancer 
the second leading cause of cancer-related death among women.(Siegel et al. 2016) The high 
incidence of breast cancer together with the high rate of survival contribute to an estimated 3.1 
million breast cancer survivors as of January 1, 2014 (American Cancer Society 2014). 
After breast cancer diagnosis, survivors may be motivated to make behavioral and 
lifestyle changes if they believe it will help improve prognosis, quality of life, and survival 
(McBride and Ostroff 2003). For the approximately 10-20% of women who are smokers at the 
time of breast cancer diagnosis (Bérubé et al. 2014; Westmaas et al. 2015), smoking cessation is 
one important behavioral change that may improve survival after breast cancer. Cigarettes are 
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known to contain more than 7,000 chemicals, including 69 known carcinogens such as benzene, 
arsenic and heavy metals, formaldehyde, vinyl chloride, N-nitrosamines, and polycyclic aromatic 
hydrocarbons (PAHs) (IARC 2004), which have the potential to increase the risk of treatment 
complications (Zhan et al. 2007), recurrence (Bishop et al. 2014), and second primary cancers 
(Neugut et al. 1994). Unlike studies of smoking and breast cancer incidence, which have yielded 
mixed results (Gaudet et al. 2013), most studies of smoking at the time of diagnosis and survival 
after breast cancer conducted to date report a positive association between smoking and breast 
cancer-specific mortality (Bérubé et al. 2014; Braithwaite et al. 2012; Calle et al. 1994; Dal 
Maso et al. 2008; Hellmann et al. 2010; Holmes et al. 1999, 2007; Manjer 2000; Pierce et al. 
2014; Tominaga et al. 1998; Warren et al. 2012; Yu et al. 1997). However, to date only one 
study (Passarelli et al. 2016) has prospectively considered the impact of post-diagnosis changes 
in smoking on survival. 
This current study aimed to examine whether smoking at the time of diagnosis and 
changes in smoking within five years after diagnosis were associated with long-term all-cause 
and breast cancer mortality among a population-based sample of women diagnosed with first 
primary breast cancer.  
Methods 
The present study used resources from the Long Island Breast Cancer Study Project 
(LIBCSP), a population-based study of newly diagnosed breast cancer cases who were residents 
of Nassau and Suffolk counties on Long Island, NY at the time of diagnosis. Details of the 
LIBCSP design have been published previously (Gammon et al. 2002c, 2002a). Institutional 
Review Board approval was obtained from all participating institutions and in accordance with 
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an assurance filed with and approved by the US Department of Health and Human Services. 
Study Population 
English-speaking women with a first primary diagnosis of in situ or invasive breast 
cancer were identified for inclusion using rapid-case ascertainment via active daily or weekly 
contact with local hospitals and confirmed by a physician and medical records. Additional 
eligibility criteria included being over the age of 20 and a resident of Nassau or Suffolk county 
on Long Island, NY, at the time of diagnosis between August 1, 1996, through July 31, 1997. 
The study reported here includes the 1,508 case women who were interviewed at baseline, on 
average within three months of diagnosis (mean=3.19 months). These women were primarily 
white (94%), with a mean age of 59 years (range: 25-98 years), and postmenopausal (68%) at 
diagnosis (Table III-1).  
Of the 1,508 women who provided signed informed consent and completed the 100-
minute, in-home, interviewer-administered, structured baseline questionnaire, 1,414 agreed to 
continued contact. Approximately 5 years after the initial diagnosis of breast cancer, these 1,414 
women were re-contacted for the follow-up interview. Informed consent was obtained by 
telephone from 1,120 of the 1,414 women (i.e., 60 refused by mail, 83 refused by telephone, no 
proxy was identified for 96 women who were not alive at follow-up, and 55 could not be 
located). A 45-minute interviewer-administered, structured questionnaire that assessed 
information similar to that obtained at the time of diagnosis, but regarding the time period since 
the initial diagnosis of breast cancer, was completed by telephone with 1,033 (68.5%) women 
(Bradshaw et al. 2012).  
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Smoking Assessment 
Smoking history, including smoking status, intensity and duration, was determined via 
interviewer-administered questionnaires at baseline and at the 5-year follow-up (Gammon et al. 
2004). Smoking status at baseline was defined as never, former, and current smoking in the year 
before diagnosis, and smoking status at the follow-up was similarly defined but in the year 
before the follow-up interview; approximately 19% of women reported being current smokers in 
the year before diagnosis and 8% reported being current smokers at the follow-up questionnaire. 
Intensity of smoking, or the number of cigarettes smoked/day, was categorized as <20 
cigarettes/day, and ≥20 cigarettes/day. Duration of smoking, or the total number of years of 
smoking excluding any time periods the women reported having not smoked, was categorized as 
<15 years, ≥15–<30 years, and ≥30 years of smoking. Cigarette pack-years was calculated by 
multiplying the average number of cigarette packs smoked per day and the total number of years 
of smoking and was categorized as >15 pack-years, >15–<30 pack-years, and ≥30 pack years. At 
baseline, smoking cessation (recency) among former smokers was categorized as <5 years, ≥5–
<10 years, and ≥10 years. In the analyses of post-diagnosis changes in smoking, each 
combination of pre-diagnosis/post-diagnosis smoking was examined (i.e., never/never smokers, 
former/former smokers, current/former smokers, and current/current smokers).  
Covariate assessment 
Covariates were assessed by interviewer-administered questionnaire. Potential 
confounders were selected using directed acyclic graphs (Greenland et al. 1999) and putative 
relationships based on previous studies of smoking and breast cancer survival. These covariates 
included age at diagnosis (years), at-diagnosis menopausal status (pre-menopausal versus post-
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menopausal), total annual household income (<$15,000–$24,999, $25,000–$49,999, and  
≥$50,000), education (<high school or high school graduate, some college or college graduate, 
and post-college), marital status (married or living as married versus not married, divorced, or 
widowed), body mass index (continuous, kg/m2), at-diagnosis recreational physical activity 
(never, former, and current physical activity of least 1 hour per week for 3 months or more), and 
at-diagnosis intake of alcoholic beverages such as beer, wine, or liquor (never, former, and 
current intake at least once a month for 6 months or more).  
Estrogen receptor status and nodal involvement were determined by medical record 
review and tumor size was obtained from the New York State Cancer Registry. At baseline, 
women were interviewed after surgery, but before initiation of most other components of the first 
course of treatment for the first primary breast cancer. Therefore, treatment received (radiation 
therapy, chemotherapy, or hormone therapy) was assessed by self-report at the follow-up 
questionnaire, which showed high agreement with medical record data (radiation therapy κ=0.97, 
chemotherapy κ=0.96, hormone therapy κ=0.92) (Cleveland et al. 2007), but were more 
complete. 
Outcome Assessment 
We used the National Death Index (NDI) (Centers for Disease Control and Prevention 
2014c) to ascertain date of death and cause of death among the 1,508 women diagnosed with 
breast cancer in 1996/1997. Breast cancer-related deaths were identified using International 
Statistical Classification of Diseases codes 174.9 and C-50.9 listed on the death certificate. 
Follow-up for mortality occurred from the date of diagnosis in 1996-1997 until December 31, 
2014. The median duration of follow-up was 17.61 years (range: 0.23-18.41 years). Among the 
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1,508 women, 597 deaths occurred by the end of follow-up at 18+ years of which 237 included 
breast cancer as a cause of death on the death certificate. 
Statistical Analysis  
We used multivariable Cox proportional hazards models to estimate hazard ratios (HR) 
and 95% confidence intervals (CIs) for the associations between at-diagnosis as well as at-/post-
diagnosis cigarette smoking and all-cause and breast cancer mortality. The proportional hazards 
assumption was assessed using exposure by time interactions and no violations of the 
proportional hazards assumptions were observed. All analyses were done using the Cox 
Regression function in IBM SPSS Statistics Version 22.0 (IBM Corp., Armonk, NY) and used 
never smokers as the referent group. In the analyses of at-diagnosis smoking, survival time began 
at the date of breast cancer diagnosis and continued until the earlier of date of death or December 
31, 2014. Age-adjusted and multivariable-adjusted models were fit for each of the exposures 
(smoking status, intensity, duration, pack-years, and recency) and for all-cause as well as breast 
cancer-specific mortality. The analyses of at-diagnosis smoking were not adjusted for disease 
and treatment characteristics, which occur and are ascertained after diagnosis and therefore do 
not meet the temporal condition necessary to be confounders. Furthermore, disease and treatment 
characteristics could be mediators if, for example, smoking influences the likelihood of estrogen 
receptor positive breast cancer, which influences treatment and subsequent prognosis (Gaudet et 
al. 2013). 
The analyses of post-diagnosis change in smoking were restricted to women who 
survived at least 5 years after diagnosis (n=1,339). Accordingly, survival time began at the date 
of completion of the follow-up questionnaire to the date of death or December 31, 2014, if alive. 
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After excluding an additional 7 women who reported being former smokers before diagnosis and 
current smokers at the follow-up questionnaire, the analytic sample consisted of 1,332 women. 
Of these, 377 (28%) were lost to follow-up and were, therefore, missing post-diagnosis smoking 
data. Because a complete-case analysis when data are not missing completely at random is 
inefficient and can potentially lead to biased results (Ibrahim et al. 2012), we employed multiple 
imputation to account for the missing data. Missing values were imputed using SPSS, which 
employs a fully conditional specification (FCS) algorithm (van Buuren 2007). The FCS method 
is an iterative Markov Chain Monte Carlo procedure that sequentially imputes missing values 
starting from the first variable with missing values by specifying a linear regression or logistic 
regression model for each continuous or categorical variable, respectively. We used 25 
imputations with 1,000 iterations and included demographics (age at diagnosis, menopausal 
status, income, education, marital status, BMI, physical activity, and alcohol intake), post-
diagnosis smoking exposures (smoking status, number of cigarettes smoked per day at follow-up 
[minimum=0], cumulative years of smoking [minimum=0], and cumulative pack-years of 
smoking [minimum=0]), disease characteristics (stage, tumor size, nodal status, estrogen receptor 
status), treatment (radiation therapy, chemotherapy, and hormone therapy), and the outcome (the 
event indicator and the Nelson-Aalen estimator of the cumulative hazard (White and Royston 
2009)).  
Results 
Prevalence of smoking among women with breast cancer 
 Among the LIBCSP population-based sample of women diagnosed with first primary 
breast cancer in 1996-1997, 19% reported smoking within a year of their diagnosis (i.e., were 
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current smokers). About five years after diagnosis, 8% of women reported continued smoking 
and 11% reported that they had quit smoking since diagnosis. 
At-diagnosis smoking and survival after breast cancer 
As shown in Table III-2, compared to never smokers, current smoking at the time of 
breast cancer diagnosis was associated with a 69% increased hazard of all-cause mortality 
(HR=1.69, 95% CI=1.36-2.11), after adjustment for age at diagnosis, body mass index, marital 
status, income, alcohol intake, and physical activity. Risk of all-cause mortality was increased 
50% (HR=1.50, 95% CI=1.10-2.03) for current smokers who smoked <20 cigarettes/day and 
85% (HR=1.85, 95% CI=1.42-2.40) for current smokers who smoked ≥20 cigarettes/day. 
Current smokers who had smoked for ≥15-<30 years had a 107% increased hazard (HR=2.07, 
95% CI=1.28-3.35) and women who smoked ≥30 years had a 62% increased hazard (HR=1.62, 
95% CI=1.28-2.05) of all-cause mortality. All-cause mortality was also increased among former 
smokers (HR=1.36, 95% CI=1.05-1.76) and current smokers (HR=1.82, 95% CI=1.39-2.37) who 
had smoked ≥30 pack-years. Additionally, risk of all-cause mortality was elevated among former 
smokers who had quit smoking within 5 years of diagnosis (HR=1.97, 95% CI=1.33-2.93), but 
not among women who had quit smoking ≥5 years before diagnosis (HR=0.94, 95% CI=0.64-
1.37). These findings were similar, but attenuated when we considered women with estrogen 
receptor positive tumors only. At-diagnosis smoking was not associated with breast cancer-
specific mortality. Results did not substantially differ when the analyses was restricted to women 
with invasive cancer only (Table III-3) or women with estrogen receptor-positive breast cancer 
(Table III-4). 
124 
At-/post-diagnosis smoking and survival after breast cancer 
Table III-5 shows the results of the full-case analyses utilizing the imputed data and 
Table III-6 shows the results of the complete-case analysis for the age-adjusted estimates. 
Overall, the results of both analyses are consistent. As shown in Table III-5, risk of all-cause 
mortality was elevated among women who continued smoking after diagnosis (HR=2.30, 95% 
CI=1.56-3.39) as compared to never smokers, after confounder adjustment. However, risk of all-
cause mortality was attenuated among women who quit smoking after diagnosis (HR=1.83, 95% 
CI=1.33-2.52). This pattern of association for women who quit smoking after diagnosis and 
women who continued smoking was consistent across high smoking intensity (HR =1.86, 95% 
CI=0.92-3.88 versus HR =2.95, 95% CI=1.77-4.93, respectively) and high cumulative duration 
of smoking (HR =1.87, 95% CI=1.24-2.83 versus HR =2.23, 95% CI=1.49-3.33, respectively). 
However, women with ≥30 cumulative pack-years of smoking who quit after diagnosis had a 
slightly greater risk of mortality (HR =2.36, 95% CI=1.43-3.89) as compared to women who did 
not quit after diagnosis (HR =2.12, 95% CI=1.32-3.43). Results did not substantially differ when 
the analyses was restricted to women with invasive cancer only (Table III-7), but appeared to be 
stronger among women with estrogen receptor positive tumors (Table III-8) and those with a 
BMI ≥25 kg/m2 (Table III-9), though data were sparse. 
Pre-/post-diagnosis smoking status, intensity, and duration were not significantly 
associated with breast cancer-specific mortality. However, we noted elevations in the breast 
cancer-specific mortality rate among women who continued smoking after diagnosis (HR=1.60, 
95% CI=0.79-3.23) and among women who continued smoking <20 cigarettes/day (HR=1.98, 
95% CI=0.94-4.17). Additionally, risk of breast cancer-specific mortality was elevated among 
women who continued smoking and who had smoked <30 cumulative pack-years (HR=2.75, 
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95% CI=1.26-5.99). Due to small numbers, we were unable to estimate the risk of mortality 
among women who continued smoking and who had smoked ≥30 cumulative pack-years. 
Discussion 
In this population-based study of women with newly diagnosed first primary breast 
cancer, smoking in the year before diagnosis was associated with a 69% increase in the risk of 
long-term all-cause mortality, but not breast cancer-specific mortality. Among women who 
continued smoking after breast cancer, risk of all-cause mortality was elevated by 130%, but was 
attenuated by approximately 20% among women who quit smoking after diagnosis. 
Additionally, among women who continued smoking, <30 cumulative pack-years of smoking 
was associated with more than a two-fold increase in the risk of breast cancer-specific mortality.  
While the carcinogenic constituents in tobacco smoke have been hypothesized to increase 
risk of incident breast cancer (Gaudet et al. 2013), very little is known about how these 
chemicals may act to increase risk of recurrence and subsequent mortality. PAHs which are 
present in tobacco smoke, for example, can exert estrogenic as well as anti-estrogenic effects 
(Santodonato 1997). Exposure to PAHs and the many other chemicals found in tobacco smoke 
may be important in hormonally sensitive breast tumors and could potentially influence survival. 
In the study reported here, at-diagnosis smoking was associated with all-cause mortality, but not 
breast cancer-specific mortality. This is inconsistent with most studies conducted to date which 
report approximately a 30% increased risk of breast cancer-specific mortality in association with 
at-diagnosis cigarette smoking (Bérubé et al. 2014). Reasons for this discrepancy are not clear. 
Studies examining smoking and mortality after breast cancer have primarily examined at-
diagnosis smoking only, and have reported positive findings (Bérubé et al. 2014). One recently 
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published study (Passarelli et al. 2016) prospectively evaluated changes in smoking status 
approximately 6 years after breast cancer diagnosis, which is an approach similar to that used in 
the study reported here. In their study, Passarelli and colleagues reported similar hazard ratios 
that were slightly larger in magnitude than those reported here for women who continued 
smoking after breast cancer for all-cause (HR=2.57, 95% CI=2.06-3.21, versus 2.30, 95% 
CI=1.56-3.39, respectively) and breast cancer-specific (HR=1.73, 95% CI=1.13-2.60, versus 
HR=1.60, 95% CI=0.79-3.23, respectively) mortality. These differences may arise from different 
approaches in addressing missing data. The response rate for the completion of our follow-up 
assessment was approximately 70%, which is higher than the 40% in the study by Passarelli et 
al., and we addressed the missing data due to potential biases that may arise from relying on a 
complete-case analysis only (Ibrahim et al. 2012). 
Similar to prior studies of smoking and mortality among breast cancer survivors, our 
study has several limitations. Our assessments of smoking relied on self-report; however, 
smoking history has been shown to be reliably recalled and self-reported (Krall et al. 1989). 
Nevertheless, it is also possible that women, particularly those that have been diagnosed with 
cancer, may misreport smoking status at- and post-diagnosis; however, our prevalence estimates 
for at-diagnosis (19%) (Bérubé et al. 2014) and post-diagnosis smoking (8%) are consistent with 
prior studies (Mayer and Carlson 2011; Westmaas et al. 2015). Third, although our study shows 
that smoking may adversely impact survival, we can only hypothesize about the biological 
mechanisms driving these associations given the complex nature of tobacco smoke. It is possible 
that our findings are confounded by changes in other behaviors such as alcohol intake after 
diagnosis, which we were unable to consider in the same models due to insufficient power; 
however, most studies of alcohol intake and breast cancer mortality have been negative (Gou et 
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al. 2013). Last, while the prospective design of our study allowed us to assess changes in 
smoking status several years after breast cancer diagnosis, a proportion of women were lost to 
follow-up and thus did not complete the follow-up assessment; however, we addressed the 
missing data using multiple imputation, which results in valid statistical inferences that properly 
reflect the uncertainty due to missing values (Sterne et al. 2009). 
Conclusions 
The results of our study show that smoking negatively impacts long-term survival after 
breast cancer. Post-diagnosis cessation of smoking may be important in reducing, in part, the 
elevated risk of all-cause as well as breast cancer mortality due to smoking. Breast cancer 
survivors may be motivated to quit smoking and may therefore benefit from aggressive smoking 
cessation programs starting as early as the time of diagnosis, but continued throughout the 
survivorship continuum. Emphasis should also be placed on systematically assessing the impact 
of smoking history, smoking status, and post-diagnosis changes in smoking on outcomes in 
clinical trials, which often fail to account for this important exposure (Land et al. 2016). 
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Table III-1. Distribution of selected at-diagnosis participant and disease characteristics of 
the LIBCSP women diagnosed with breast cancer in 1996-1997 (N=1,508), overall and by 
pre- and at-diagnosis smoking status. 
   At-diagnosis Smoking Statusc 
 Total 
 Never  
Smokers 





 (N=1,508)  (n=674)  (n=544)  (n=290) 
At-diagnosis characteristic n (%)  n (%)  n (%)  n (%) 
Age at diagnosis (years)        
<50 407 (27.0%)  192 (28.5%)  122 (22.4%)  93 (32.1%) 
50–64 582 (38.6%)  230 (34.1%)  219 (40.3%)  133 (45.9%) 
≥65 519 (34.4%)  252 (37.4%)  203 (37.3%)  64 (22.1%) 
Mean (SD) 58.8 (12.7)  59.4 (13.6)  59.9 (11.9)  55.5 (11.3) 
Menopausal status        
Premenopausal 472 (31.9%)  216 (32.6%)  146 (27.3%)  110 (39.0%) 
Postmenopausal 1,006 (68.1%)  446 (67.4%)  388 (72.7%)  172 (61.0%) 
Income        
<$15,000–$24,999 286 (19.0%)  154 (22.9%)  78 (14.4%)  54 (18.7%) 
$25,000–$49,999 488 (32.4%)  205 (30.5%)  189 (34.9%)  94 (32.5%) 
≥$50,000 730 (48.5%)  314 (46.7%)  275 (50.7%)  141 (48.8%) 
Education        
<HS/HS graduate 721 (48.0%)  334 (49.7%)  240 (44.3%)  147 (51.0%) 
Some college/college 
graduate 
551 (36.7%)  223 (33.2%)  214 (39.5%)  114 (39.6%) 
Post-college 230 (15.3%)  115 (17.1%)  88 (16.2%)  27 (9.4%) 
Marital Status        
Married or living as married 1,029 (68.3%)  459 (68.1%)  388 (71.3%)  182 (63.0%) 
Not married 478 (31.7%)  215 (31.9%)  156 (28.7%)  107 (37.0%) 
BMI at diagnosis (kg/m2)        
<25.0 683 (45.8%)  284 (42.6%)  237 (44.1%)  162 (56.3%) 
25.0–29.9 476 (31.9%)  227 (34.1%)  174 (32.4%)  75 (26.0%) 
≥30.0 332 (22.3%)  155 (23.3%)  126 (23.5%)  51 (17.7%) 
Mean (SD) 26.6 (5.7)  26.9 (5.8)  26.9 (5.6)  25.5 (5.5) 
Physical activitya        
Never 334 (22.5%)  157 (23.6%)  109 (20.3%)  68 (23.9%) 
Former 253 (17.0%)  102 (15.4%)  97 (18.0%)  54 (18.9%) 
Current 900 (60.5%)  405 (61.0%)  332 (61.7%)  163 (57.2%) 
Alcohol intakeb        
Never 588 (39.0%)  329 (48.8%)  163 (30.0%)  96 (33.1%) 
Former 212 (14.1%)  76 (11.3%)  90 (16.6%)  46 (15.9%) 
Current 707 (46.9%)  269 (39.9%)  290 (53.4%)  148 (51.0%) 
Stage        
Invasive 1,273 (84.4%)  567 (84.1%)  454 (83.5%)  252 (86.9%) 
In situ 235 (15.6%)  107 (15.9%)  90 (16.5%)  38 (13.1%) 
Nodal involvement        
No 213 (25.5%)  89 (24.7%)  86 (27.4%)  38 (23.6%) 
Yes 622 (74.5%)  271 (75.3%)  228 (72.6%)  123 (76.4%) 
Tumor size (cm)        
≤2.0 622 (75.5%)  258 (72.1%)  247 (79.2%)  117 (76.0%) 
>2.0 202 (24.5%)  100 (27.9%)  65 (20.8%)  37 (24.0%) 
Mean (SD) 1.7 (1.6)  1.8 (1.6)  1.6 (1.5)  1.8 (1.8) 
Estrogen receptor status        
Negative 264 (26.7%)  123 (28.0%)  88 (25.1%)  53 (26.6%) 
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   At-diagnosis Smoking Statusc 
 Total 
 Never  
Smokers 





 (N=1,508)  (n=674)  (n=544)  (n=290) 
At-diagnosis characteristic n (%)  n (%)  n (%)  n (%) 
Positive 726 (73.3%)  317 (72.1%)  263 (74.9%)  146 (73.4%) 
Treatment received        
Radiation 625 (60.9%)  261 (57.1%)  235 (63.5%)  129 (64.8%) 
Chemotherapy  423 (41.4%)  197 (43.4%)  146 (39.6%)  80 (40.2%) 
Hormone therapy 616 (61.1%)  280 (62.5%)  228 (63.0%)  108 (54.3%) 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, 
followed-up for vital status through December 31, 2014. 
aAt-diagnosis recreational physical activity was defined as never, former, and current physical activity of least 1 hour per week for 3 months or 
more. 
bAt-diagnosis intake of alcoholic beverages was defined as never, former, and current intake of alcoholic beverages such as beer, wine, or liquor 
at least once a month for 6 months or more. 
























Table III-2. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between pre- and at-
diagnosis cigarette smoking and mortality in the LIBCSP women diagnosed with breast cancer in 1996-1997 (N=1,508). 
 All-Cause Mortality (n deaths=597)  Breast Cancer-Specific Mortality (n deaths=237) 












At-diagnosis Smoking Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
Never smokersa 258 416 1 (Ref)  1 (Ref)  112 562 1 (Ref)  1 (Ref) 
            
Cigarette smoking status            
Former smokers 206 338 0.98 (0.82-1.18)  1.01 (0.84-1.22)  74 470 0.81 (0.60-1.09)  0.82 (0.61-1.11) 
Current smokers 133 157 1.69 (1.37-2.10)  1.69 (1.36-2.11)  51 239 1.14 (0.81-1.59)  1.08 (0.77-1.51) 
Intensity of smoking            
Former smokers            
<20 cigarettes/day 93 416 0.80 (0.63-1.01)  0.86 (0.67-1.09)  35 255 0.70 (0.48-1.03)  0.72 (0.49-1.06) 
≥20 cigarettes/day 109 138 1.21 (0.96-1.51)  1.18 (0.93-1.48)  39 208 0.96 (0.67-1.39)  0.97 (0.67-1.41) 
Current smokers            
<20 cigarettes/day 53 73 1.47 (1.09-1.98)  1.50 (1.10-2.03)  23 103 1.15 (0.73-1.80)  1.10 (0.70-1.73) 
≥20 cigarettes/day 80 83 1.90 (1.48-2.46)  1.85 (1.42-2.40)  28 135 1.13 (0.75-1.72)  1.06 (0.70-1.61) 
Duration of smoking            
Former smokers            
<15 years 45 131 0.79 (0.58-1.09)  0.84 (0.61-1.17)  23 153 0.75 (0.48-1.18)  0.78 (0.49-1.24) 
≥15–<30 years 61 123 0.90 (0.68-1.19)  0.94 (0.70-1.25)  20 164 0.65 (0.40-1.04)  0.65 (0.40-1.06) 
≥30 years 100 84 1.17 (0.93-1.48)  1.17 (0.92-1.49)  31 153 1.04 (0.69-1.56)  1.04 (0.69-1.57) 
Current smokers            
<15 years 5 6 1.72 (0.71-4.17)  1.57 (0.57-4.28)  <5 9 –  – 
≥15–<30 years 21 48 2.09 (1.30-3.37)  2.07 (1.28-3.35)  15 54 1.39 (0.79-2.46)  1.32 (0.74-2.36) 
≥30 years 106 103 1.62 (1.29-2.03)  1.62 (1.28-2.05)  34 175 1.05 (0.72-1.54)  0.99 (0.67-1.46) 
Pack-years of smoking            
Former smokers            
<15 pack-years 87 196 0.84 (0.66-1.07)  0.90 (0.70-1.15)  37 246 0.77 (0.53-1.11)  0.80 (0.55-1.17) 
≥15–<30 pack-years 30 70 0.74 (0.51-1.09)  0.73 (0.49-1.08)  11 89 0.61 (0.33-1.14)  0.61 (0.33-1.14) 
≥30 pack-years 83 63 1.39 (1.08-1.78)  1.36 (1.05-1.76)  26 120 1.14 (0.74-1.76)  1.16 (0.75-1.79) 
Current smokers            
<15 pack-years 27 47 1.50 (1.00-2.25)  1.58 (1.05-2.39)  13 61 1.10 (0.62-1.97)  1.18 (0.66-2.11) 
≥15–<30 pack-years 29 43 1.58 (1.07-2.34)  1.39 (0.94-2.06)  16 56 1.37 (0.81-2.33)  1.10 (0.65-1.89) 
≥30 pack-years 76 65 1.78 (1.38-2.30)  1.82 (1.39-2.37)  22 119 1.04 (0.66-1.64)  1.01 (0.63-1.60) 
Smoking cessation recency            
Former smokers            
<5 years 29 31 1.92 (1.30-2.82)  1.97 (1.33-2.93)  12 48 1.43 (0.79-2.60)  1.46 (0.80-2.67) 







 All-Cause Mortality (n deaths=597)  Breast Cancer-Specific Mortality (n deaths=237) 












At-diagnosis Smoking Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
≥10 years 147 245 0.90 (0.74-1.11)  0.94 (0.76-1.16)  51 341 0.76 (0.55-1.06)  0.79 (0.56-1.10) 
Current smokers 133 157 1.70 (1.38-2.11)  1.70 (1.36-2.12)  51 239 1.14 (0.82-1.59)  1.08 (0.77-1.52) 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
aNever smokers were the referent group in all analyses. 










Table III-3. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between pre- and at-
diagnosis cigarette smoking and mortality in the LIBCSP women diagnosed with invasive breast cancer in 1996-1997 
(n=1,273). 
 All-Cause Mortality (n deaths=548)  Breast Cancer-Specific Mortality (n deaths=229) 












At-diagnosis Smoking Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
Never smokersa 240 327 1 (Ref)  1 (Ref)  107 460 1 (Ref)  1 (Ref) 
            
Cigarette smoking status            
Former smokers 187 267 0.97 (0.80-1.17)  1.00 (0.82-1.22)  74 380 0.86 (0.64-1.15)  0.88 (0.65-1.19) 
Current smokers 121 131 1.59 (1.27-1.99)  1.57 (1.25-1.98)  48 204 1.07 (0.76-1.51)  1.01 (0.71-1.43) 
Intensity of smoking            
Former smokers            
<20 cigarettes/day 85 157 0.80 (0.61-1.00)  0.84 (0.65-1.09)  35 207 0.74 (0.51-1.08)  0.76 (0.51-1.13) 
≥20 cigarettes/day 98 107 1.20 (0.95-1.52)  1.17 (0.92-1.50)  39 166 1.03 (0.72-1.49)  1.05 (0.72-1.53) 
Current smokers            
<20 cigarettes/day 51 57 1.47 (1.09-2.00)  1.51 (1.10-2.05)  23 85 1.18 (0.75-1.86)  1.11 (0.70-1.76) 
≥20 cigarettes/day 70 74 1.69 (1.29-2.22)  1.62 (1.22-2.14)  25 119 0.98 (0.63-1.53)  0.93 (0.60-1.44) 
Duration of smoking            
Former smokers            
<15 years 43 107 0.78 (0.56-1.08)  0.82 (0.58-1.15)  23 127 0.76 (0.48-1.19)  0.77 (0.48-1.23) 
≥15–<30 years 56 92 0.93 (0.69-1.24)  0.98 (0.73-1.33)  20 128 0.72 (0.44-1.15)  0.73 (0.45-1.19) 
≥30 years 88 68 1.13 (0.88-1.44)  1.14 (0.88-1.47)  31 125 1.12 (0.74-1.68)  1.15 (0.76-1.74) 
Current smokers            
<15 years 5 6 1.51 (0.62-3.67)  1.30 (0.47-3.55)  <5 9 –  – 
≥15–<30 years 19 39 1.82 (1.11-2.99)  1.76 (1.06-2.91)  14 44 1.28 (0.71-2.30)  1.21 (0.67-2.18) 
≥30 years 96 86 1.53 (1.21-1.95)  1.53 (1.20-1.96)  32 150 1.00 (0.67-1.48)  0.94 (0.63-1.40) 
Pack-years of smoking            
Former smokers            
<15 pack-years 80 160 0.81 (0.63-1.05)  0.87 (0.67-1.13)  37 203 0.79 (0.54-1.15)  0.81 (0.55-1.20) 
≥15–<30 pack-years 27 51 0.75 (0.50-1.11)  0.76 (0.50-1.15)  11 67 0.69 (0.37-1.29)  0.72 (0.38-1.34) 
≥30 pack-years 74 48 1.40 (1.08-1.82)  1.37 (1.05-1.80)  26 96 1.25 (0.81-1.93)  1.27 (0.82-1.98) 
Current smokers            
<15 pack-years 26 38 1.45 (0.96-2.19)  1.49 (0.97-2.27)  13 51 1.11 (0.62-1.98)  1.14 (0.64-2.05) 
≥15–<30 pack-years 27 34 1.55 (1.03-2.31)  1.36 (0.91-2.05)  15 46 1.32 (0.76-2.27)  1.06 (0.61-1.85) 
≥30 pack-years 67 59 1.61 (1.23-2.12)  1.63 (1.23-2.15)  20 106 0.92 (0.57-1.48)  0.89 (0.55-1.45) 
Smoking cessation recency            
Former smokers            







 All-Cause Mortality (n deaths=548)  Breast Cancer-Specific Mortality (n deaths=229) 












At-diagnosis Smoking Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
≥5–<10 years 24 50 0.84 (0.55-1.28)  0.85 (0.56-1.30)  11 63 0.73 (0.39-1.36)  0.72 (0.39-1.35) 
≥10 years 134 196 0.89 (0.72-1.10)  0.93 (0.74-1.16)  51 279 0.80 (0.57-1.12)  0.83 (0.59-1.17) 
Current smokers 121 131 1.59 (1.27-2.00)  1.57 (1.25-1.98)  48 204 1.07 (0.76-1.51)  1.01 (0.71-1.43) 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
aNever smokers were the referent group in all analyses. 










Table III-4. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between pre- and at-
diagnosis cigarette smoking and mortality in the LIBCSP women diagnosed with estrogen receptor-positive breast cancer in 
1996-1997 (n=726). 
 All-Cause Mortality (n deaths=317)  Breast Cancer-Specific Mortality (n deaths=237) 















At-diagnosis Smoking Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
Never smokersa 138 179 1 (Ref)  1 (Ref)  60 257 1 (Ref)  1 (Ref) 
            
Cigarette smoking status            
Former smokers 124 149 1.01 (0.79-1.29)  1.02 (0.78-1.32)  41 222 0.83 (0.56-1.23)  0.86 (0.57-1.30) 
Current smokers 65 81 1.41 (1.04-1.91)  1.36 (0.99-1.86)  23 123 0.81 (0.50-1.32)  0.75 (0.46-1.24) 
Intensity of smoking            
Former smokers            
<20 cigarettes/day 51 80 0.83 (0.60-1.15)  0.88 (0.63-1.23)  19 112 0.75 (0.45-1.26)  0.80 (0.47-1.36) 
≥20 cigarettes/day 62 68 1.22 (0.91-1.65)  1.18 (0.86-1.62)  22 108 0.92 (0.57-1.50)  0.93 (0.57-1.55) 
Current smokers            
<20 cigarettes/day 24 37 1.14 (0.74-1.77)  1.16 (0.75-1.82)  11 50 0.89 (0.47-1.70)  0.86 (0.45-1.65) 
≥20 cigarettes/day 41 44 1.66 (1.16-2.37)  1.54 (1.06-2.23)  12 73 0.75 (0.40-1.40)  0.68 (0.36-1.28) 
Duration of smoking            
Former smokers            
<15 years 26 53 0.83 (0.54-1.26)  0.85 (0.55-1.30)  15 64 0.91 (0.52-1.61)  0.94 (0.53-1.68) 
≥15–<30 years 32 52 0.97 (0.66-1.43)  1.06 (0.71-1.58)  12 72 0.76 (0.41-1.42)  0.79 (0.42-1.50) 
≥30 years 56 44 1.15 (0.84-1.57)  1.11 (0.80-1.54)  14 86 0.81 (0.45-1.46)  0.83 (0.45-1.51) 
Current smokers            
<15 years <5 <5 –  –  <5 6 –  – 
≥15–<30 years 11 21 2.05 (1.06-3.95)  1.90 (0.97-3.73)  9 23 1.37 (0.65-2.89)  1.19 (0.55-2.57) 
≥30 years 50 56 1.32 (0.95-1.83)  1.29 (0.92-1.81)  13 93 0.65 (0.36-1.19)  0.62 (0.34-1.14) 
Pack-years of smoking            
Former smokers            
<15 pack-years 51 82 0.90 (0.66-1.25)  0.95 (0.69-1.32)  22 111 0.85 (0.52-1.39)  0.89 (0.54-1.47) 
≥15–<30 pack-years 14 35 0.62 (0.36-1.07)  0.60 (0.33-1.09)  6 43 0.57 (0.25-1.32)  0.58 (0.25-1.36) 
≥30 pack-years 48 30 1.46 (1.05-2.03)  1.38 (0.98-1.96)  13 65 1.04 (0.57-1.90)  1.06 (0.57-1.98) 
Current smokers            
<15 pack-years 13 22 1.27 (0.71-2.27)  1.29 (0.70-2.36)  8 27 1.11 (0.53-2.35)  1.19 (0.56-2.52) 
≥15–<30 pack-years 16 23 1.39 (0.82-2.35)  1.19 (0.70-2.36)  8 31 1.00 (0.47-2.11)  0.76 (0.35-1.64) 
≥30 pack-years 35 36 1.42 (0.98-2.06)  1.40 (0.95-2.06)  7 64 0.54 (0.25-1.17)  0.52 (0.24-1.24) 
Smoking cessation recency            







 All-Cause Mortality (n deaths=317)  Breast Cancer-Specific Mortality (n deaths=237) 















At-diagnosis Smoking Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
<5 years 18 13 1.93 (1.18-3.15)  2.07 (1.23-3.48)  6 25 1.24 (0.54-2.88)  1.36 (0.58-3.22) 
≥5–<10 years 10 25 0.75 (0.39-1.42)  0.73 (0.38-1.41)  <5 32 0.40 (0.12-1.26)  0.39 (0.12-1.23) 
≥10 years 86 111 0.95 (0.73-1.25)  0.96 (0.73-1.28)  32 165 0.86 (0.56-1.33)  0.91 (0.58-1.42) 
Current smokers 65 81 1.41 (1.04-1.91)  1.36 (0.99-1.86)  23 123 0.81 (0.50-1.31)  0.75 (0.46-1.23) 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
aNever smokers were the referent group in all analyses. 









Table III-5. Cox regression hazard ratios (HRs)  and 95% confidence intervals (CIs) for the association between at-/post-
diagnosis cigarette smoking and mortality in the LIBCSP women diagnosed with breast cancer in 1996-1997 (n=1,332).  
 All-Cause Mortality (n deaths=426)  Breast Cancer-Specific Mortality (n deaths=125) 














Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
Never/Never smokersa 185 416 1 (Ref)  1 (Ref)  59 542 1 (Ref)  1 (Ref) 
            
Cigarette smoking status            
Former/Former smokers 144 333 0.96 (0.86-1.07)  1.00 (0.80-1.25)  40 437 0.84 (0.68-1.03)  0.86 (0.57-1.30) 
Current/Former smokers 55 90 1.73 (1.27-2.36)  1.83 (1.32-2.52)  12 133 0.92 (0.47-1.80)  1.01 (0.51-1.98) 
Current/Current 
smokers 
42 67 2.25 (1.54-3.28)  2.30 (1.56-3.39)  14 95 1.48 (0.75-2.90)  1.60 (0.79-3.23) 
Intensity of smokingb            
Former/Former smokers            
<20 cigarettes/day 79 198 0.89 (0.67-1.18)  0.91 (0.69-1.22)  19 258 0.73 (0.43-1.24)  0.73 (0.43-1.26) 
≥20 cigarettes/day 65 135 1.05 (0.78-1.42)  1.11 (0.82-1.51)  21 179 0.97 (0.57-1.66)  1.03 (0.60-1.78) 
Current/Former smokers            
<20 cigarettes/day 35 70 1.70 (1.17-2.49)  1.79 (1.21-2.66)  10 95 0.94 (0.41-2.13)  1.00 (0.44-2.29) 
≥20 cigarettes/day 20 20 1.79 (0.89-3.60)  1.86 (0.92-3.88)  <5 38 –  – 
Current/Current 
smokers 
           
<20 cigarettes/day 22 39 1.80 (1.06-3.05)  1.85 (1.09-3.16)  11 50 1.93 (0.93-4.00)  1.98 (0.94-4.17) 
≥20 cigarettes/day 20 28 2.93 (1.77-4.85)  2.95 (1.77-4.93)  <5 45 –  – 
Duration of smoking            
Former/Former smokers            
<30 years 82 241 0.91 (0.70-1.19)  0.94 (0.71-1.23)  23 300 0.75 (0.46-1.24)  0.74 (0.45-1.23) 
≥30 years 62 92 1.03 (0.76-1.39)  1.10 (0.80-1.50)  17 137 1.00 (0.54-1.86)  1.15 (0.61-2.16) 
Current/Former smokers            
<30 years 31 47 1.76 (1.12-2.77)  1.77 (1.11-2.82)  5 73 0.72 (0.20-2.55)  0.79 (0.22-2.83) 
≥30 years 24 43 1.71 (1.15-2.55)  1.87 (1.24-2.83)  7 60 1.07 (0.48-2.41)  1.17 (0.51-2.67) 
Current/Current 
smokers 
           
<30 years <5 12 –  –  <5 12 –  – 
≥30 years 38 55 2.17 (1.47-3.20)  2.23 (1.49-3.33)  10 83 1.27 (0.58-2.75)  1.36 (0.61-3.03) 
Pack-years of smoking            
Former/Former smokers            
<30 pack-years 90 260 0.87 (0.67-1.13)  0.90 (0.69-1.18)  24 326 0.71 (0.44-1.15)  0.71 (0.44-1.17) 







 All-Cause Mortality (n deaths=426)  Breast Cancer-Specific Mortality (n deaths=125) 














Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
Current/Former smokers            
<30 pack-years 33 66 1.51 (1.01-2.27)  1.56 (1.03-2.39)  7 91 0.78 (0.33-1.86)  0.83 (0.35-2.01) 
≥30 pack-years 22 24 2.15 (1.32-3.50)  2.36 (1.43-3.89)  5 42 1.18 (0.41-3.42)  1.35 (0.46-3.99) 
Current/Current 
smokers 
           
<30 pack-years 14 27 2.43 (1.32-4.46)  2.65 (1.45-4.84)  9 32 2.44 (1.14-5.21)  2.75 (1.26-5.99) 
≥30 pack-years 28 40 2.14 (1.35-3.40)  2.12 (1.32-3.43)  <5 63 -  - 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
Missing data analyses exclude women who died within 5 years of breast cancer diagnosis (n=169) and women who reported post-, but not pre-, diagnosis smoking (n=7). 
aNever/Never smokers were the referent group in all analyses. 
bIntensity of smoking was based on most recent smoking status 








Table III-6. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between at-/post-
diagnosis cigarette smoking and mortality in the LIBCSP women diagnosed with breast cancer in 1996-1997, using a complete-
case analysis (n=955).  
 All-Cause Mortality (n deaths=426)  Breast Cancer Mortality (n deaths=125) 
COMPLETE-CASE 
ANALYSIS 
  Age-Adjusted    Age-Adjusted 
At-/Post-diagnosis Smoking Deaths Censored HR (95% CI)  Deaths Censored HR (95% CI) 
Never/Never smokersa 107 305 1 (Ref)  37 375 1 (Ref) 
        
Cigarette smoking status        
Former/Former smokers 90 248 0.98 (0.74-1.29)  26 312 0.85 (0.51-1.40) 
Current/Former smokers 20 53 1.50 (0.93-2.44)  7 66 1.10 (0.49-2.48) 
Current/Current smokers 29 54 2.25 (1.48-3.43)  10 73 1.50 (0.74-3.04) 
Intensity of smokingb        
Former/Former smokers        
<20 cigarettes/day 44 142 0.86 (0.61-1.22)  12 174 0.70 (0.37-1.35) 
≥20 cigarettes/day 45 104 1.12 (0.79-1.59)  14 35 1.05 (0.57-1.95) 
Current/Former smokers        
<20 cigarettes/day 18 46 1.59 (0.96-2.65)  6 58 1.09 (0.46-2.59) 
≥20 cigarettes/day <5 7 –  <5 8 – 
Current/Current smokers        
<20 cigarettes/day 14 30 1.82 (1.04-3.20)  8 36 2.13 (0.99-4.61) 
≥20 cigarettes/day 15 23 3.07 (1.76-5.34)  <5 36 – 
Duration of smoking        
Former/Former smokers        
<30 years 47 181 0.88 (0.63-1.25)  15 213 0.72 (0.40-1.32) 
≥30 years 43 67 1.10 (0.77-1.58)  11 99 1.11 (0.56-2.22) 
Current/Former smokers        
<30 years <5 18 –  <5 20 – 
≥30 years 17 35 1.54 (0.92-2.58)  6 46 1.32 (0.56-3.12) 
Current/Current smokers        
<30 years 3 10 –  <5 10 – 
≥30 years 26 44 2.15 (1.39-3.33)  7 63 1.23 (0.55-2.77) 
Pack-years of smoking        
Former/Former smokers        
<30 pack-years 54 191 0.86 (0.62-1.20)  16 229 0.71 (0.40-1.28) 
≥30 pack-years 34 50 1.26 (0.86-1.86)  10 74 1.36 (0.67-2.77) 
Current/Former smokers        
<30 pack-years 12 37 1.36 (0.74-2.49)  <5 45 – 







 All-Cause Mortality (n deaths=426)  Breast Cancer Mortality (n deaths=125) 
COMPLETE-CASE 
ANALYSIS 
  Age-Adjusted    Age-Adjusted 
At-/Post-diagnosis Smoking Deaths Censored HR (95% CI)  Deaths Censored HR (95% CI) 
Current/Current smokers        
<30 pack-years 12 21 2.90 (1.57-5.36)  8 25 3.02 (1.38-6.64) 
≥30 pack-years 16 31 1.89 (1.11-3.21)  <5 45 – 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for 
vital status through December 31, 2014. Complete-case analyses exclude women who died within 5 years of breast cancer diagnosis (n=169), women 
who reported post-, but not pre-, diagnosis smoking (n=7), and women who were lost to follow-up (n=377.) 
aNever/Never smokers were the referent group in all analyses. 







Table III-7. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between at-/post-
diagnosis cigarette smoking and mortality in the LIBCSP women diagnosed with invasive breast cancer in 1996-1997 
(n=1,106).  
 All-Cause Mortality (n deaths=385)  Breast Cancer-Specific Mortality (n deaths=120) 














Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
Never/Never smokersa 172 327 1 (Ref)  1 (Ref)  57 442 1 (Ref)  1 (Ref) 
            
Cigarette smoking status            
Former/Former smokers 127 263 0.92 (0.82-1.03)  0.95 (0.75-1.21)  40 350 0.88 (0.71-1.08)  0.89 (0.58-1.35) 
Current/Former smokers 47 78 1.62 (1.17-2.26)  1.72 (1.22-2.41)  13 115 0.82 (0.41-1.65)  0.92 (0.45-1.86) 
Current/Current 
smokers 
39 53 1.96 (1.30-2.93)  2.06 (1.36-3.13)  10 79 1.24 (0.61-2.51)  1.44 (0.69-3.00) 
Intensity of smokingb            
Former/Former smokers            
<20 cigarettes/day 66 154 0.83 (0.62-1.12)  0.86 (0.63-1.17)  19 201 0.76 (0.44-1.29)  0.75 (0.44-1.30) 
≥20 cigarettes/day 61 109 1.03 (0.75-1.42)  1.08 (0.78-1.50)  21 149 1.03 (0.60-1.77)  1.07 (0.61-1.85) 
Current/Former smokers            
<20 cigarettes/day 30 59 1.56 (1.05-2.33)  1.65 (1.10-2.49)  8 81 0.85 (0.37-1.95)  0.93 (0.41-2.15) 
≥20 cigarettes/day 17 19 1.80 (0.88-3.72)  1.91 (0.89-4.07)  <5 34 –  – 
Current/Current 
smokers 
           
<20 cigarettes/day 21 29 1.69 (0.98-2.92)  1.78 (1.02-3.11)  10 40 1.65 (0.77-3.57)  1.80 (0.82-3.96) 
≥20 cigarettes/day 18 24 2.34 (1.36-4.03)  2.46 (1.40-4.34)  <5 39 –  – 
Duration of smoking            
Former/Former smokers            
<30 years 79 193 0.88 (0.67-1.17)  0.90 (0.67-1.21)  24 248 0.79 (0.48-1.29)  0.76 (0.46-1.26) 
≥30 years 48 70 0.96 (0.70-1.32)  1.03 (0.74-1.44)  16 102 1.06 (0.57-1.98)  1.20 (0.64-2.27) 
Current/Former smokers            
<30 years 24 41 1.55 (0.95-2.54)  1.57 (0.95-2.59)  <5 61 –  – 
≥30 years 23 37 1.69 (1.11-2.55)  1.85 (1.21-2.83)  6 54 1.03 (0.46-2.31)  1.13 (0.49-2.61) 
Current/Current 
smokers 
           
<30 years <5 10 –  –  <5 11 –  – 
≥30 years 34 43 1.92 (1.27-2.90)  2.04 (1.33-3.12)  9 68 1.12 (0.51-2.46)  2.19 (0.52-9.13) 
Pack-years of smoking            
Former/Former smokers            







 All-Cause Mortality (n deaths=385)  Breast Cancer-Specific Mortality (n deaths=120) 














Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
≥30 pack-years 48 62 1.13 (0.80-1.61)  1.19 (0.84-1.70)  16 94 1.27 (0.69-2.35)  1.34 (0.72-2.52) 
Current/Former smokers            
<30 pack-years 24 52 1.37 (0.89-2.12)  1.43 (0.91-2.24)  6 70 0.71 (0.29-1.78)  0.78 (0.31-1.95) 
≥30 pack-years 23 26 2.12 (1.29-3.49)  2.33 (1.39-3.91)  <5 45 –  – 
Current/Current 
smokers 
           
<30 pack-years 15 20 2.43 (1.29-4.58)  2.61 (1.39-4.90)  9 26 2.16 (0.97-4.81)  2.58 (1.13-5.88) 
≥30 pack-years 24 33 1.74 (1.04-2.89)  1.82 (1.08-3.08)  <5 53 –  – 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
Missing data analyses exclude women who died within 5 years of breast cancer diagnosis (n=169) and women who reported post-, but not pre-, diagnosis smoking (n=5). 
aNever/Never smokers were the referent group in all analyses. 
bIntensity of smoking was based on most recent smoking status 








Table III-8. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between at- and post-
diagnosis cigarette smoking and mortality in the LIBCSP women diagnosed with estrogen receptor positive breast cancer in 
1996-1997 (n=992).  
 All-Cause Mortality (n deaths=337)  Breast Cancer-Specific Mortality (n deaths=100) 

















Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
Never smokersa 148 296 1 (Ref)  1 (Ref)  49 395 1 (Ref)  1 (Ref) 
            
Cigarette smoking status            
Former/Former smokers 111 245 0.95 (0.73-1.22)  0.99 (0.75-1.29)  31 325 0.78 (0.49-1.24)  0.79 (0.48-1.28) 
Current/Former smokers 49 76 1.70 (1.20-2.40)  1.80 (1.26-2.59)  10 114 0.82 (0.39-1.69)  0.93 (0.44-1.97) 
Current/Current 
smokers 
29 38 2.40 (1.55-3.72)  2.48 (1.55-3.95)  10 57 1.57 (0.76-3.26)  1.82 (0.85-3.91) 
Pack-years of smoking            
Former/Former smokers            
<30 pack-years 70 183 0.89 (0.66-1.20)  0.92 (0.67-1.26)  20 234 0.68 (0.39-1.17)  0.67 (0.38-1.18) 
≥30 pack-years 41 62 1.06 (0.72-1.57)  1.13 (0.75-1.68)  12 91 1.03 (0.51-2.08)  1.09 (0.53-2.24) 
Current/Former smokers            
<30 pack-years 29 53 1.51 (0.97-2.34)  1.56 (0.98-2.49)  6 75 0.72 (0.28-1.86)  0.79 (0.30-2.09) 
≥30 pack-years 20 23 2.04 (1.16-3.60)  2.31 (1.28-4.15)  <5 39 -  - 
Current/Current 
smokers 
           
<30 pack-years 10 14 2.98 (1.43-6.23)  3.54 (1.71-7.33)  7 17 3.15 (1.34-7.39)  4.17 (1.72-10.13) 
≥30 pack-years 19 25 2.16 (1.27-3.68)  2.12 (1.20-3.77)  <5 41 -  - 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
Missing data analyses exclude women who died within 5 years of breast cancer diagnosis (n=169) and women who reported post-, but not pre-, diagnosis smoking (n=7). 
aNever/Never smokers were the referent group in all analyses. 

















Table III-9. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between at- and post-
diagnosis cigarette smoking and mortality among LIBCSP overweight and obese (BMI ≥25 kg/m2) women diagnosed with 
breast cancer in 1996-1997 (n=711).  
 All-Cause Mortality (n deaths=255)  Breast Cancer-Specific Mortality (n deaths=71) 
















Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
Never/Never smokers 120 220 1 (Ref)  1 (Ref)  34 306 1 (Ref)  1 (Ref) 
            
Cigarette smoking status            
Former/Former smokers 93 168 0.97 (0.74-1.27)  1.04 (0.78-1.38)  26 235 0.98 (0.59-1.63)  0.96 (0.56-1.64) 
Current/Former smokers 28 44 1.56 (1.02-2.38)  1.62 (1.04-2.51)  7 65 1.09 (0.46-2.59)  1.22 (0.50-2.97) 
Current/Current 
smokers 
14 24 2.36 (1.24-4.49)  2.29 (1.20-4.36)  <5 34 -  - 
Pack-years of smoking            
Former/Former smokers            
<30 pack-years 60 126 0.91 (0.66-1.25)  0.97 (0.69-1.36)  16 171 0.81 (0.43-1.52)  0.75 (0.39-1.43) 
≥30 pack-years 33 42 1.11 (0.73-1.68)  1.18 (0.77-1.79)  10 65 1.40 (0.65-2.99)  1.47 (0.68-3.16) 
Current/Former smokers            
<30 pack-years 17 31 1.44 (0.82-2.54)  1.47 (0.81-2.66)  <5 44 -  - 
≥30 pack-years 11 13 1.77 (0.84-3.77)  1.93 (0.88-4.25)  <5 21 -  - 
Current/Current 
smokers 
           
<30 pack-years 7 10 3.08 (1.34-7.11)  3.35 (1.44-7.80)  <5 14 -  - 
≥30 pack-years 7 13 1.93 (0.80-4.65)  1.75 (0.73-4.18)  <5 20 -  - 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
Missing data analyses exclude women who died within 5 years of breast cancer diagnosis (n=169) and women who reported post-, but not pre-, diagnosis smoking (n=7). 











American Cancer Society. 2014. Cancer Treatment & Survivorship Facts and Figures 2014-
2015. 
Bérubé S, Lemieux J, Moore L, Maunsell E, Brisson J. 2014. Smoking at time of diagnosis and 
breast cancer-specific survival: new findings and systematic review with meta-analysis. 
Breast Cancer Res. 16: R42. 
Bishop JD, Killelea BK, Chagpar AB, Horowitz NR, Lannin DR. 2014. Smoking and breast 
cancer recurrence after breast conservation therapy. Int. J. Breast Cancer 2014: 327081. 
Bradshaw PT, Ibrahim JG, Stevens J, Cleveland R, Abrahamson PE, Satia JA, et al. 2012. 
Postdiagnosis change in bodyweight and survival after breast cancer diagnosis. 
Epidemiology 23: 320–7. 
Braithwaite D, Izano M, Moore DH, Kwan ML, Tammemagi MC, Hiatt RA, et al. 2012. 
Smoking and survival after breast cancer diagnosis: a prospective observational study and 
systematic review. Breast Cancer Res. Treat. 136: 521–33. 
Calle EE, Miracle-McMahill HL, Thun MJ, Heath, Clark W. J. 1994. Cigarette smoking and risk 
of fatal breast cancer. Am. J. Epidemiol. 139: 1001–7. 
Centers for Disease Control and Prevention. 2014. National Death Index. Available: 
http://www.cdc.gov/nchs/ndi.htm. 
Cleveland RJ, Eng SM, Abrahamson PE, Britton J a, Teitelbaum SL, Neugut AI, et al. 2007. 
Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiol. 
Biomarkers Prev. 16: 1803–11. 
Dal Maso L, Zucchetto A, Talamini R, Serraino D, Stocco CF, Vercelli M, et al. 2008. Effect of 
obesity and other lifestyle factors on mortality in women with breast cancer. Int. J. Cancer 
123: 2188–94. 
Gammon MD, Eng SM, Teitelbaum SL, Britton JA, Kabat GC, Hatch M, et al. 2004. 
Environmental tobacco smoke and breast cancer incidence. Environ. Res. 96: 176–85. 
Gammon MD, Neugut AI, Santella RM, Teitelbaum SL, Britton JA, Terry MB, et al. 2002a. The 
Long Island Breast Cancer Study Project: description of a multi-institutional collaboration 
to identify environmental risk factors for breast cancer. Breast Cancer Res. Treat. 74: 235–
54. 
Gammon MD, Wolff MS, Neugut AI, Eng SM, Teitelbaum SL, Britton JA, et al. 2002b. 
Environmental toxins and breast cancer on Long Island. II. Organochlorine compound 
levels in blood. Cancer Epidemiol. Biomarkers Prev. 11: 686–97. 
Gaudet MM, Gapstur SM, Sun J, Diver WR, Hannan LM, Thun MJ. 2013. Active smoking and 
breast cancer risk: original cohort data and meta-analysis. J. Natl. Cancer Inst. 105: 515–25. 
Gou Y-J, Xie D-X, Yang K-H, Liu Y-L, Zhang J-H, Li B, et al. 2013. Alcohol consumption and 
breast cancer survival: a meta-analysis of cohort studies. Asian Pac J Cancer Prev 14: 4785–
90. 
145 
Greenland S, Pearl J, Robins JM. 1999. Causal diagrams for epidemiologic research. 
Epidemiology 10: 37–48. 
Hellmann SS, Thygesen LC, Tolstrup JS, Grønbæk M. 2010. Modifiable risk factors and survival 
in women diagnosed with primary breast cancer: results from a prospective cohort study. 
Eur. J. Cancer Prev. 19: 366–73. 
Holmes MD, Murin S, Chen WY, Kroenke CH, Spiegelman D, Colditz GA. 2007. Smoking and 
survival after breast cancer diagnosis. Int. J. cancer 120: 2672–7. 
Holmes MD, Stampfer MJ, Colditz GA, Rosner B, Hunter DJ, Willett WC. 1999. Dietary factors 
and the survival of women with breast carcinoma. Cancer 86: 826–35. 
IARC. 2004. IARC Monographs on evaluation of carcinogenic risks to humans: Tobacco smoke 
and involuntary smoking. International Agency for Research on Cancer. 
Ibrahim JG, Chu H, Chen M-H. 2012. Missing data in clinical studies: issues and methods. J. 
Clin. Oncol. 30: 3297–303. 
Krall EA, Valadian I, Dwyer JT, Gardner J. 1989. Accuracy of recalled smoking data. Am. J. 
Public Health 79: 200–2. 
Land SR, Toll BA, Moinpour CM, Mitchell SA, Ostroff JS, Hatsukami DK, et al. 2016. 
Research priorities, measures, and recommendations for assessment of tobacco use in 
clinical cancer research. Clin. Cancer Res. 1–24. 
Manjer J. 2000. Survival of women with breast cancer in relation to smoking. Eur. J. Surg. 166: 
852–8. 
Mayer DK, Carlson J. 2011. Smoking patterns in cancer survivors. Nicotine Tob. Res. 13: 34–
40. 
McBride CM, Ostroff JS. 2003. Teachable moments for promoting smoking cessation: the 
context of cancer care and survivorship. Cancer Control 10: 325–33. 
Neugut AI, Murray T, Santos J, Amols H, Hayes MK, Flannery JT, et al. 1994. Increased risk of 
lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer 73: 1615–20. 
Passarelli MN, Newcomb PA, Hampton JM, Trentham-Dietz A, Titus LJ, Egan KM, et al. 2016. 
Cigarette smoking before and after breast cancer diagnosis: mortality from breast cancer 
and smoking-related diseases. J. Clin. Oncol. 34: 1–8. 
Pierce JP, Patterson RE, Senger CM, Flatt SW, Caan BJ, Natarajan L, et al. 2014. Lifetime 
cigarette smoking and breast cancer prognosis in the After Breast Cancer Pooling Project. J. 
Natl. Cancer Inst. 106: 1–8. 
Santodonato J. 1997. Review of the estrogenic and antiestrogenic activity of polycyclic aromatic 
hydrocarbons: relationship to carcinogenicity. Chemosphere 34: 835–48. 
Siegel RL, Miller KD, Jemal A. 2016. Cancer statistics, 2016. CA. Cancer J. Clin. 66: 7–30. 
Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC. 2014. Past, 
present, and future challenges in breast cancer treatment. J. Clin. Oncol. 32: 1979–86. 
146 
Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. 2009. Multiple 
imputation for missing data in epidemiological and clinical research: potential and pitfalls. 
BMJ 338: 1–19. 
Tominaga K, Andow J, Koyama Y, Numao S, Kurokawa E, Ojima M, et al. 1998. Family 
environment, hobbies and habits as psychosocial predictors of survival for surgically treated 
patients with breast cancer. Jpn. J. Clin. Oncol. 28: 36–41. 
van Buuren S. 2007. Multiple imputation of discrete and continuous data by fully conditional 
specification. Stat. Methods Med. Res. 16: 219–42. 
Warren GW, Kasza KA, Reid ME, Cummings KM, Marshall JR. 2012. Smoking at diagnosis 
and survival in cancer patients. Int. J. cancer 132: 401–10. 
Westmaas JL, Newton CC, Stevens VL, Flanders WD, Gapstur SM, Jacobs EJ. 2015. Does a 
recent cancer diagnosis predict smoking cessation? An analysis from a large prospective US 
cohort. J. Clin. Oncol. 33: 1647–52. 
White IR, Royston P. 2009. Imputing missing covariate values for the Cox model. Stat. Med. 28: 
1982–98. 
Yu GP, Ostroff JS, Zhang ZF, Tang J, Schantz SP. 1997. Smoking history and cancer patient 
survival: a hospital cancer registry study. Cancer Detect. Prev. 21: 497–509. 
Zhan M, Flaws JA, Gallicchio L, Tkaczuk K, Lewis LM, Royak-Schaler R. 2007. Profiles of 
tamoxifen-related side effects by race and smoking status in women with breast cancer. 
Cancer Detect. Prev. 31: 384–90. 
147 
CHAPTER IV: POST-DIAGNOSIS CHANGES IN ENVIRONMENTAL TOBACCO 
SMOKE EXPOSURE AND SURVIVAL FOLLOWING BREAST 
CANCER 
Overview 
Environmental tobacco smoke (ETS) exposure is hypothesized to influence survival after 
breast cancer, but few studies have examined this association. A population-based cohort of 
women (N=1,508) diagnosed with first primary invasive or in situ breast cancer in 1996-1997 
was interviewed shortly after diagnosis and again approximately 5 years later to assess ETS 
exposure, and women were followed for over 18 years using the National Death Index; 597 
deaths (237 associated with breast cancer) were identified. Multivariable Cox regression was 
used to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CIs) for mortality 
among women with breast cancer as related to at-diagnosis and at-/post-diagnosis changes in 
ETS exposure. There was little or no association between at-diagnosis ETS exposure and all-
cause (HR=1.04, 95% CI=0.78-1.40) or breast cancer-specific (HR=0.98, 95% CI=0.63-1.52) 
mortality. Mortality was elevated among women who reported cessation in post-diagnosis ETS 
exposure up to one year before the follow-up assessment, for all-cause (HR=1.81, 95% CI=0.87-
3.74) and breast cancer mortality (HR=1.89, 95% CI=0.68-5.24); however, estimates were 
imprecise. We found little evidence of an association between at-diagnosis ETS exposure and 
mortality after breast cancer. Post-diagnosis cessation of ETS exposure was positively associated 
with mortality, although we could not rule out chance and reverse causation as possible 
explanations. Exposure to ETS does not appear to influence mortality after breast cancer. 
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Introduction  
Few studies (Boone et al. 2015; Kakugawa et al. 2015; Sagiv et al. 2007; Wartenberg et 
al. 2000) have examined whether exposure to environmental tobacco smoke (ETS) increases the 
risk of mortality among women with breast cancer and no studies to date have prospectively 
examined whether post-diagnosis changes in ETS exposure impact mortality. This study 
examined whether ETS exposure was associated with long-term all-cause and breast cancer-
specific mortality among a population-based sample of women. 
Methods 
Participants of the Long Island Breast Cancer Study Project (LIBCSP), a population-
based cohort of women newly diagnosed with breast cancer, were interviewed shortly after 
diagnosis and again about 5 years later, and now continue to be followed for vital status. Details 
of the LIBCSP have been published previously (Bradshaw et al. 2012; Sagiv et al. 2007). 
Institutional Review Board approval was obtained from of all participating institutions.  
Environmental Tobacco Smoke Exposure Assessment 
ETS exposure was determined via structured interviews (Sagiv et al. 2007). Women were asked 
to report whether any members of the household smoked in their presence, the relationship of the 
smoker, the participant’s ages at first and last exposure, and any time periods the household 
member did not smoke. Duration of exposure (years) was categorized as <15 years, ≥15–<30 
years, and ≥30 years of exposure. Recency of exposure (years) was categorized as <5 years, ≥5-
<10 years, and ≥10 years. 
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Covariate assessment 
Covariates assessed via questionnaire included: at-diagnosis age, menopausal status, total 
annual household income, education, marital status, body mass index, physical activity, and 
intake of alcoholic beverages, and cigarette smoking, and treatment. Estrogen receptor status and 
nodal involvement were determined by medical record review and tumor size was obtained from 
the New York State Cancer Registry. 
Outcome Assessment 
Vital status of the 1,508 women diagnosed with breast cancer was determined using the 
National Death Index. Follow-up for mortality occurred from the date of diagnosis in 1996-1997 
until December 31, 2014 (median=17.61 years). We identified 597 deaths; 234 were associated 
with breast cancer. 
Statistical Analysis 
We used multivariable Cox models to estimate hazard ratios (HR) and 95% confidence 
intervals (CIs) for the associations between at-diagnosis as well as at-/post-diagnosis changes in 
ETS exposure and mortality. All analyses were conducted using the Cox Regression function in 
IBM SPSS Statistics Version 22.0 (IBM Corp., Armonk, NY). 
In the analyses of at-diagnosis ETS exposure, survival time began at the date of breast 
cancer diagnosis and ended on the date of death or, if alive, December 31, 2014. In the analyses 
examining post-diagnosis ETS exposure, survival time began at the date of completion of the 
follow-up questionnaire and ended on the date of death or, if alive, December 31, 2014. Missing 
covariates were imputed using SPSS. We used 25 imputations with 1,000 iterations and the 
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imputation models included age at diagnosis, menopausal status, income, education, marital 
status, BMI, physical activity, and alcohol intake, smoking status), post-diagnosis ETS exposure 
[minimum=0], disease characteristics (stage, tumor size, nodal involvement estrogen receptor 
status), treatment (radiation therapy, chemotherapy, and hormone therapy), and the outcome (the 
event indicator and the Nelson-Aalen estimator of the cumulative hazard). 
Results 
Approximately 15% of women reported ETS exposure in the year before diagnosis and 
14% reported current exposure at the follow-up questionnaire. 
At-Diagnosis Environmental Tobacco Smoke Exposure 
There was little or no association between current ETS exposure and all-cause (HR=1.04, 
95% CI=0.78-1.40) or breast cancer-specific (HR=0.98, 95% CI=0.63-1.52) mortality after 
adjustment for covariates (Table IV-1). Results did not substantially differ when the analyses 
was restricted to women with invasive cancer only (Table IV-2). Risk of mortality was slightly 
elevated for all-cause (HR=1.17, 95% CI=0.74-1.86) and breast cancer-specific mortality 
(HR=1.13, 95% CI=0.57-2.27) when we restricted the analyses to never smokers, though data 
were sparse and the corresponding estimates imprecise.  
At-/Post-Diagnosis Environmental Tobacco Smoke Exposure 
Though no associations were observed among women with ongoing ETS exposure, HRs 
were elevated 81% (HR=1.81, 95% CI=0.87-3.74) for all-cause mortality and 89% (HR=1.89, 
95% CI=0.68-5.24) for breast cancer-specific mortality among women who reported cessation in 
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post-diagnosis ETS exposure up to the year before the follow-up assessment (Table IV-3). 
Results did not substantially differ when the analyses was restricted to women with invasive 
cancer only (Table IV-4). 
Discussion 
 Exposure to the constituents of tobacco smoke, either through active smoking or 
exposure to ETS, is hypothesized to influence breast cancer progression through several 
mechanisms, including directly by influencing cell proliferation, tumor growth, and metastasis 
(Dasgupta et al. 2009), and indirectly by disrupting the endocrine system (Bekki et al. 2013). 
Additionally, because up to 70% of tar in ETS is in the vapor phase, whereas all of the tar in 
direct smoking is in the particulate phase, ETS may be an important source of exposure to 
carcinogens since particulate smoke is cleared into the mouth and swallowed, but vapor phase 
constituents are inhaled and absorbed into the bloodstream and into the lymph system (Wells 
1991). Despite these hypothesized mechanisms, the few studies conducted to date (Boone et al. 
2015; Kakugawa et al. 2015; Sagiv et al. 2007; Wartenberg et al. 2000), including the 
sufficiently powered study reported here, provide limited or no evidence of an association 
between ETS exposure and survival after breast cancer. While we observed an elevated risk of 
mortality among women with post-diagnosis cessation of ETS exposure, we could not rule out 
chance and reverse causation as possible explanations.
 
 
Table IV-1. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between pre-diagnosis 
and at-diagnosis environmental tobacco smoke (ETS) exposure and mortality in the LIBCSP women diagnosed with breast 
cancer in 1996-1997 (N=1,508).  
 All-Cause Mortality (n deaths=597)  Breast Cancer-Specific Mortality (n deaths=237) 












At-diagnosis Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
ETS exposure statusa            
Never  119 176 1 (Ref)  1 (Ref)  49 246 1 (Ref)  1 (Ref) 
Former  376 585 1.00 (0.81-1.23)  0.98 (0.80-1.22)  141 820 0.87 (0.63-1.21)  0.89 (0.64-1.24) 
Current  84 138 1.25 (0.94-1.66)  1.04 (0.78-1.40)  38 184 1.04 (0.68-1.59)  0.98 (0.63-1.52) 
Duration of ETS 
exposure 
           
Never  119 176 1 (Ref)  1 (Ref)  49 246 1 (Ref)  1 (Ref) 
Former            
<15 years 50 91 1.05 (0.75-1.46)  1.13 (0.80-1.59)  24 117 1.02 (0.62-1.66)  1.10 (0.67-1.81) 
≥15–<30 years 131 289 0.89 (0.69-1.14)  0.90 (0.69-1.16)  60 360 0.84 (0.57-1.23)  0.84 (0.57-1.24) 
≥30 years 175 187 1.06 (0.84-1.34)  1.00 (0.79-1.28)  54 308 0.90 (0.61-1.33)  0.89 (0.60-1.33) 
Current            
<15 years 7 7 1.74 (0.81-3.73)  1.52 (0.70-3.27)  <5 12 –  – 
≥15–<30 years 13 22 1.59 (0.89-2.84)  1.32 (0.74-2.36)  6 29 1.08 (0.46-2.55)  0.97 (0.41-2.29) 
≥30 years 62 106 1.14 (0.83-1.55)  0.93 (0.67-1.29)  30 138 1.07 (0.68-1.69)  1.01 (0.63-1.61) 
ETS exposure recency            
Never  119 176 1 (Ref)  1 (Ref)  49 246 1 (Ref)  1 (Ref) 
Former            
<5 years 26 41 1.05 (0.69-1.60)  0.95 (0.62-1.47)  12 55 1.07 (0.57-2.01)  0.99 (0.52-1.87) 
≥5–<10 years 47 69 1.07 (0.77-1.51)  1.00 (0.71-1.41)  16 100 0.82 (0.47-1.45)  0.76 (0.43-1.35) 
≥10 years 303 475 0.99 (0.80-1.22)  0.99 (0.79-123)  113 665 0.86 (0.62-1.21)  0.90 (0.64-1.27) 
Current 84 138 1.25 (0.94-1.66)  1.04 (0.78-1.40)  38 184 1.04 (0.68-1.59)  0.98 (0.63-1.53) 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
aETS exposure status was defined as never, former, and current exposure to tobacco smoke from any household members. 









Table IV-2. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between pre-diagnosis 
and at-diagnosis environmental tobacco smoke (ETS) exposure and mortality in the LIBCSP women diagnosed with invasive 
breast cancer in 1996-1997 (n=1,273).  
 All-Cause Mortality (n deaths=548)  Breast Cancer-Specific Mortality (n deaths=229) 












At-diagnosis Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
ETS exposure statusa            
Never  113 131 1 (Ref)  1 (Ref)  48 196 1 (Ref)  1 (Ref) 
Former  342 473 0.94 (0.76-1.16)  0.94 (0.75-1.17)  134 681 0.82 (0.59-1.14)  0.85 (0.60-1.19) 
Current  76 112 1.18 (0.88-1.59)  1.01 (0.74-1.37)  38 150 1.01 (0.65-1.55)  1.00 (0.64-1.55) 
Duration of ETS 
exposure 
           
Never  113 131 1 (Ref)  1 (Ref)  48 196 1 (Ref)  1 (Ref) 
Former            
<15 years 47 67 1.03 (0.73-1.45)  1.12 (0.79-1.60)  22 92 0.97 (0.58-1.60)  1.04 (0.62-1.73) 
≥15–<30 years 122 236 0.83 (0.64-1.08)  0.86 (0.66-1.12)  58 300 0.78 (0.53-1.15)  0.81 (0.54-1.19) 
≥30 years 156 153 0.99 (0.78-1.26)  0.96 (0.75-1.24)  52 257 0.86 (0.58-1.27)  0.88 (0.59-1.32) 
Current            
<15 years 7 6 1.75 (0.82-2.62)  1.46 (0.67-3.15)  <5 11 –  – 
≥15–<30 years 13 19 1.46 (0.82-2.62)  1.36 (0.76-2.44)  6 26 0.95 (0.40-2.25)  0.95 (0.40-2.24) 
≥30 years 56 86 1.08 (0.78-1.49)  0.91 (0.65-1.27)  30 112 1.04 (0.66-1.65)  1.03 (0.64-1.66) 
ETS exposure recency            
Never  113 131 1 (Ref)  1 (Ref)  48 196 1 (Ref)  1 (Ref) 
Former            
<5 years 25 34 1.05 (0.68-1.62)  0.99 (0.64-1.54)  11 48 0.93 (0.48-1.78)  0.90 (0.46-1.74) 
≥5–<10 years 43 48 1.15 (0.81-1.63)  1.12 (0.78-1.60)  15 76 0.84 (0.47-1.50)  0.82 (0.46-1.48) 
≥10 years 274 391 0.90 (0.73-1.13)  0.91 (0.73-1.14)  108 557 0.80 (0.57-1.13)  0.85 (0.60-1.20) 
Current 76 112 1.18 (0.88-1.59)  1.01 (0.74-1.37)  38 150 1.01 (0.65-1.55)  1.00 (0.64-1.55) 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
aETS exposure status was defined as never, former, and current exposure to tobacco smoke from any household members. 








Table IV-3. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between at-/post-
diagnosis environmental tobacco smoke exposure (ETS) and mortality in the LIBCSP women diagnosed with breast cancer in 
1996-1997 (n=1,339).  
 All-Cause Mortality (n deaths=428)  Breast Cancer-Specific Mortality (n deaths=126) 














Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
ETS exposure status 
Never/Never 79 163 1 (Ref)  1 (Ref)  23 219 1 (Ref)  1 (Ref) 
Never/Former 10 18 1.14 (0.44-2.94)  0.94 (0.35-2.58)  <5 24 –  – 
Former/Never 251 529 1.03 (0.79-1.35)  1.03 (0.78-1.36)  69 711 0.93 (0.56-1.54)  0.92 (0.55-1.54) 
Former/Former 5 14 0.96 (0.21-4.54)  0.72 (0.14-3.58)  <5 18 –  – 
Former/Current 21 48 1.32 (0.72-2.43)  1.05 (0.56-1.99)  8 61 1.16 (0.43-3.18)  0.87 (0.31-2.46) 
Current/Never 22 43 1.29 (0.76-2.20)  1.19 (0.67-2.09)  6 58 1.00 (0.38-2.63)  0.88 (0.32-2.42) 
Current/Former 14 18 1.99 (0.97-4.09)  1.81 (0.87-3.74)  6 26 2.20 (0.81-5.97)  1.89 (0.68-5.24) 
Current/Current 26 78 1.18 (0.70-1.99)  1.02 (0.59-1.77)  8 96 0.82 (0.33-2.06)  0.66 (0.24-1.81) 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
Complete-case analyses exclude women who died within 5 years of breast cancer diagnosis (n=169) 
aAdjusted for age at diagnosis, body mass index, marital status, income, alcohol intake, physical activity, stage, tumor size, nodal involvement, estrogen receptor status, chemotherapy treatment, and 









Table IV-4. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between at-/post-
diagnosis environmental tobacco smoke exposure (ETS) and mortality in the LIBCSP women diagnosed with invasive breast 
cancer in 1996-1997 (n=1,111).  
 All-Cause Mortality (n deaths=386)  Breast Cancer-Specific Mortality (n deaths=121) 














Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
ETS exposure status 
Never/Never 74 123 1 (Ref)  1 (Ref)  23 174 1 (Ref)  1 (Ref) 
Never/Former 9 12 1.26 (0.51-3.11)  1.01 (0.37-2.78)  <5 17 –  – 
Former/Never 225 425 0.98 (0.74-1.29)  0.99 (0.74-1.32)  66 585 0.86 (0.52-1.42)  0.86 (0.52-1.45) 
Former/Former 5 13 0.83 (0.17-4.13)  0.64 (0.12-3.32)  <5 16 –  – 
Former/Current 18 39 1.12 (0.58-2.17)  0.93 (0.47-1.84)  6 50 0.90 (0.31-2.58)  0.71 (0.24-2.15) 
Current/Never 18 35 1.17 (0.66-2.08)  1.07 (0.58-1.96)  6 48 0.94 (0.36-2.47)  0.85 (0.31-2.37) 
Current/Former 13 14 1.98 (0.94-2.08)  1.80 (0.86-3.74)  6 21 2.13 (0.78-5.83)  1.90 (0.69-5.27) 
Current/Current 24 64 1.17 (0.68-2.03)  1.03 (0.58-1.83)  8 80 0.77 (0.31-1.94)  0.67 (0.25-1.82) 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
Complete-case analyses exclude women who died within 5 years of breast cancer diagnosis (n=169) 
aAdjusted for age at diagnosis, body mass index, marital status, income, alcohol intake, physical activity, stage, tumor size, nodal involvement, estrogen receptor status, chemotherapy treatment, and 
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CHAPTER V: POST-DIAGNOSIS CHANGES IN GRILLED, BARBECUED, AND 
SMOKED MEAT INTAKE AND SURVIVAL FOLLOWING BREAST 
CANCER 
Overview 
Grilled, barbecued and smoked meat intake, a prevalent dietary source of polycyclic 
aromatic hydrocarbon (PAH) carcinogens, may increase the risk of incident breast cancer. 
However, no studies have examined whether intake of this PAH source influences survival after 
breast cancer. We interviewed a population-based cohort of 1,508 women diagnosed with first 
primary invasive or in situ breast cancer in 1996-1997 at baseline and again approximately 5 
years later to assess grilled/barbecued and smoked meat intake. After 18+ years of follow-up, 597 
deaths, of which 237 were breast cancer-related, were identified. Multivariable Cox regression 
was used to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI) for mortality 
as related to pre-diagnosis intake, comparing high (above the median) to low intake, as well as 
post-diagnosis changes in intake, comparing every combination of pre-/post-diagnosis intake to 
low pre-/post-diagnosis intake. High pre-diagnosis grilled/barbecued and smoked meat intake 
was associated with a 23% increased risk of all-cause mortality (HR=1.23, 95% CI=1.03-1.46). 
High pre-diagnosis smoked beef/lamb/pork intake was positively associated with all-cause 
(HR=1.17, 95% CI=0.99-1.38) and breast cancer-specific (HR=1.23, 95% CI=0.95-1.60) 
mortality. Among women with continued high grilled/barbecued and smoked meat intake after 
diagnosis, all-cause mortality risk was elevated 31% (HR=1.31, 95% CI=0.96-1.78). Breast 
cancer-specific mortality was decreased (HR=0.55, 95% CI=0.31-0.97) among women with any 
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pre- and post-diagnosis intake of smoked poultry/fish. High pre- and post-diagnosis intake of 
grilled/barbecued and smoked meat may increase mortality after breast cancer.  
Introduction 
In the United States (US), there are over 3.1 million women who are survivors of breast 
cancer; these women represent approximately 40% of female cancer survivors (American Cancer 
Society 2014). After a diagnosis of breast cancer, survivors are faced with making behavioral 
and dietary choices as they attempt to improve their long-term prognoses. Dietary changes after 
breast cancer diagnosis and treatment are one area in which breast cancer survivors may choose 
to make more healthful changes. To aid in this decision making, recommendations and 
guidelines are available for cancer survivors in general (Rock et al. 2012) and, more recently, for 
breast cancer survivors specifically (Runowicz et al. 2016). For example, the American Cancer 
Society, together with the American Society of Clinical Oncology, recently released their breast 
cancer survivorship care guidelines which recommend that survivors be counseled to “achieve a 
dietary pattern that is high in vegetables, fruits, whole grains, and legumes, and limit alcohol 
intake to no more than one drink per day (Runowicz et al. 2016).” These recommendations are 
based on limited, but suggestive, evidence of improved survival among women with such diets 
(Chlebowski et al. 2006; Pierce et al. 2007a). No recommendations exist for breast cancer 
survivors that specifically address intake of high-temperature cooked meat, including intake of 
grilled, barbecued, and smoked meat, though, in relation to primary prevention of breast cancer 
incidence, it is recommended (World Cancer Research Fund / American Institute for Cancer 
Research 2009) that women limit intake of processed meats and high temperature cooked meat 
due to the formation of polycyclic aromatic hydrocarbons (PAHs) and other carcinogenic 
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chemicals during the cooking process (Moorthy et al. 2015). 
Grilled/barbecued and smoked meat intake is a highly prevalent source of PAHs among 
US women (Steck et al. 2007) and has been associated with breast cancer incidence (White et al. 
2016), but whether intake is related to survival after breast cancer is unknown. This study 
examined whether intake of grilled/barbecued and smoked meat prior to breast cancer diagnosis 
and post-diagnosis changes in intake were associated with long-term all-cause and breast cancer-




Adult female residents of Nassau and Suffolk counties on Long Island, NY with a first 
diagnosis of in situ or invasive breast cancer during August 1, 1996 and July 31, 1997 were 
identified for inclusion in the Long Island Breast Cancer Study Project (LIBCSP) (Gammon et 
al. 2002a). Identification of patients was done via active daily or weekly contact with local 
hospitals and by confirmation by a physician and medical records. After obtaining informed 
consent, the cohort of 1,508 women with breast cancer were interviewed in person by trained 
interviewers via structured questionnaire at baseline, on average within three months of breast 
cancer diagnosis.  
Approximately five years after the initial diagnosis of breast cancer, the 1,414 women 
who at baseline consented to continued contact were re-contacted for the follow-up interview. Of 
these, 143 refused, no proxy was identified for 96 women who were not alive at follow-up, and 
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55 could not be located, resulting in 1,120 women providing consent and 1,033 women 
completing the follow-up questionnaire (Bradshaw et al. 2012). The follow-up interview was 
conducted over the telephone by trained interviewers using a structured questionnaire that 
assessed information similar to that obtained at the time of diagnosis, but regarding the time 
period since the initial diagnosis of breast cancer. 
Grilled, Barbecued, and Smoked Meat Intake Assessment 
As part of the main baseline questionnaire, participants were asked about their intake 
(number of times per week, month, or year) of four types of grilled/barbecued and smoked 
meats: (1) grilled/barbecued beef, lamb, and pork, (2) smoked beef, lamb, and pork, such as 
bacon or ham, (3) grilled/barbecued poultry and fish, and (4) smoked poultry and fish, such as 
smoked turkey or lox. The women were asked about their intake in each decade of life (<20 
years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, ≥60 years) and were asked to specify 
the seasons in which the foods were most frequently consumed (Gammon et al. 2002b; Steck et 
al. 2007). At baseline, intake during the decade prior to breast cancer diagnosis was used to 
represent the average intake before diagnosis; we also examined whether lifetime intake of 
grilled/barbecued meat was associated with mortality. At the 5-year follow-up, participants 
responded to the same questions which asked about the time-period since the baseline 
questionnaire.  
Responses given as per week or per month were first multiplied by 52 or by 12, 
respectively, and then multiplied by the proportion of the year that the foods were consumed 
(i.e., 25% if they were consumed during one season, 50% if they were consumed during two 
seasons, etc.) to obtain measures of intake in number of times/year. The continuous measures 
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were dichotomized at the median for each of the four meat types: grilled/barbecued 
beef/lamb/pork (Low=0-10 vs. High=11+ times/year pre-diagnosis; Low=0-8 vs. High=9+ 
times/year post-diagnosis), grilled/barbecued poultry/fish (Low=0-9 vs. High=10+ times/year 
pre-diagnosis; Low=0-6 vs. High=7+ times/year post-diagnosis), smoked barbecued 
beef/lamb/pork (Low=0-4 vs. High=5+ times/year pre-diagnosis and post-diagnosis), and 
smoked poultry/fish (None=0 vs. Any intake=1+ times/year pre-diagnosis and post-diagnosis), 
separately. Intake of the four meat types were also summed to create an overall measure of 
intake of grilled/barbecued and smoked meat (times/year), which was dichotomized at the 
median (Low=0-43 vs. High=44+ times/year pre-diagnosis; Low=0-35 vs. High=36+ times/year 
post-diagnosis). Lifetime intake of each of the four types of meat was dichotomized at the 
median as Low=0-4,724 vs. High=4,725+ times throughout the lifetime. In the analysis of post-
diagnosis intake of grilled/barbecued and smoked meat, every combination of pre-
diagnosis/post-diagnosis annual intake was examined (i.e., low/low intake, low/high intake, etc.).  
Covariate assessment 
Most covariates were assessed by interviewer-administered questionnaire. Potential 
confounders included age at diagnosis (years), menopausal status (pre-menopausal versus post-
menopausal), annual household income (<$15,000–$24,999, $25,000–$49,999, and  ≥$50,000), 
education (<high school/high school graduate, some college/college graduate, and post-college), 
marital status (married or living as married versus not married, divorced, or widowed), body 
mass index (continuous, kg/m2), at-diagnosis physical activity (never, former, and current 
physical activity of least 1 hour per week for 3 months or more), at-diagnosis intake of alcoholic 
beverages such as beer, wine, or liquor (never, former, and current intake at least once a month 
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for 6 months or more), at-diagnosis consumption of energy (kcal/day), at-diagnosis fruit and 
vegetable intake (servings/day), and at-diagnosis multivitamin supplement use (ever/never). 
Other covariates, including estrogen receptor status and nodal involvement were 
determined by medical record review, and tumor size was obtained from the New York State 
Cancer Registry. At baseline, women were interviewed after surgery, but before initiation of 
most other components of the first course of treatment for the first primary breast cancer. 
Therefore, treatment received (radiation therapy, chemotherapy, or hormone therapy) was 
assessed by self-report at the follow-up questionnaire, which showed high agreement with 
medical record data (kappas ranged from 0.92 to 0.97) (Cleveland et al. 2007), but were more 
complete. 
Outcome Assessment 
Vital status, date of death and cause of death, was determined using the National Death 
Index (Centers for Disease Control and Prevention 2014c) among the 1,508 women diagnosed 
with breast cancer in 1996/1997. Indicators for death from any cause, and those associated with 
breast cancer were created with breast cancer deaths identified using International Statistical 
Classification of Diseases codes 174.9 and C-50.9 listed on the death certificate. Follow-up for 
mortality occurred from the date of diagnosis in 1996-1997 until December 31, 2014. The 
median duration of follow-up was 17.6 years (range=0.2-18.4 years). Among the 1,508 case 
women, 597 deaths were identified, 237 (40%) of which were related to breast cancer. 
Statistical Analysis 
Age-adjusted and multivariable-adjusted Cox proportional hazards models were fit for 
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each of the four types of grilled and smoked meat intake, separately, and for the total measure of 
annual intake and for all-cause and breast cancer-specific mortality. For analyses using breast 
cancer-specific mortality as the outcome, non-breast cancer deaths were censored at time of 
death. We estimated hazard ratios (HR) and 95% confidence intervals (CIs) for the associations 
between pre-diagnosis, lifetime and average annual intake, as well as post-diagnosis changes in 
grilled, barbecued, and/or smoked meat intake and all-cause and breast cancer-specific mortality. 
Tests for trend used continuous measures of grilled/barbecued and smoked intake in the 
proportional hazards models. Survival time began at the date of breast cancer diagnosis in the 
analyses of pre-diagnosis grilled/barbecued and smoked meat intake, and at the date of the 
follow-up interview for the corresponding analyses on post-diagnosis intake. Survival times for 
all analyses ended at the date of death or, if alive, date of censoring. All analyses were done 
using the Cox Regression function in IBM SPSS Statistics Version 22.0 (IBM Corp., Armonk, 
NY). 
In the analyses of post-diagnosis changes in grilled/barbecued and smoked meat intake 
and survival, we employed multiple imputation to account for the missing exposure data after 
excluding 169 women who died within 5 years of diagnosis; 377 (28%) participants were lost to 
follow-up and thus were missing data on intake of grilled/barbecued and smoked meat. Missing 
values were imputed using SPSS, which employs a fully conditional specification algorithm, an 
iterative Markov Chain Monte Carlo procedure that sequentially imputes missing values starting 
from the first variable with missing values (van Buuren 2007). SPSS applies linear regression to 
continuous scale variables and logistic or multinomial logistic regression to categorical variables. 
We used 25 imputations with 1,000 iterations and included demographics (age at diagnosis, 
menopausal status, income, education, marital status, BMI, physical activity, and alcohol intake, 
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smoking status), pre-diagnosis and post-diagnosis categorized grilled and smoked meat intake, 
disease characteristics (stage, tumor size, nodal involvement estrogen receptor status), treatment 
(radiation therapy, chemotherapy, and hormone therapy), and the outcome (the event indicator 
and the Nelson-Aalen estimator of the cumulative hazard (White and Royston 2009)). As a 
sensitivity analysis, we also conducted a complete-case analysis, where the missing exposure 
data are ignored. This alternative approach is commonly employed in follow-up studies with 
multiple exposure assessments over time. However, the imputation approach is designed to 
reduce the bias associated with the complete case analysis (Sterne et al. 2009). In analyses that 
used follow-up data, survival time began at the date of completion of the follow-up questionnaire 
to the date of death or December 31, 2014, if alive.  
Results 
Participant demographic characteristics as well as disease, tumor, and treatment 
characteristics are presented in Table V-1. Women with high intake of total grilled/barbecued 
and smoked meat were younger at diagnosis (56.7 years versus 60.9 years) and a higher 
proportion had an annual income ≥$50,000 (54.2% versus 40.4%) compared to women with low 
intake. Women with high intake were also more likely to be married (73.2% versus 60.4%). A 
higher proportion of women with high intake reported being physically active at diagnosis 
(64.5% versus 58.7%) and were current alcohol drinkers (48.9% versus 43.2%). Disease and 
treatment characteristics were similar across total intake of grilled/barbecued and smoke meat. 
Pre-diagnosis intake of grilled/barbecued and smoked meat 
Table V-2 shows the associations between pre-diagnosis annual intake of 
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grilled/barbecued and smoked meat and mortality. Compared to low intake, high intake of 
grilled/barbecued and smoked meat prior to diagnosis was associated with a 23% increased 
hazard (HR=1.23, 95% CI=1.03-1.46; PTrend=0.02) of all-cause mortality. High intake of smoked 
beef, lamb, and pork intake was associated with a 17% increased hazard (HR=1.17, 95% 
CI=0.99-1.38; PTrend=0.10) of all-cause and a 23% increased hazard (HR=1.23, 95% CI=0.95-
1.60; PTrend=0.09) of breast cancer-specific mortality, but the confidence intervals include the 
null value. In contrast, any intake of, relative to no intake, was associated with a 20% decreased 
hazard of breast cancer-specific mortality (HR=0.80, 95% CI=0.59-1.07; PTrend=0.63), but again 
the confidence intervals included the null. Lifetime grilled/barbecued and smoked meat intake 
and pre-diagnosis annual intake of grilled/barbecued beef/lamb/pork and poultry/fish were not 
associated with mortality (Table V-2). Results did not substantially differ when the analyses was 
restricted to women with invasive cancer only (Table V-3). 
Post-diagnosis changes in intake grilled, barbecued, and smoked meat 
Table V-4 shows the associations between post-diagnosis changes in annual intake of 
grilled/barbecued and smoked meat and mortality after imputation of missing covariates. 
Compared to women with low pre-diagnosis and low post-diagnosis intake of grilled/barbecued 
and smoked meat, continued high intake was associated with a 31% increased hazard (HR=1.31, 
95% CI=0.96-1.78) of all-cause mortality. The increase in risk of death from any cause was 
similar in magnitude (HR=1.28, 95% CI=0.97-1.68) among women who reported high pre-
diagnosis and low post-diagnosis intake of grilled/barbecued and smoked meat. Smoked 
beef/lamb/pork intake was positively associated with all-cause (HR=1.36, 95% CI=1.01-1.82) 
and breast cancer-specific mortality (HR=1.71, 95% CI=1.00-2.92) among women who had high 
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intake at pre-diagnosis and low post-diagnosis intake, relative to low pre- and low post-diagnosis 
intake, but not among women with continued high post-diagnosis intake. Additionally, women 
who reported any post-diagnosis intake of smoked poultry and fish had a reduced risk of breast 
cancer mortality for both those who reported no intake at baseline (HR=0.56, 95% CI=0.23-1.34) 
and high intake at baseline (HR=0.55, 95% CI=0.31-0.97) compared to no intake at pre- and 
post-diagnosis. Post-diagnosis changes in intake of grilled/barbecued poultry/fish were not 
associated with all-cause and breast cancer-specific mortality. Results did not substantially differ 
when the analyses was restricted to women with invasive cancer only (Table V-5). Age-adjusted 
results from the complete-case analyses are presented in Table V-6, which are mostly similar to 
the imputation-based results, except for total grilled/barbecued and smoked meat intake, which 
are null in the complete case-analysis. 
Discussion 
In this population-based prospective study of grilled/barbecued and smoked meat intake 
and mortality among a cohort of women diagnosed with first primary breast cancer, high pre-
diagnosis annual intake of total grilled/barbecued and smoked meat was associated with an 
elevated risk of all-cause mortality. When each of the four types of grilled/barbecued and 
smoked meat were examined individually, pre-diagnosis annual intake of smoked 
beef/lamb/pork was positively associated with all-cause and breast cancer-specific mortality, 
whereas intake of smoked poultry/fish was inversely associated with mortality. Additionally, 
when considering post-diagnosis changes in intake, we observed that women who continued to 
consume a high amount of grilled/barbecued and smoked meat after diagnosis had a 31% 
increased risk of all-cause mortality. Post-diagnosis smoked beef/lamb/pork intake was also 
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positively associated with all-cause and breast cancer mortality, with risk of mortality highest 
among women who reported high pre-diagnosis and low post-diagnosis intake. Consistent with 
the associations observed for pre-diagnosis intake, risk of breast cancer-specific mortality was 
inversely associated with high post-diagnosis intake of smoked poultry/fish.  
Grilled and smoked meat intake is a source of polycyclic aromatic hydrocarbons, 
including benzo[a]pyrene, chrysene, and fluoranthene, and is the primary route of PAH exposure 
among non-smokers (Phillips 1999). PAHs, a group of over 100 different chemicals, are formed 
during the incomplete combustion or pyrolysis of organic substances (Agency for Toxic 
Substances and Disease Registry (ATSDR) 1995b). Specifically, during grilling and barbecuing, 
PAHs are formed when fat and juices from meat grilled directly over an open fire drip onto the 
fire, creating flames and smoke. The PAHs adhere to the surface of the meat upon contact 
(Larsson 1986). Wood smoke, which is used to cook and preserve foods, contains a large number 
of PAHs, which also contaminate the foods upon contact (Stumpe-Vīksna et al. 2008).  
Dietary PAH exposures from intake of grilled/barbecued and smoked meat have been 
associated with increased risk of breast cancer incidence; effect estimates range from 1.5 to 2.2 
when comparing the highest to the lowest quantiles of intake of well-done meat (Dai et al. 2002; 
De Stefani et al. 1997; Knekt et al. 1994; Steck et al. 2007; Zheng et al. 1998). Dietary PAH 
exposures are hypothesized to be etiologically related to breast carcinogenesis as PAHs are 
known to form DNA adducts which can cause mutations during DNA replication and may alter 
promoter methylation or promoter binding, leading to inheritable abnormal gene expression, 
early steps in carcinogenesis (Moorthy et al. 2015). While a second primary cancer due to PAH 
exposure is one possible mechanism by which intake of grilled and smoked foods may influence 
survival after the initial primary breast cancer diagnosis, PAHs may be more likely to influence 
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prognosis by other mechanisms, including endocrine disruption; several PAHs or derivatives 
including chrysene and fluoranthene show estrogenic activity in vitro, while others, such as 
benzo[k]fluoranthene, benzo[a]pyrene, and benz[a]anthracene, can be anti-estrogenic (Arcaro 
1999; Chaloupka et al. 1992; Fertuck et al. 2001). 
Our findings of a positive association with death and intake for smoked beef/lamb/pork 
may possibly be explained by the higher saturated fat content of these meats compared to poultry 
and fish. Though results are inconsistent, higher risk of mortality has been observed among 
women with high intake of total fat, saturated fat, and monounsaturated fat (Makarem et al. 
2013; Rock 2002; Zhang et al. 1995). Furthermore, the higher fat content may also result in the 
formation of more PAHs (Phillips 1999). However, we did not observe the same elevated risk of 
mortality among women with continued post-diagnosis high intake when we examined at-
diagnosis intake of these meats cooked by grilling/barbecuing. The lack of association between 
mortality and intake of grilled/barbecued beef/lamb/pork may be due to the method of 
preparation; marinating meat before grilling, as is often done, may inhibit the formation of PAHs 
(Viegas et al. 2014). Our finding of an inverse association between smoked poultry/fish intake 
and mortality could also be related to the different fat composition of these meats. Moreover, it 
has been hypothesized that the amino acid content of white meat supports proper immune system 
function (Delfino et al. 2000), while intake of fish, a source of omega-3 polyunsaturated fatty 
acids, could improve survival (Khankari et al. 2015; Makarem et al. 2013) by reducing pro-
inflammatory derivatives (Fabian et al. 2015). Nonetheless, we did not observe reductions in 
mortality risk associated with the intake of grilled/barbecued poultry/fish intake.  
Ours is the first study to examine the associations between grilled/barbecued and smoked 
meat intake and mortality after breast cancer. Strengths of our study include the population-based 
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cohort design, which utilized data collected shortly after diagnosis and again 5-year post-
diagnosis. Women were followed for over 18 years using the National Death Index, which has 
accurate ascertainment of vital status (Cowper et al. 2002). However, this study also has several 
limitations. Women were asked to self-report their intake of grilled/barbecued and smoked 
meats. This could have resulted in non-differential misclassification of the exposure; which 
would bias estimates towards the null (Wacholder et al. 1995). Given the prospective design, 
approximately 28% of women did not complete the follow-up assessment. Analyses using a 
complete-case approach could result in biased estimates (Ibrahim et al. 2012); therefore, we used 
multiple imputation, a methodologically sound approach, to address the missing data. Lastly, 
given the complexity of diet, it is possible that our results are confounded by other correlated 
dietary factors; however, few dietary exposures have been consistently linked to breast cancer 
survival (Rock 2002). 
Results of our study indicate that grilled/barbecued and, particularly, smoked meat 
consumed prior to and after breast cancer diagnosis may influence survival. Our findings, which 
imply that women should avoid intake of smoked red meat and perhaps increase intake of 
smoked white meat and fish, coupled with confirmation from future studies, may help inform the 
limited dietary intake guidelines currently available (Runowicz et al. 2016) for the more than 3 




Table V-1. Distribution of participant characteristics at diagnosis among the LIBCSP 
women diagnosed with first primary breast cancer in 1996-1997, overall and by 
grilled/barbecued and smoked meat intake (N=1,508). 
 
 
 Pre-diagnosis grilled/barbecued, and 
smoked meat intakec 
 Total  Low  High 
 (N=1,508)  (n=732)  (n=726) 
At-diagnosis Characteristic n (%)  n (%)  n (%) 
Age at diagnosis (years)      
<50 407 (27.0%)  160 (21.9%)  128 (26.7%) 
50–64 582 (38.6%)  271(37.0%)  201 (42.0%) 
≥65 519 (34.4%)  301 (41.1%)  150 (31.3%) 
Mean (SD) 58.8 (12.7)  60.9 (12.7)  56.7 (12.3) 
Menopausal status      
Premenopausal 472 (31.9%)  180 (25.1%)  155 (33.2%) 
Postmenopausal 1,006 (68.1%)  538 (74.9%)  312 (66.8%) 
Income      
<$15,000–$24,999 286 (19.0%)  165 (22.7%)  85 (17.8%) 
$25,000–$49,999 488 (32.4%)  269 (36.9%)  134 (28.0%) 
≥$50,000 730 (48.5%)  294 (40.4%)  259 (54.2%) 
Education      
<HS/HS graduate 721 (48.0%)  355 (48.8%)  223 (46.6%) 
Some college/college graduate 551 (36.7%)  271 (37.3%)  171 (35.8%) 
Post-college 230 (15.3%)  101 (13.9%)  84 (17.6%) 
Marital Status      
Married or living as married 1,029 (68.3%)  442 (60.4%)  350 (73.2%) 
Not married 478 (31.7%)  290 (39.6%)  128 (26.8%) 
BMI at diagnosis (kg/m2)      
<25.0 683 (45.8%)  343 (47.4%)  224 (47.0%) 
25-29.9 476 (31.9%)  237 (32.8%)  152 (31.9%) 
≥30.0 332 (22.3%)  143 (19.8%)  101 (21.2%) 
Mean (SD) 26.6 (5.7)  26.3 (5.5)  26.8 (5.8) 
Physical activitya      
Never 334 (22.5%)  176 (24.4%)  88 (18.7%) 
Former 253 (17.0%)  122 (16.9%)  79 (16.8%) 
Current 900 (60.5%)  424 (58.7%)  304 (64.5%) 
Alcohol intakeb      
Never 588 (39.0%)  297 (40.6%)  179 (37.5%) 
Former 212 (14.1%)  119 (16.3%)  65 (13.6%) 
Current 707 (46.9%)  316 (43.2%)  234 (48.9%) 
Stage      
Invasive 1,273 (84.4%)  608 (83.1%)  402 (83.9%) 
In situ 235 (15.6%)  124 (16.9%)  77 (16.1%) 
Nodal involvement 622 (74.5%)  286 (73.0%)  192 (73.6%) 
Tumor size (cm)      
≤2.0 622 (75.5%)  299 (76.9%)  200 (78.1%) 
>2.0 202 (24.5%)  90 (23.1%)  56 (21.9%) 
Mean (SD) 1.7 (1.6)  1.7 (1.7)  1.7 (1.5) 
Estrogen receptor status      
Negative 264 (26.7%)  129 (27.3%)  87 (28.1%) 
Positive 726 (73.3%)  343 (72.7%)  223 (71.9%) 
Treatment received      
Radiation 625 (60.9%)  295 (59.5%)  192 (59.3%) 
Chemotherapy 423 (41.4%)  181 (36.7%)  121 (37.5%) 




 Pre-diagnosis grilled/barbecued, and 
smoked meat intakec 
 Total  Low  High 
 (N=1,508)  (n=732)  (n=726) 
At-diagnosis Characteristic n (%)  n (%)  n (%) 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and 
July 31, 1997, followed-up for vital status through December 31, 2014. 
aAt-diagnosis recreational physical activity was defined as never, former, and current physical activity of least 1 hour per 
week for 3 months or more. 
bAt-diagnosis intake of alcoholic beverages was defined as never, former, and current intake of alcoholic beverages such as 
beer, wine, or liquor at least once a month for 6 months or more. 





Table V-2. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between pre-diagnosis 
lifetime and annual intake of grilled/barbecued and smoked meat and mortality in the LIBCSP women diagnosed with breast 
cancer in 1996-1997 and followed for 18+ years (N=1,508).  
 All-Cause Mortality (n=597 deaths)  Breast Cancer Specific-Mortality (n=237 deaths) 














Pre-diagnosis Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
Lifetime grilled, barbecued, and smoked meat intakea 
Low 280 441 1 (Ref)  1 (Ref)  117 604 1 (Ref)  1 (Ref) 
High 285 4365 0.99 (0.84-1.17)  1.02 (0.86-1.21)  105 616 0.88 (0.68-1.15)  0.89 (0.68-1.17) 
PTrend   0.34  0.16    0.47  0.59 
Annual grilled, barbecued, and smoked meat intakeb 
Low 297 435 1 (Ref)  1 (Ref)  112 620 1 (Ref)  1 (Ref) 
High 279 447 1.14 (0.96-1.34)  1.23 (1.03-1.46)  114 612 1.03 (0.79-1.34)  1.11 (0.85-1.46) 
PTrend   0.06  0.02    0.17  0.07 
Annual grilled, barbecued beef, lamb, and pork intakec 
Low 323 422 1 (Ref)  1 (Ref)  118 627 1 (Ref)  1 (Ref) 
High 262 478 1.02 (0.86-1.21)  1.09 (0.91-1.30)  113 627 0.94 (0.72-1.22)  1.04 (0.79-1.37) 
PTrend   0.21  0.10    0.50  0.40 
Annual smoked beef, lamb, and pork intaked 
Low 288 453 1 (Ref)  1 (Ref)  106 635 1 (Ref)  1 (Ref) 
High 302 441 1.13 (0.96-1.33)  1.17 (0.99-1.38)  127 616 1.20 (0.93-1.55)  1.23 (0.95-1.60) 
PTrend   0.06  0.10    0.10  0.09 
Annual grilled, barbecued poultry and fish intakee 
Low 330 403 1 (Ref)  1 (Ref)  115 618 1 (Ref)  1 (Ref) 
High 254 492 0.95 (0.80-1.12)  1.06 (0.89-1.26)  114 632 0.94 (0.72-1.23)  1.07 (0.81-1.41) 
PTrend   0.95  0.38    0.59  0.31 
Annual smoked poultry and fish intakef 
None 428 556 1 (Ref)  1 (Ref)  169 815 1 (Ref)  1 (Ref) 
Any 161 341 0.80 (0.67-0.97)  0.89 (0.74-1.08)  66 436 0.72 (0.54-0.96)  0.80 (0.59-1.07) 
PTrend   0.43  0.09    0.99  0.63 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
aLow intake =0-4,724 vs High intake=4,725+ times throughout the lifetime. 
bLow intake=0-43 vs High intake=44+ times/year in the most recent decade prior to diagnosis. 
cLow intake=0-10 vs High intake=11+ times/year in the most recent decade prior to diagnosis. 
dLow intake=0-4 vs High intake=5+ times/year in the most recent decade prior to diagnosis. 
eLow intake=0-9 vs High intake=10+ times/year in the most recent decade prior to diagnosis. 
fNone=0 vs Any intake= 1+ times/year in the most recent decade prior to diagnosis. 








Table V-3. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between pre-diagnosis 
lifetime and annual intake of grilled/barbecued and smoked meat and mortality in the LIBCSP women diagnosed with 
invasive breast cancer in 1996-1997 and followed for 18+ years (N=1,273).  
 All-Cause Mortality (n=548 deaths)  Breast Cancer Specific-Mortality (n=229 deaths) 














Pre-diagnosis Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
Lifetime grilled, barbecued, and smoked meat intakea 
Low 254 349 1 (Ref)  1 (Ref)  113 490 1 (Ref)  1 (Ref) 
High 264 353 0.98 (0.83-1.17)  1.01 (0.85-1.21)  101 516 0.86 (0.66-1.12)  0.86 (0.66-1.14) 
PTrend   0.62  0.47    0.36  0.39 
Annual grilled, barbecued, and smoked meat intakeb 
Low 268 340 1 (Ref)  1 (Ref)  106 502 1 (Ref)  1 (Ref) 
High 259 363 1.09 (0.92-1.30)  1.16 (0.97-1.39)  112 510 1.02 (0.78-1.33)  1.08 (0.82-1.43) 
PTrend   0.07  0.04    0.13  0.08 
Annual grilled, barbecued beef, lamb, and pork intakec 
Low 295 332 1 (Ref)  1 (Ref)  115 512 1 (Ref)  1 (Ref) 
High 241 383 1.01 (0.84-1.20)  1.07 (0.89-1.28)  108 516 0.89 (0.68-.17)  0.98 (0.74-1.30) 
PTrend   0.20  0.13    0.47  0.44 
Annual smoked beef, lamb, and pork intaked 
Low 264 356 1 (Ref)  1 (Ref)  102 518 1 (Ref)  1 (Ref) 
High 277 356 1.09 (0.92-1.30)  1.12 (0.94-1.33)  123 510 1.18 (0.91-1.54)  1.21 (0.92-1.58) 
PTrend   0.09  0.20    0.09  0.09 
Annual grilled, barbecued poultry and fish intakee 
Low 302 327 1 (Ref)  1 (Ref)  110 519 1 (Ref)  1 (Ref) 
High 233 387 0.96 (0.80-1.14)  1.06 (0.88-1.27)  111 509 0.97 (0.74-1.28)  1.09 (0.82-1.45) 
PTrend   0.80  0.33    0.48  0.27 
Annual smoked poultry and fish intakef 
None 394 452 1 (Ref)  1 (Ref)  165 681 1 (Ref)  1 (Ref) 
Any 146 263 0.80 (0.66-0.96)  0.89 (0.73-1.09)  62 347 0.72 (0.54-0.97)  0.80 (0.59-1.08) 
PTrend   0.43  0.12    0.84  0.59 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
aLow intake =0-4,724 vs High intake=4,725+ times throughout the lifetime. 
bLow intake=0-43 vs High intake=44+ times/year in the most recent decade prior to diagnosis. 
cLow intake=0-10 vs High intake=11+ times/year in the most recent decade prior to diagnosis. 
dLow intake=0-4 vs High intake=5+ times/year in the most recent decade prior to diagnosis. 
eLow intake=0-9 vs High intake=10+ times/year in the most recent decade prior to diagnosis. 
fNone=0 vs Any intake= 1+ times/year in the most recent decade prior to diagnosis. 







Table V-4. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between pre-
diagnosis/post-diagnosis annual intake of grilled/barbecued and smoked meat and mortality in the LIBCSP women diagnosed 
with breast cancer in 1996-1997 and followed for 18+ years (n=1,339).  
 All-Cause Mortality (n=428 deaths)  Breast Cancer Specific-Mortality (n=126 deaths) 
















Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
Total grilled, barbecued, and smoked meat intakea 
Low/Low 160 295 1 (Ref)  1 (Ref)  42 413 1 (Ref)  1 (Ref) 
Low/High 60 156 1.05 (0.73-1.50)  1.10 (0.75-1.62)  16 201 0.78 (0.38-1.63)  0.77 (0.36-1.64) 
High/Low 101 158 1.24 (0.96-1.62)  1.28 (0.97-1.68)  28 231 1.18 (0.71-1.98)  1.14 (0.67-1.93) 
High/High 108 302 1.18 (0.88-1.58)  1.31 (0.96-1.78)  41 169 1.09 (0.66-1.80)  1.08 (0.63-1.83) 
Grilled, barbecued beef, lamb, and pork intakeb 
Low/Low 183 291 1 (Ref)  1 (Ref)  43 430 1 (Ref)  1 (Ref) 
Low/High 52 137 0.98 (0.68-1.40)  1.00 (0.69-1.45)  16 174 0.93 (0.48-1.81)  0.88 (0.45-1.75) 
High/Low 81 156 1.06 (0.80-1.40)  1.10 (0.83-1.46)  19 219 0.86 (0.48-1.56)  0.88 (0.48-1.61) 
High/High 112 327 1.10 (0.84-1.43)  1.14 (0.87-1.51)  48 390 1.25 (0.78-1.98)  1.24 (0.76-2.03) 
Smoked beef, lamb, and pork intakec 
Low/Low 142 326 1 (Ref)  1 (Ref)  36 432 1 (Ref)  1 (Ref) 
Low/High 66 138 1.25 (0.87-1.80)  1.18 (0.81-1.71)  20 185 1.29 (0.65-2.58)  1.22 (0.60-2.50) 
High/Low 93 148 1.34 (1.01-1.77)  1.36 (1.01-1.82)  31 210 1.75 (1.04-2.94)  1.71 (1.00-2.92) 
High/High 126 299 1.20 (0.92-1.56)  1.20 (0.91-1.59)  40 386 1.25 (0.76-2.04)  1.19 (0.71-1.99) 
Grilled, barbecued poultry and fish intaked 
Low/Low 201 302 1 (Ref)  1 (Ref)  45 459 1 (Ref)  1 (Ref) 
Low/High 41 110 1.01 (0.64-1.59)  1.04 (0.65-1.65)  13 138 0.97 (0.43-2.19)  0.95 (0.41-2.19) 
High/Low 93 180 1.01 (0.78-1.31)  1.03 (0.78-1.34)  29 244 1.21 (0.73-2.02)  1.22 (0.72-2.05) 
High/High 93 318 0.98 (0.73-1.30)  1.06 (0.79-1.43)  39 373 1.06 (0.64-1.76)  1.11 (0.66-1.88) 
Smoked poultry and fish intakee 
None/None 275 489 1 (Ref)  1 (Ref)  83 682 1 (Ref)  1 (Ref) 
None/Any 32 76 0.82 (0.52-1.30)  0.84 (0.51-1.37)  8 100 0.62 (0.27-1.45)  0.56 (0.23-1.34) 
Any/None 51 122 0.89 (0.64-1.24)  0.97 (0.69-1.35)  19 154 0.96 (0.56-1.63)  0.97 (0.57-1.67) 
Any/Any 70 224 0.79 (0.59-1.06)  0.88 (0.64-1.20)  18 277 0.52 (0.30-0.92)  0.55 (0.31-0.97) 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
Missing data analyses exclude women who died within 5 years of breast cancer diagnosis (n=169). 
aLow intake=0-43 vs High intake=44+ times/year pre-diagnosis in the most recent decade prior to diagnosis and Low intake=0-35 vs High intake=36+ times/year post-diagnosis  
bLow intake=0-10 vs High intake=11+ times/year pre-diagnosis in the most recent decade prior to diagnosis and Low intake=0-8 vs High intake=9+ times/year post-diagnosis 
cLow intake=0-4 vs High intake=5+ times/year pre-diagnosis in the most recent decade prior to diagnosis and post-diagnosis 
dLow intake=0-9 vs High intake=10+ times/year pre-diagnosis in the most recent decade prior to diagnosis and Low intake=0-6 vs High intake=7+ times/year post-diagnosis 
eNone=0 vs Any intake= 1+ times/year in the most recent decade prior to diagnosis and post-diagnosis 







Table V-5. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between pre-
diagnosis/post-diagnosis annual intake of grilled/barbecued and smoked meat and mortality in the LIBCSP women diagnosed 
with invasive breast cancer in 1996-1997 and followed for 18+ years (n=1,111).  
 All-Cause Mortality (n=386 deaths)  Breast Cancer Specific-Mortality (n=121 deaths) 
















Deaths Censored HR (95% CI)  HR (95% CI)  Deaths Censored HR (95% CI)  HR (95% CI) 
Total grilled, barbecued, and smoked meat intakea 
Low/Low 133 237 1 (Ref)  1 (Ref)  41 329 1 (Ref)  1 (Ref) 
Low/High 62 115 1.00 (0.68-1.48)  1.07 (0.72-1.61)  14 163 0.68 (0.31-1.48)  0.68 (0.30-1.50) 
High/Low 91 135 1.14 (0.87-1.50)  1.16 (0.87-1.54)  27 201 1.01 (0.60-1.72)  0.99 (0.58-1.70) 
High/High 100 236 1.18 (0.87-1.59)  1.28 (0.93-1.75)  39 297 1.08 (0.65-1.78)  1.06 (0.63-1.81) 
Grilled, barbecued beef, lamb, and pork intakeb 
Low/Low 160 239 1 (Ref)  1 (Ref)  43 356 1 (Ref)  1 (Ref) 
Low/High 50 99 0.98 (0.66-1.43)  1.01 (0.68-1.52)  14 135 1.02 (0.52-2.01)  0.94 (0.46-1.91) 
High/Low 68 123 1.06 (0.79-1.41)  1.08 (0.80-1.45)  16 175 0.84 (0.46-1.46)  0.83 (0.44-1.54) 
High/High 108 264 1.12 (0.84-1.48)  1.15 (0.86-1.53)  48 324 1.23 (0.77-1.99)  1.18 (0.71-1.95) 
Smoked beef, lamb, and pork intakec 
Low/Low 121 255 1 (Ref)  1 (Ref)  32 344 1 (Ref)  1 (Ref) 
Low/High 68 108 1.30 (0.89-1.90)  1.20 (0.81-1.78)  21 155 1.33 (0.66-2.68)  1.26 (0.62-2.58) 
High/Low 83 113 1.27 (0.94-1.72)  1.29 (0.95-1.76)  31 165 1.69 (0.99-2.89)  1.75 (1.00-3.05) 
High/High 114 249 1.20 (0.91-1.59)  1.19 (0.88-1.59)  37 326 1.23 (0.74-2.04)  1.23 (0.72-2.10) 
Grilled, barbecued poultry and fish intaked 
Low/Low 171 256 1 (Ref)  1 (Ref)  41 386 1 (Ref)  1 (Ref) 
Low/High 48 78 1.05 (0.65-1.70)  1.10 (0.67-1.81)  15 111 1.04 (0.47-2.31)  0.96 (0.41-2.23) 
High/Low 82 152 1.01 (0.77-1.33)  1.01 (0.76-1.35)  28 206 1.21 (0.73-2.02)  1.18 (0.70-2.00) 
High/High 85 239 1.00 (0.74-1.36)  1.07 (0.78-1.47)  37 287 1.10 (0.66-1.84)  1.08 (0.63-1.85) 
Smoked poultry and fish intakee 
None/None 244 393 1 (Ref)  1 (Ref)  80 557 1 (Ref)  1 (Ref) 
None/Any 33 64 0.80 (0.50-1.29)  0.80 (0.48-1.31)  7 90 0.64 (0.28-1.47)  0.51 (0.21-1.23) 
Any/None 40 105 0.80 (0.56-1.15)  0.88 (0.61-1.27)  17 128 0.89 (0.51-1.57)  0.92 (0.52-1.64) 
Any/Any 69 163 0.82 (0.60-1.11)  0.90 (0.65-1.24)  17 215 0.57 (0.33-0.99)  0.55 (0.31-0.97) 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
Missing data analyses exclude women who died within 5 years of breast cancer diagnosis (n=169). 
aLow intake=0-43 vs High intake=44+ times/year pre-diagnosis in the most recent decade prior to diagnosis and Low intake=0-35 vs High intake=36+ times/year post-diagnosis  
bLow intake=0-10 vs High intake=11+ times/year pre-diagnosis in the most recent decade prior to diagnosis and Low intake=0-8 vs High intake=9+ times/year post-diagnosis 
cLow intake=0-4 vs High intake=5+ times/year pre-diagnosis in the most recent decade prior to diagnosis and post-diagnosis 
dLow intake=0-9 vs High intake=10+ times/year pre-diagnosis in the most recent decade prior to diagnosis and Low intake=0-6 vs High intake=7+ times/year post-diagnosis 
eNone=0 vs Any intake= 1+ times/year in the most recent decade prior to diagnosis and post-diagnosis 







Table V-6. Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between pre-
diagnosis/post-diagnosis annual intake of grilled/barbecued and smoked meat and mortality in the LIBCSP women diagnosed 
with breast cancer in 1996-1997 and followed for 18+ years, using a complete-case analysis (n=962).  
COMPLETE-CASE 
ANALYSIS 
Type of Meat Intake 
All-Cause Mortality  
(n=276 deaths) 
 
Breast Cancer Specific-Mortality  
(n=92 deaths) 
  Age-Adjusted    Age-Adjusted 
Pre-diagnosis/ 
Post-diagnosis 
Deaths Censored HR (95% CI)  Deaths Censored HR (95% CI) 
Total grilled, barbecued, and smoked meat intakea 
Low/Low 89 192 1 (Ref)  26 255 1 (Ref) 
Low/High 39 107 1.12 (0.76-1.64)  10 136 0.74 (0.36-1.55) 
High/Low 53 114 1.10 (0.79-1.55)  16 151 1.05 (0.56-1.95) 
High/High 63 234 1.00 (0.72-1.40)  29 268 1.05 (0.60-1.81) 
Grilled, barbecued beef, lamb, and pork intakeb 
Low/Low 106 206 1 (Ref)  28 284 1 (Ref) 
Low/High 33 104 0.96 (0.65-1.42)  11 126 0.93 (0.46-1.88) 
High/Low 44 110 1.04 (0.73-1.48)  12 142 0.90 (0.45-1.77) 
High/High 73 247 1.08 (0.79-1.47)  34 286 1.23 (0.72-2.09) 
Smoked beef, lamb, and pork intakec 
Low/Low 82 229 1 (Ref)  21 290 1 (Ref) 
Low/High 44 95 1.44 (1.00-2.08)  13 126 1.45 (0.72-2.89) 
High/Low 56 111 1.29 (0.92-1.81)  22 145 1.99 (1.09-3.61) 
High/High 73 231 1.08 (0.79-1.49)  28 276 1.36 (0.77-2.41) 
Grilled, barbecued poultry and fish intaked 
Low/Low 112 211 1 (Ref)  25 298 1 (Ref) 
Low/High 24 83 0.97 (0.62-1.52)  8 99 0.97 (0.43-2.19) 
High/Low 56 128 1.06 (0.77-1.47)  21 163 1.50 (0.84-2.69) 
High/High 62 245 0.95 (0.69-133)  28 279 1.17 (0.66-2.08) 
Smoked poultry and fish intakee 
None/Any 162 353 1 (Ref)  54 461 1 (Ref) 
Any/None 19 56 0.76 (0.47-1.22)  6 69 0.74 (0.32-1.71) 
Any/Any 31 89 0.84 (0.57-1.23)  13 107 1.00 (0.54-1.83) 
None/Any 46 173 0.77 (0.55-1.07)  12 207 0.50 (0.27-0.94) 
Long Island Breast Cancer Study Project (LIBCSP) participants diagnosed with breast cancer between August 1, 1996 and July 31, 1997, followed-up for vital status through December 31, 2014. 
Missing data analyses exclude women who died within 5 years of breast cancer diagnosis (n=169). 
aLow intake=0-43 vs High intake=44+ times/year pre-diagnosis in the most recent decade prior to diagnosis and Low intake=0-35 vs High intake=36+ times/year post-diagnosis  
bLow intake=0-10 vs High intake=11+ times/year pre-diagnosis in the most recent decade prior to diagnosis and Low intake=0-8 vs High intake=9+ times/year post-diagnosis 
cLow intake=0-4 vs High intake=5+ times/year pre-diagnosis in the most recent decade prior to diagnosis and post-diagnosis 
dLow intake=0-9 vs High intake=10+ times/year pre-diagnosis in the most recent decade prior to diagnosis and Low intake=0-6 vs High intake=7+ times/year post-diagnosis 
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CHAPTER VI: DISCUSSION 
Summary 
The purpose of this dissertation was to examine whether the primary PAH sources of 
exposure (active cigarette smoking [Aim 1A], environmental tobacco smoke [Aim 1B], and 
intake of grilled and smoked meat [Aim 2]) pre- or at diagnosis, as well as changes in exposure 
after diagnosis, were associated with all-cause and breast cancer-specific mortality among a 
cohort of women diagnosed with first primary breast cancer in 1996/1997. Results of Aim 1A, 
examining tobacco smoke exposure from active smoking, showed that smoking in the year 
before diagnosis was associated with a 69% increase in the risk of long-term all-cause mortality, 
but not breast cancer-specific mortality. Among women who continued smoking after breast 
cancer, risk of all-cause mortality was elevated by 130%, but this was attenuated by 
approximately 20% among women who quit smoking after diagnosis. Additionally, <30 
cumulative pack-years of smoking was associated with more than a two-fold increase in the risk 
of breast cancer-specific mortality. My Aim 1A effect estimates for at-diagnosis smoking were 
consistent with most studies conducted to date for all-cause mortality, but inconsistent with the 
approximate 30% increase in risk of breast cancer-specific mortality reported by others (Bérubé 
et al. 2014). However, for changes in smoking after diagnosis, my Aim 1 findings were 
consistent with the one other study conducted to date (Passarelli et al. 2016), which reports an 
attenuated, but still elevated risk in all-cause and breast cancer-specific mortality among women 
who have post-diagnosis cessation in active smoking. 
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Results of Aim 1B on environmental tobacco smoke exposure were largely null despite 
hypothesized mechanisms linking the constituents of tobacco smoke with breast cancer 
progression, including directly by influencing cell proliferation, tumor growth, and metastasis 
(Dasgupta et al. 2009) and indirectly by disrupting the endocrine system (Bekki et al. 2013). The 
results of the Aim 1B regarding at-diagnosis ETS exposure were in agreement with the few 
studies conducted to date (Kakugawa et al. 2015; Sagiv et al. 2007; Wartenberg et al. 2000), but 
not all (Boone et al. 2015), which provide little evidence of an association with survival after 
breast cancer. No previous studies have examined changes in post-diagnosis ETS exposure, and 
my null results for both all-cause and breast cancer-specific mortality await confirmation by 
others.  
In Aim 2, examining intake of grilled/barbecued and smoked meat intake, at-diagnosis 
high intake of total grilled, barbecued, and smoked meat was associated with a 23% increased 
risk of all-cause mortality. When each of the four categories of grilled/smoked meat were 
examined individually, at-diagnosis intake of smoked beef/lamb/pork was positively associated 
with all-cause and breast cancer mortality while intake of smoked poultry and fish was inversely 
associated with mortality. Additionally, women who continued to consume high intake of 
grilled/barbecued and smoked meat after diagnosis had a further elevated risk of all-cause 
mortality; risk increased slightly from 23% to 31%. Post-diagnosis smoked beef/lamb/pork 
intake was also positively associated with all-cause and breast cancer mortality with risk of 
mortality highest among women who reported high at-diagnosis and low post-diagnosis intake. 
Consistent with the associations I observed for at-diagnosis intake, risk of breast cancer-specific 
mortality was inversely associated with high post-diagnosis intake of smoked poultry/fish. Mine 
is the first study to examine whether dietary PAH exposures from intake of grilled/barbecued and 
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smoked meat are associated with mortality after breast cancer. 
Biologic Plausibility 
This dissertation examined the primary sources of PAH exposure, tobacco smoke and 
intake of grilled/barbecued and smoked meat. PAHs are generally lipophilic, a property which 
increases with increasing complexity of the compounds (Boström et al. 2002), and known to be 
stored in adipose tissues, including the breast (Li et al. 1999; Perera et al. 1995). PAHs are 
hypothesized to be etiologically related to breast carcinogenesis (Gammon and Santella 2008) 
because they are able to form DNA adducts which can cause mismatch in DNA replication and 
may alter promoter methylation or promoter binding, leading to somatic DNA mutations or 
abnormal gene expression, early steps in carcinogenesis (Moorthy et al. 2015). While a second 
primary cancer due to PAH exposure is one possible mechanism by which PAHs may influence 
survival after the initial primary breast cancer diagnosis, PAHs may be more likely to influence 
prognosis by other mechanisms including endocrine disruption. Several PAHs or derivatives 
including chrysene and fluoranthene show estrogenic activity in vitro while others such as 
benzo[k]fluoranthene, benzo[a]pyrene, and benz[a]anthracene can be anti-estrogenic (Arcaro 
1999; Chaloupka et al. 1992; Fertuck et al. 2001), which may be especially important for 
hormonally sensitive tumors, such as breast cancer. 
Study Advantages and Limitations 
Results of my dissertation are based on the LIBCSP population-based cohort of 1,508 
women with a first primary breast cancer, all diagnosed within a single year. The LIBCSP was 
initiated as a case-control study to examine risk factors for breast cancer incidence, and 
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continued as a follow-up study to examine factors related to survival. Thus, the LIBCSP follow-
up approach, allowed for assessment of exposures in early life that were self-reported at the time 
of diagnosis (participants were interviewed on average within three months of breast cancer 
diagnosis), in addition to exposures that occurred close to the time of breast cancer diagnosis. 
The follow-up assessment five years after diagnosis further allowed for examination of changes 
in these risk and prognostic factors. For my dissertation, specifically, I was able to evaluate 
exposure to tobacco smoke and intake of grilled/barbecued meat and changes in exposure in 
relation to survival after establishing temporality of exposures (PAH sources) and outcome 
(mortality). In addition to being a necessary condition for causation, establishing temporality also 
allowed me to consider various windows of exposure (pre-diagnosis, at-diagnosis, 5-years post-
diagnosis) as related to survival. This is in contrast to alternative but other commonly used 
strategies, including either recruitment of a convenience sample of survivors anywhere from two 
to ten years after diagnosis (Pierce et al. 2007a; Zhang et al. 1995) or prospective cohort studies 
initiated to examine etiologic associations but extended to also consider prognostic associations 
(Allemani et al. 2011; Blair et al. 2007; Kroenke et al. 2005). Both of these alternative strategies, 
can obscure important exposure-outcome associations by masking key windows of exposure 
(although with care, the extended cohort design could potentially avoid this pitfall). Because of 
the LIBSCP approach, my dissertation should yield results that are more easily interpretable and 
generalizable. Nonetheless, despite several methodologic advantages, there are corresponding 
limitations to my dissertation approach, which are discussed below.  
First, the LIBCSP follow-up included comprehensive questionnaires administered by 
trained interviewers shortly after diagnosis and again approximately five years later to assess 
potential prognostic factors for breast cancer including PAH sources. While a limitation of my 
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dissertation is that I only had data regarding one post-diagnosis change in exposure, most studies 
rely on one measurement of exposure – generally pre- or at-diagnosis assessments only. The 
LIBCSP approach of using repeated structured interviews with trained interviewers at specific 
time intervals is likely to provide more valid responses, compared to either single or multiple 
self-completed questionnaires, for example, where the timing of the exposure relative to the 
diagnosis is ambiguous or perhaps not reflective of the appropriate window of susceptibility. For 
example, for other exogenous hormone exposures, including pregnancies and oral contraceptive 
use, risk of mortality after breast cancer is only elevated for exposures that occur within five 
years of diagnosis (Trivers et al. 2007a, 2007b), which underscores the need to adequately assess 
endocrine-related exposures during the most likely appropriate window of exposure relative to 
the disease diagnosis and the outcome.  
A concern with the interview approach, however, is the reliance on self-reported 
measures of active smoking, environmental tobacco smoke exposure, and intake of 
grilled/barbecued and smoked meat which were therefore subject to errors in participant recall. 
The assessments of smoking and ETS exposure were not confirmed by biomarker. The measure 
of ETS exposure, in particular, could have benefitted from an objective measure of exposure as I 
did not have data on intensity of exposure; however, biochemical confirmation of tobacco smoke 
exposure is costly and repeated measurements may not be feasible in a large epidemiologic 
study. Additionally, self-reported smoking history has been shown to be reliably recalled and 
reported (Krall et al. 1989) and the prevalence estimates for at-diagnosis (19%) (Bérubé et al. 
2014) and post-diagnosis smoking (8%) are consistent with estimates from prior studies (Mayer 
and Carlson 2011; Westmaas et al. 2015). In the LIBCSP, approximately 15% of women 
reported at-diagnosis residential ETS exposure, which is lower than previous studies in which 
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current ETS exposure was estimated at 25% (Wartenberg et al. 2000) to 30% (Boone et al. 
2015). Women were asked to report their intake of grilled/barbecued, and smoked meats. To 
limit the potential bias that may result from exposure misclassification, my study focused on 
intake shortly prior to diagnosis and in the five years after diagnosis, though long-term intake 
was also examined. Any misclassification that may have occurred would likely have been non-
differential with respect to mortality, which would bias estimates towards the null (Wacholder et 
al. 1995).  
 Second, despite the long follow-up of over 18 years currently available in the LIBCSP, an 
additional limitation of my dissertation is that we only observed 597 deaths from any cause and 
237 due to breast cancer. In survival analyses, power is directly related to the number of events 
rather than to the number of participants (Bradburn et al. 2003); larger studies are needed to 
confirm the findings presented here and obtain more precise estimates of association. The modest 
number of deaths also precluded me from examining effect measure modification of the hazard 
ratio for potentially important covariates including estrogen receptor status and body mass index. 
However, I was able to conduct restricted analyses among women with ER+ disease and those 
considered overweight or obese based on body mass index (i.e., BMI ≥25 kg/m2). 
A third limitation is that given the prospective design, approximately 28% of women did 
not complete the follow-up assessment and only one follow-up questionnaire was conducted. 
Due to the missingness in the 5-year post-diagnosis variables, I chose to address this issue rather 
than ignore it as is often done in prospective epidemiologic studies, including those focused on 
breast cancer prognosis (Passarelli et al. 2016). This is an important consideration as analyses 
using a complete-case approach could potentially bias estimates (Ibrahim et al. 2012). I used 
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multiple imputation to address missing data and patterns of association were similar when I 
imputed data using a fully Bayesian approach (data not shown). 
Lastly, the LIBCSP cohort of women with breast cancer is comprised primarily of white 
women, which reflects the underlying source population residing in Long Island NY, but may 
limit its generalizability to the nation as a whole. However, white postmenopausal women are at 
highest risk of developing breast cancer in the US (Ban and Godellas 2014), and white women 
comprise the largest proportion of breast cancer survivors in the US (DeSantis et al. 2014). 
Therefore, my dissertation results are applicable to the largest group of women in the US 
currently living with breast cancer. Importantly, the majority of women in the LIBCSP cohort 
were diagnosed with hormone responsive tumors, and ER+ breast cancer is the most commonly 
diagnosed tumor among all women in the US, regardless of race or ethnicity (DeSantis et al. 
2014). Further, the biologic behavior of a tumor within a specific subtype is not believed to vary 
substantially by race (O’Brien et al. 2010). Thus, my results for ER+ are generalizable to the 
most common tumor diagnosed in the US, regardless of race or ethnicity – and therefore are 
informative to the majority of American women living with breast cancer. 
Future Directions 
The results of my dissertation should be replicated and confirmed. Emphasis should be 
placed on addressing the limitations identified in the previous section (Chapter VI. Study 
Advantages and Limitations) and on exploring these associations in other race and ethnicity 
groups where there are differences in the prevalence of exposures such as smoking (Centers for 
Disease Control and Prevention 2014b) and survival (National Cancer Institute 2016). Future 
studies should rely on resources from population-based studies, rather than convenience sample 
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recruitment and all attempts should be made to recruit, enroll, and interview participants as close 
to diagnosis as possible. This will limit the potential biases introduced through selection of 
participants and recall of exposures before breast cancer diagnosis and will allow for 
examination of relevant exposure windows for survival. 
If associations observed in my dissertation are confirmed by others, as prior researchers 
have noted (Land et al. 2016), efforts should be made to develop effective smoking cessation 
interventions among breast cancer patients and to understand the optimal strategies for and 
timing of tobacco dependence treatment. Future research should continue to address the gaps in 
our understanding of the biological mechanisms underlying these associations.  
In my dissertation results focused on active smoking status and survival, at-diagnosis and 
post-diagnosis changes in smoking were associated with all-cause mortality, but not breast 
cancer-specific mortality. These results may highlight an association between smoking and 
mortality from cardiovascular disease or other outcomes, rather than to breast cancer recurrence. 
It has been well documented that long-term breast cancer survivors are at increased risk for 
cardiovascular-related mortality compared to women in the general population (Bradshaw et al. 
2016) most likely due to the cardiotoxic effects of breast cancer treatments (Carver et al. 2007). 
It is also known that the constituents of cigarette smoke, including nicotine, carbon monoxide, 
and polycyclic aromatic hydrocarbons (PAHs) can cause cardiovascular disease (Centers for 
Disease Control and Prevention 2010); however how cigarette smoke constituents influence 
tumor proliferation, angiogenesis, metastasis, and the tumor microenvironment is poorly 
understood.(Land et al. 2016). Together, the chemicals in cigarette smoke and breast cancer 
treatment(s) may act synergistically to increase risk of long-term mortality from cardiovascular 
disease, but the LIBCSP was underpowered to examine disease-specific causes of death other 
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than breast cancer as related to post-diagnosis changes in smoking and ETS exposure for which 
the baseline prevalences were 19% and 15%, respectively. The results of Aim 1A, however, do 
not appear to provide strong evidence that PAHs influence survival after breast cancer through 
an estrogen pathway; at-diagnosis cigarette smoking was not strongly associated with breast 
cancer-specific mortality. This hypothesis, however, is difficult to rule out as PAHs can be both 
estrogenic and anti-estrogenic, as mentioned in the previous section (Chapter VI. Biologic 
Plausibility). Although estimates were imprecise, I did observe elevated risks in breast cancer-
specific mortality when I considered post-diagnosis changes in active smoking, which highlights 
the need to identify and examine the appropriate timing of exposure as it relates to prognosis. 
Given the consistent associations observed between tobacco smoke exposure through active 
smoking and all-cause and breast cancer-specific mortality in my dissertation and the findings 
from others (Bérubé et al. 2014), potential prognostic associations with other tobacco products 
including cigars, pipe tobacco, snuff, and chewing tobacco should be also examined. 
 In regards to the findings of my second aim, a better understanding of the biological 
mechanisms linking dietary PAH exposure and mortality after breast cancer also require 
elucidation. How the PAHs found in grilled/barbecued and smoked meats impact tumor growth, 
angiogenesis, and metastasis may help us understand how other similar chemicals work to 
impact mortality after breast cancer. Furthermore, understanding how diet and breast cancer 
treatment interact to impact mortality would be an interesting question to address, given that 
patients may be especially receptive to dietary counseling during cancer treatment, and surgery, 
radiation, and chemotherapy can significantly affect nutritional needs (Rock et al. 2012). In 
addition, future studies, with increased power to adequately explore effect modification, should 
also consider interactions between intake grilled/barbecued and smoked meat and other dietary 
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exposures such intake of fruits and vegetables, use of multivitamin supplements, and even 
specific macro and micronutrients.  
It may also be important to consider assessing multiple post-diagnosis changes in 
exposures. An innovation of my dissertation was that I considered how post-diagnosis changes 
impacted survival; however, I was limited by only having data related to exposures pre-/at-
diagnosis and five years post-diagnosis. My dissertation assumes that exposures at 5-years post-
diagnosis persist throughout the 18 years of follow-up, which may not be a realistic assumption. 
If feasible, multiple questionnaires should be used to assess how exposures change at all the 
points of the breast cancer continuum including pre-diagnosis, at-diagnosis and post-diagnosis 
before initiation of treatment, during breast cancer treatment, and long-term post-treatment. 
Importantly, careful attention should be given in regard to the study design. Studies initiated as 
prospective cohort studies, in which all participants are free of the outcome at baseline and cases 
develop over time, may have serial measurements of exposure; however, selecting the exposure 
or exposures that best represent important windows of exposure may require careful attention. 
Often, multiple measurements are made before the disease develops, in which case selecting the 
exposure measured at the time point closest to diagnosis would be important. Similarly, 
measurements made after diagnosis should be consistent across participants so that the exposures 
are examined in consideration to the participants’ time of diagnosis and treatment. 
Understanding how epidemiologic exposures influence survivals at all points of the breast cancer 
continuum will help us to identify the optimal point(s) of intervention.  
Public Health Impact 
The more than 3.1 million women who are survivors of breast cancer - the largest group 
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of cancer survivors in the US (American Cancer Society 2014) - are faced with making 
behavioral and dietary choices to help improve long-term prognosis. How epidemiologic factors 
impact breast cancer survival is understudied. This is an important area of research as it is 
projected that by 2030 the number of breast cancer survivors will increase by as much as 50% 
(AACR 2015). A better understanding of the contribution of environmental exposures, especially 
exogenous compounds which are modifiable and with the potential to influence estrogen, 
estrogen receptors, or biologically relevant pathways involved in breast cancer progression, on 
survival can help us to substantially reduce the burden of breast cancer. 
Conclusions 
The biologically plausible results of this dissertation showed that the primary sources of 
PAH exposure, active smoking and intake of grilled/barbecued and smoked meat, were 
associated with mortality after breast cancer. Importantly, results of the first aim indicate that 
post-diagnosis cessation of active smoking may be important to reduce mortality. Results of the 
second aim indicate that women should avoid intake of smoked meat, in particular smoked red 
meat. The results of this dissertation strengthen the scientific evidence supporting smoking 
cessation efforts and inform the limited dietary intake guidelines currently available (Runowicz 
et al. 2016) for the more than 3 million women who are survivors of breast cancer (American 
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APPENDIX: EXCERPTS FROM THE LIBSCP BASELINE QUESTIONNAIRE 
SECTION I: SMOKING 
 Now I have some questions about smoking. 
I1. Before (REFERENCE DATE), did you ever smoke at least 1 cigarette a day for 6 months or longer? 
   YES……...…………………………………1 
   NO………………………………………….2 (I8) 
 
I2. How old were you when you first started smoking cigarettes on a regular basis?  
   AGE STARTED |__|__| 
I3. Were you smoking cigarettes on (REFERENCE DATE), that is when you were (AGE)? 
   YES...………………………………………1 (I5) 
   NO………………………………………….2  
 
I4. At what age did you stop smoking cigarettes? 
   AGE STOPPED |__|__| 
I5. Thinking about the years between (AGE FROM I2) and (AGE FROM I4/AGE FROM I3), was there ever a 
period of 1 year or more in which you did not smoke cigarettes? 
   YES...………………………………………1  
   NO………………………………………….2 (I7) 
 
I6. For how many years between (AGE FROM I2) and (AGE FROM I4/AGE FROM I3), did you not smoke 
cigarettes? 
   YEARS |__|__| 
I7. (During periods when you smoked), how many cigarettes (do/did) you usually smoke per day or per week? One 
package contains 20 cigarettes. 
   NUMBER |__|__|__|    Per: (circle one) 
       DAY……..…1 
       WEEK……...2 




I8. At any time in your life, did any member of your household, including caregivers, smoke in your presence? 
   YES...…………………………1 







What was the 
relationship to you of 
the (first/next) person 
who smoked? 
I10. 
How old were you 
when you were first 




How old were you 
when you were last 




For how many years 
since (REFERENCE 
DATE) were you 























































Now I have a few questions about grilled, barbecued, or smoked foods. 
 
C52. Have you ever eaten grilled, barbecued, or smoked foods? 
              
YES…………………………………………1  








Have you ever eaten 
(FOOD)? 
C54. 
Before the age of 20,  
how often did you 
usually eat (FOOD)? 
 
C55. 
Between the ages of  
20 and 20, how often did 
you usually eat (FOOD)? 
C56. 
Between the ages of  
30 and 39, (how often did 
you usually eat 
(FOOD))? 
a. Grilled or barbecued 




Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
b. Grilled or barbecued 
poultry or fish 
Yes……1 
       No…….2 (C53c) 
|__|__| 
Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
c. Smoked beef, lamb or 





Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
d. Smoked poultry or fish 





Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 











Between the ages of 40 
and 40, (how often did 
you usually eat FOOD))? 
C58. 
Between the ages of  
50 and 59, (how often did 
you usually eat FOOD))? 
C59. 
Since the age of 60, (how 
often did you usually eat 
(FOOD))? 
C60. 
Which seasons of the year 
did you usually eat 
(FOOD)? (CIRCLE ALL 
THAT APPLY) 
|__|__| 
Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 








Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 








Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 








Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
|__|__| 
Times    Week………..1 
Per         Month………2 
              Year………...3 
Never……………...000 
WINTER….…………..1 
SPRING….…………...2 
SUMMER……….…....3 
FALL………………....4 
ALL YEAR…………..5 
